var title_f25_20_25920="Epistaxis control";
var content_f25_20_25920=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F50603&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F50603&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Control of benign epistaxis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 337px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The child on the right is showing the correct way to stop a nosebleed. The nasal alae should be pressed together closing off the nasal airway. The incorrect way to stop a nosebleed is demonstrated by the child on the left.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Anna H Messner, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_20_25920=[""].join("\n");
var outline_f25_20_25920=null;
var title_f25_20_25921="Hippocampal sprouting";
var content_f25_20_25921=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F56930&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F56930&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 484px\">",
"   <div class=\"ttl\">",
"    Axonal sprouting and hyperexcitability in epilepsy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 464px; height: 352px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Stafstrom, CE. An introduction to seizures and epilepsy: cellular mechanisms underlying classification and treatment. In: Epilepsy and the Ketogenic Diet, Stafstrom, CE, Rho, JM (Eds), Humana Press, Totowa, New Jersey 2004. Copyright &copy;2004 Springer Science and Business Media.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_20_25921=[""].join("\n");
var outline_f25_20_25921=null;
var title_f25_20_25922="Triclosan and fluoride (dental): Drug information";
var content_f25_20_25922=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Triclosan and fluoride (dental): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F230880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Colgate Total&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F230887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibacterial, Dental;",
"     </li>",
"     <li>",
"      Mineral, Oral, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F230881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Prevention of dental caries and gingivitis:",
"     </b>",
"     Oral: Brush teeth thoroughly after each meal or at least twice daily",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F14386360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Prevention of dental caries and gingivitis:",
"     </b>",
"     Children &ge;6 years: Refer to adult dosing",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F230882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F230875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gel, oral [toothpaste]: Triclosan 0.30% and sodium fluoride 0.24% (119 g, 170 g, 221 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paste, oral [toothpaste]: Triclosan 0.30% and sodium fluoride 0.24% (119 g, 170 g, 221 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F1623903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F14386361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Apply a pea-sized amount of paste/gel to a dry soft bristle toothbrush and brush for at least 2 minutes after each meal or at a minimum twice daily.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F230876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Used exclusively in dental applications for the prevention of cavities, plaque, and gingivitis",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F230869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Antigingivitis and antiplaque effects have not been determined in children &lt;6 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Accidental ingestion: If an amount greater than used for brushing is swallowed, seek professional assistance of contact a poison control center immediately.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Self-medication (OTC use): Patients should consult healthcare provider or dentist prior to use if experiencing oral pain, swelling, pus, loose teeth, increased spacing between teeth, or if experiencing oral bleeding or redness lasting longer than 2 weeks.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6223463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14287366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to fluoride monograph.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14287367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to fluoride monograph.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F11390212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Close Up Toothpaste (NZ);",
"     </li>",
"     <li>",
"      Colgate 2 in 1 Toothpaste (NZ)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F230868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Triclosan is an antibacterial agent which helps to prevent gingivitis with regular use. Fluoride promotes remineralization of decalcified enamel, inhibits the cariogenic microbial process in dental plaque, and increases tooth resistance to acid dissolution",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Binney A, Addy M, Owens J, et al, &ldquo;A Comparison of Triclosan and Stannous Fluoride Toothpastes for Inhibition of Plaque Growth,&rdquo;",
"      <i>",
"       J Clin Periodontol",
"      </i>",
"      , 1997, 24(3):166-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/20/25922/abstract-text/9083900/pubmed\" id=\"9083900\" target=\"_blank\">",
"        9083900",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ellwood RP, Worthington HV, Blinkhorn AS, et al, &ldquo;Effect of a Triclosan/Copolymer Dentifrice on the Incidence of Periodontal Attachment Loss in Adolescents,&rdquo;",
"      <i>",
"       J Clin Periodontol",
"      </i>",
"      , 1998, 25(5):363-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/20/25922/abstract-text/9650871/pubmed\" id=\"9650871\" target=\"_blank\">",
"        9650871",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mandel ID, &ldquo;The New Toothpastes,&rdquo;",
"      <i>",
"       J Calif Dent Assoc",
"      </i>",
"      , 1998, 26(3):186-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/20/25922/abstract-text/9709653/pubmed\" id=\"9709653\" target=\"_blank\">",
"        9709653",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rosling B, Wannfors B, Volpe AR, et a, &ldquo;The Use of a Triclosan/Copolymer Dentifrice May Retard the Progression of Periodontitis,&rdquo;",
"      <i>",
"       J Clin Periodontol",
"      </i>",
"      , 1997, 24:873-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/20/25922/abstract-text/9442423/pubmed\" id=\"9442423\" target=\"_blank\">",
"        9442423",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10299 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-FE77A46CF4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_20_25922=[""].join("\n");
var outline_f25_20_25922=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230880\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230887\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230881\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14386360\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230882\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230875\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1623903\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14386361\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230876\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230869\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300172\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6223463\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287366\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287367\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390212\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230868\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10299\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10299|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_20_25923="Anemic palmar pallor";
var content_f25_20_25923=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F70130&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F70130&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Palmar pallor in a patient with severe anemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The anemic child's palm is cradled in the palm of the less anemic mother.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Terrie Taylor, DO.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_20_25923=[""].join("\n");
var outline_f25_20_25923=null;
var title_f25_20_25924="Unactivated prothrombin complex concentrates (4 factors: II, VII, IX, and X with proteins C and S): Drug information";
var content_f25_20_25924=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Unactivated prothrombin complex concentrates (4 factors: II, VII, IX, and X with proteins C and S): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?36/55/37747?source=see_link\">",
"    see \"Unactivated prothrombin complex concentrates (4 factors: II, VII, IX, and X with proteins C and S): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5541091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Octaplex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F5541095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Blood Product Derivative;",
"     </li>",
"     <li>",
"      Hemostatic Agent;",
"     </li>",
"     <li>",
"      Prothrombin Complex Concentrate (PCC)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F5541713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosing should be individualized based on severity of disorder, extent and location of bleeding, and clinical status of patient.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Bleeding/perioperative prophylaxis of bleeding during vitamin K antagonist therapy:",
"     </b>",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Maximum dose not to exceed 120 mL: Approximate doses required for normalization of INR (&le;1.2 within 1 hour):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Initial INR: 2-2.5: Administer 0.9-1.3 mL/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     2.5-3: Administer 1.3-1.6 mL/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     3-3.5: Administer 1.6-1.9 mL/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &gt;3.5: Administer &gt;1.9 mL/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     With the correction of vitamin K antagonist-induced impairment of hemostasis in patients who have been treated concomitantly with an appropriate vitamin K dose, repeat dosing with PCC is usually not necessary.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F5541712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &ge;17 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F5541714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F10076333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Octaplex&reg;: Human coagulation factor II: 11-38 units/mL; factor VII: 9-24 units/mL; factor IX: 20-31 units/mL; factor X: 18-30 units/mL: protein C: 7-31 units/mL; protein S: 7-32 units/mL (20 mL) [contains heparin 4-15.5 units/mL, polysorbate 80 &le;50 mcg/mL, sodium citrate 17-27 mmoL/L; packaged with diluent]",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11234286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5541715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Measure pulse rate before and during infusion. Administer at a rate of 1 mL/minute initially, followed by 2-3 mL/minute. Reduce infusion rate or interrupt infusion if patient&rsquo;s pulse rate increases significantly.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F5541182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not introduce other medications into the same I.V. line.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F5541097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prophylaxis (perioperative) and treatment of bleeding due to acquired deficiency (eg, overdose of vitamin K antagonist) of one or more of the prothrombin complex coagulation factors II, VII, IX, and X, when rapid correction of factor deficiency is necessary",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F5541172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Incidence based on small study population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Hypertension (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: Transaminases increased (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Injection site burning (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Parvovirus B19 seropositive (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Postmarketing and/or case reports: Peripheral ischemia, transient ischemic attack",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F5541101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component of the formulation; heparin-induced thrombocytopenia type II or known allergy to heparin; non-life-threatening bleeds in individuals with recent myocardial infarction, high risk of thrombosis, or angina pectoris; untreated disseminated intravascular coagulation (DIC); bleeding associated with hepatic parenchyme disorders, esophageal varices, or major hepatic surgery",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5541102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Antibody formation: Development of antibodies to one or more of the human prothrombin factors may occur rarely resulting in an inadequate clinical response; monitor for signs of antibody formation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hematologic events: Use has been associated with thrombosis and may be associated with an increased risk of DIC and thromboembolic complications including MI, in patients with acquired or congenital factor deficiency, particularly with repeated dosing or in treatment of isolated factor VII deficiency; use with caution in patients with a history of any condition (eg, MI, coronary artery disease CAD) that increases the risk for thromboembolic events or DIC; monitor closely for signs/symptoms of thrombosis or intravascular coagulation; use with caution in hepatic dysfunction, peri/postoperative patients and neonates; use in DIC and hyperfibrinolysis only after appropriate therapy (eg, heparin, antithrombin, antifibrinolytics) for disruption of the consumptive coagulation process has been administered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity reactions: Prophylactic treatment with antihistamines and/or glucocorticoids may be necessary in patients predisposed to allergies. Glucocorticoids and/or antihistamines also may be used to control mild allergic reactions. Severe hypersensitivity and anaphylactic reactions may rarely occur with use; immediate medical treatment (including epinephrine 1:1000) should be readily available in the event of a severe reaction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Chronic liver disease or transplantation: Monitor antithrombin (AT) levels in patients being treated for bleeding as a result of chronic liver disease or liver transplantation. If AT levels are deficient, AT should be administered concomitantly with PCC. No clinical data is available for use of PCC to treat bleeding due to liver parenchyme disorders, major liver surgery, or esophageal varices; use of PCC for these indications is contraindicated and the preferred method of treatment is fresh frozen plasma (FFP).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypercoagulopathy: Administration of PCC may exacerbate underlying hypercoagulable states in recipients of vitamin K antagonists.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in patients &lt;17 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Heparin: Formulation contains heparin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer. Hepatitis B vaccination is recommended for all patients. Hepatitis A vaccination is also recommended for seronegative patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Coagulation factor deficiency: Hepatic synthesis of the prothrombin complex (Factors II, VII, IX and X) coagulation factors is vitamin K dependent. Severe hepatic dysfunction, inadequate absorption of vitamin K (eg, pancreatic disorders, diarrhea) or vitamin K antagonist therapy or overdose may lead to coagulation factor deficiencies. In patients with an acquired deficiency of the vitamin K dependent coagulation factors, administer prothrombin complex concentrate (PCC) only if a rapid correction (eg, emergency surgery, major bleeding) is necessary. If not indicated and caused by Vitamin K antagonist therapy, coagulation factor deficiencies may be managed by reducing or discontinuing therapy of the vitamin K antagonist and/or administration of vitamin K.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5541098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Moderate-to-significant decreases in fetal body weight have been observed in some animal studies. There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if clearly needed. Parvovirus B19 or hepatitis A, which may be present in plasma-derived products, may affect a pregnant woman more seriously than a nonpregnant woman.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F5541100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5541717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Coagulation factor assays, protein C, protein S, aPTT, PT, INR, CBC, AT, D-dimer, fibrinogen; transaminases; development of circulating coagulation factor antibodies (inhibitors); blood pressure, heart rate (before and during administration), temperature (during and following administration)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F5541709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prothrombin complex concentrate provides an increase in the levels of the vitamin K-dependent coagulation factors (II, VII, IX, and X) with the addition of protein C and protein S. Coagulation factors II, IX, and X are part of the intrinsic coagulation pathway, while factor VII is part of the extrinsic coagulation pathway. In the",
"     <i>",
"      extrinsic",
"     </i>",
"     pathway, damaged blood vessels release endothelial tissue factor (TF) which complexes with factor VII to form TF-factor VIIa. Within the",
"     <i>",
"      intrinsic",
"     </i>",
"     pathway, factor IX is converted to IXa. Factor IXa (as well as TF-factor VIIa) converts factor X to factor Xa in the final common pathway of coagulation. Factor Xa activates prothrombin (factor II) into thrombin (IIa) which converts fibrinogen into fibrin resulting in clot formation. Proteins C and S are vitamin K-dependent inhibiting enzymes involved in regulating the coagulation process. Protein S serves as a cofactor for protein C which is converted to activated protein C (APC). APC is a serine protease which inactivates factors Va and VIIIa, limiting thrombotic formation.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F5541197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Rapid; significant INR decline within 10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: ~6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Factor II: 48&ndash;60 hours; Factor VII: 1.5-6 hours; Factor IX: 20-24 hours; Factor X: 24-48 hours; Protein C: 1.5&ndash;6 hours; Protein S: 24-48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Half-lives may be significantly reduced in severe hepatocellular damage, DIC, or extended catabolic metabolism.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Cartmill M, Dolan G, Byrne JL, et al, &ldquo;Prothrombin Complex Concentrate for Oral Anticoagulant Reversal in Neurosurgical Emergencies,&rdquo;",
"      <i>",
"       Br J Neurosurg",
"      </i>",
"      , 2000, 14(5):458-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/20/25924/abstract-text/11198768/pubmed\" id=\"11198768\" target=\"_blank\">",
"        11198768",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):7-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/20/25924/abstract-text/22315257/pubmed\" id=\"22315257\" target=\"_blank\">",
"        22315257",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lubetsky A, Hoffman R, Zimlichman R, et al, &ldquo;Efficacy and Safety of a Prothrombin Complex Concentrate (Octaplex&reg;) for Rapid Reversal of Oral Anticoagulation,&rdquo;",
"      <i>",
"       Thromb Res",
"      </i>",
"      , 2004, 113(6):371-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/20/25924/abstract-text/15226091/pubmed\" id=\"15226091\" target=\"_blank\">",
"        15226091",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Makris M, &ldquo;Optimization of the Prothrombin Complex Concentrate Dose for Warfarin Reversal,&rdquo;",
"      <i>",
"       Thromb Res",
"      </i>",
"      , 2005, 115(6):451-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/20/25924/abstract-text/15792674/pubmed\" id=\"15792674\" target=\"_blank\">",
"        15792674",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morgenstern LB, Hemphill JC, Anderson C, et al, \"Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association,\"",
"      <i>",
"       Stroke",
"      </i>",
"      , 2010, 41(9):2108-29.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/20/25924/abstract-text/20651276/pubmed\" id=\"20651276\" target=\"_blank\">",
"        20651276",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9450 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-75F91836D7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_20_25924=[""].join("\n");
var outline_f25_20_25924=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5541091\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5541095\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5541713\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5541712\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5541714\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10076333\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11234286\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5541715\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5541182\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5541097\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5541172\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5541101\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5541102\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5541098\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5541100\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5541717\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5541709\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5541197\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9450\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9450|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/55/37747?source=related_link\">",
"      Unactivated prothrombin complex concentrates (4 factors: II, VII, IX, and X with proteins C and S): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_20_25925="Oral hairy leukoplakia";
var content_f25_20_25925=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86947&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86947&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Oral hairy leukoplakia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    White plaques are present on the tongue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Image created by Sook-Bin Woo, MS, DMD, MMSc. Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_20_25925=[""].join("\n");
var outline_f25_20_25925=null;
var title_f25_20_25926="Pulmonary nodules in GPA";
var content_f25_20_25926=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F67766&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F67766&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 667px\">",
"   <div class=\"ttl\">",
"    Lung nodules in granulomatosis with polyangiitis (Wegener's)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 647px; height: 503px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAH3AocDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOh+HeP+FgeGM9P7Utf/Rq191bSeBz9K+GPhsN3xF8LD11W1H/AJGWvvlYFHAwf8aAKUNux5OMfyq5BGkZOcLhcnPFSohdgqL2q19kWCItNggqeMcGgCiWA4AqQNwu7msbUdYtLIM8rjjtXB+IPiZDBuW05I70AevW7wxuPMdQT79KvwtBISElXn3r5WvviDqNxOSsp2dvUGlt/iLqUBGJmFAH1VLJDBjMqA+x6VUkv4B92RSfcivlXUPiFq1wS3nNWY/jDVmJPnvjr1oA+tXvUJzuBH1povI8d+Oa+XtN+IWp2hG+QuPfmu30b4rQSKFvYBnsQaAPb0uUbvj60/duxg85xz3rzrSfHeiXbAeeYyexWumttf01gPLu4uemWHNAHRHdjOR7VHIGPGPqPeobG+guW2ieM46ENWpaRCdvkYHHOQe1ADkkaFFVsKP4ec59zUv2m2k4lVc+tPurV3ChMdMdcVT/ALNnyeB+YoAsNFpsudwX8yKZ/ZmnPyvHvuqt/Zl1nOAfbIp7WFwqk7eQOxzmgBTo1sC22YewPOP1o/suNR8sit34qqdPvN5JQ/gRT0tLxW4RhQAxikZXaoZW5BHIIPeq7NsnOeB2rVltpWjUyjkVWmtwYy/TA5oAqM5I4PSm5JJ68U1+AMYxmq91cCBNzuEUc5Y0AWQ+M5Oaj+0bWyp5HXrXFa9430zSgxlufNfP3VOa82134tXcrldOhVF/vNQB77JfNtG5wo+uajXWUi/5eE47Fq+V7/xtrl5nfdMAf7oxWcus6gxy91MTn+8aAPse28RaZKmy5u4UYHH3x0qf+2NPAK21/bsT38wV8Wy6jeSvn7TJnv8AMaRNUvo2+S5lGP8AaNAH2xBIZFwksM2fQg1HdWKyA7R5Up9RxXyBp3jHW7BlaC+m655Ymu88MfGrU7K4SPVlW5gHBO0ZoA9vmDwEpOoyO/aopFR9wP8ALp71d0PXtI8W6Ws1i4MmM7f4lqnLCbVyrdM9aAKstsQMqTn6YqqyH+IYNa8eNow2Rng5olgRs5UD3oAxlBLEgggq3T6U3KjkgE9CDVyS2aMngldp5P0qtIo2g8+mOvNAHPeJ/C2na/BieJVlGCHUYPWit7lQdo5B9elFAH5+0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHS/DM4+JHhQ/8AUWtP/RyV+gtvbSXLEp93P3j6V+fnwuTzPiZ4RT+9q9oP/IyV+jl7cW2j6c80zKkaL37mgCpcy2WiWTXF46qoGcHqa8Z8X/E9JLqWO1OAuQuOn8q5D4n/ABAudavJYLWVvs4OOnBrzXc8sm5mJPrQB0Gs+J7zUmdWkbHTArBlYvy7ZqBs55GKlCEqCSMUANjxnGRz1pSnz4ppABxn9alVhuVs59eaAIUUsSgxmn7VjiYfxVYuIgsqzRYKtz24NVHOXPHNADY03565HapNoAyo5pYozhgB19BT4cK2GHHNAEYaQP8AumIA6ipEvLxQD5rKQccN196Y42SZHQ0sq7wGU89+aANC18RatbEGC8kTHo1dDpvxK8SaecpfSFvc1xv3cEfep8YM0gBzkDPFAHoa/GLxIj5MoY9Tz1NWo/jh4jVONh9MivLnUPJsQHHTpTJQokbbwo4AxQB63D8dvEEWGmSJvbH/ANaus8JfGubU5Vhv1jhc8A4HJr518h5XAUEjNWURrZ0Kqdw5yM4BoA+xIvFF26K67GVunAp7+I7xh8uxTj0rx/4beI/tFutrcuTIOlejY4G044oAuX+vTRW7zXM/yoMnpXlmv/GC4jZ7bTow4BI3ucE132oQpPaTRuNwKngmvmnxCiwa5eRlSgDnH50AdbcfFDX5c5dRz/DWFqni3WNS3Ce6kVfRTisa22MefwFW3s1RBIed3pzigChNLJMv7xnY9ySarmPPzY4+mKstCwjYLgjd2FRkqv7tvu/zoArycopHXPSmruIGMgetWby1EUcbAgg9OelRHDIoGTj3oAXBAG45J71ZgEUyOCPmA4qNh8ibgOBTSdrYBxkUANQGT51yAOM0kiqsRYklvQDJ/Kp94MYijX5e59aY8Z42g5oA2vB3ijUPDOoJcWkzCPPzJ619L+HPFFn4n0qOeJ1MwGHTuDXyg8XyoG+8e2K6rwLqN1o+pI0chSJjhl9qAPpVQVP7vG30qQS54wcgVnaddx3VtHLC4YsATg1dbDDPf0zQBNERIGGB905zVC5g8pvlA2noKsIxRn5/hNKziRMOoI96AMx41OCpYEdlOB+NFSXa+VkjofaigD89qKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDq/hPx8UvBxPT+2bP/ANHpX098dfHZnuX0nT5h5acORXyd4NumsfF+h3afet76CUfVZFP9K9H1G7m1C/lubhizSMSTQBXLMzEvye+af5fzA7hzSKqtIozz60jblkKntxQASQllyD1pYw3kkkjA9qajFRnt7063YMzI2BnmgAVhkEmndSSCPWkVVVsY5FPkhZOV6UATWJXzPLc/I36VWu4hFKVBHX2qXAKK3fvVm4iFxAsqH5l4IoApRruAKDkU5UDnnAarFrbP5bPjGB0qK2jV3O84x3oAna3RLHc+S56GqMQZW69frWrewuLKNsFkzjdVWzspJ3WOFWd8enFAD59Nkgto7l2ULIeAG5H4Va061LWk8gX5iMDI9RWtDospRZb+RQkY+5kZrP1O+kuSIbaIRRLwAD1oAzBaRoxMkyqfbBpk8NskfyZZ+nPFT/YolG+a5Ab0wTWdOSPutu5wKAJkDhOGVF9sZqSMu7BIgzMewGSTWn4d8P6hrs6paQNs7sw4FexeDvAdpo2Li6AmuuvzDhaAOV+HfhXUlu4725UwRdQOma9dGRgc8Cn/AC9BwBwBSYHJyKABAhXa2Dxg15R8S/BQuJmv7JGOeWC16t0/w9aVlEiFXAYe9AHyne2FxazANG6npyKmhvRbxMhj3k9civoXXPCtlfkyCAeaOnFcPrPw/RVZ0XDH25oA810yGW8ukSCMYkOMHpUWt6VLpl00Uroz9eK6K60G90ttoOcHOR2qnHodzqTGRdzt0JOetAHMHc2N7E465zipYoiRlQxFW9RsJdPuTHcJtZegqKN3aPaoxn0FADZBjGew6ULGGwccDnmrD2zxRKzA4bkUWsEs8wjjBPsKAKwySAo6etWre1kcthTlRknHSr9po05nzJE/Bxt2nmt1bIC08nPlyP8AM3HIHpQByvlHeCBvbPU9BWxZQM0AYnp3xWzB4eWWILCrNz16Zq+bH+zYdkyqoIx83agCpo3iifQrhcyF4+4OcCvZPDut22s2ST27qW/iA6ivnXxA8Rc+UwI9qv8Aw/8AEcuh6um8gwSEBsnFAH0wYs575U9B7VAgKMwz9CataJMl/p6yx/Mu3PBznNMnjKOR3Hcd6AK90iyA5xkdD2opJT/FlgcYPPWigD87KKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigC5o5xq1kR1E6f+hCvTMEV5npH/ACFrL/run/oQr1IAk5JIHpQBXbjnHzCrRj3qJOuRxUshhYDcvzHuKt232Up5Y4bsTQBlAAAKw/SpYYRJMq9CTgGp76BoZU3KNhAw3Y0BxFIrqBnqDigCG6t2tLrEmRnmozMWBOTgV0Ud/barbC3vYwkg4WQCsq606W1DYG6M9GFAFWAowG88/lVrTYybxUPKE8jPWs9VcHgEVsaEvm38bDIweaAE1KVRdGCJdqDggVSTCllBz36Vc1eHbq8gjBC9c1Lfab5Fkl2uWD+goAkSZZtNKStwnIApINY+zxFbVArDjdjk1jIzENkED0qPnIC+vTFAGhPNfTKZrhpDG3TJ4qCKZkzycEY60qyyzRiEsSmeBTZIDDwc59KAIJpecBMtXo/w9+HU9+0V7qyFYCdyxHqfrVT4Q+Hjqurtd3UW6CI/KGGea+ibaAQQgAKDjsKAMvTNIgsrdIrWBYVA+6Bg1ZNm+eKvfNnGB7Gjoe2TQBmmBhk4OMVFtK9c/WtYorDGPyqpPEeoPP060AU8dex6VJGhI6Zp8Sl26DHf3q9HGF7c9xQBT8o8017cOCGUGr1ski26C6eKScD53iQohPqASSB+JqQoCDQBwnifRvPG+NM4424rGuLZdN0wl4hHjrgda9KmjXHIzXl/xRvsQmBGKrjnigDy3xJK+oahJJncM8c1n6ZA9xfwxDuwyDxVeebazsDzU+iXC213HPOcgcjNAHXa1pRe5hhhIICj/wDXXV+GPA6wWRvpOWf7ornNBuX1fWlkKnycgbjxivWNX1i20Tw8rwPGzJxnNAGGsFrpVlc3V8iRMmRGGwc/hXFxTx3d3IyLvmY53Gq2ta7Nr95maT92p4ANP32+np54kUME+Ud6AOqa+stJ0xZLmULKvOyvOfF3idtVm+T5YhwBisrU7+XUC7s5bLdCaz2G11H5igB5kDgbhz7VGwAYYz65qWOEyozADCmmGVQcKMge1AH0F8Btf+2xtp8xJcRnGT+Ven6vB5USTYPB2NXyt8NtZbRvFNpMAfLLANg4yM19d3IW9s5BEQRJGJB7ZH+FAHIyBVOTyCc4opm5VmaJyN+P0zRQB+dtFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBc0b/kL2OOvnp/6EK9TAPJIry3RTjWLAnp58f8A6EK9X8pcFlfI7gmgCOZAqrnnIzToEycYIOOOanu4v3cTgZHrTbfqT3waANKHZ5Pl3jB48fKe4rPurciUCEbkJ4IPaoxuxy2T6HvTvLlhAfJAPQUANWJ0UqRyKs2WotGfLnO+I8EUlr++lCSMRu9aiu4AkzohJ29/WgC3dQQyjzLX5h1IzzUvh4bNVhfgR5wwNZySrARs+8evPFaGnuLqQquEcdMUAaHiVVh1MIqFt6jDHndxVy6Fy/hdWjH+r+9t7Cp9Vj+1abHKuDcQjBrBi1y7jtJYFZdjcFRg5oAy7eO4vSQQRjuateTaWx+c+Y44IHSozdsUCqNmT2qGKLdJuB6dfegCwtxACzJFjuCazJZGluRg4JPetBwPLOGBzU/hjw5d61fjyo2MYb5jzigD2/4O2P2fw+jMEG45yOe9ehsQCPfpWD4Xsl03TYLZAPkGDj1rbbkjFACg9MjBpM470hz2I9DSg8e38qAHA+pzTHBOSfrxSjgZNLjPbrQBDDGE4Axj2qUthcsQo75PA+tL9KTruz9KABSuCVOQDjIPcdqcCD6mmKFUBVVVUdgMClXPOME9qAGTYPAzn1ryf4o2hdWdTk4r1uQkJ8wGcdB0rgfGyGSFhxjHTFAHztNHIZjwS+cCrVpbCYxichcdc9MVqanZiO9Z1+XnvVC5iEZDFiT2zQBo3OplEW3sWWKFQFJHUn1qHVdQnlto7RrguowxHOPw9az4Ld55VVSvPU56U+4RY2ZVxIV75oAEuXhYiHr3OelPtXeWK6eRi2FI61FOBCABjc4yafbeWLKZVJDNnORQAy1iDI0gPI/h9aWKwubmXcsbY7selJBN5BxtBx61Yn1S5kBClVT0UUARXBWKMwwvuYHDYHeqYTJywwacQ7cqCfwqWTbtQM2D1PFADY2aKTeowVGRzX158L9dj1bwTp9zNIQ0REB3dSeAB+tfIaoME7snBr6B/Zt1Bjpeo2bSk+W29V7DJoA7rxDamC/fZhVb5lz+FFaPioKTA+MFl64ooA8Eb9nHweDj+0PEH/gRD/8AGqIv2cPBzsAdR8QD1/fw/wDxqvb5nV1OeGPUnqBVdDiQ7TwRQB5Cv7NHg0hydT8QcA9J4ex/65VWm/Zw8HxttGo+ICec/v4cD/yFXvO7Ak45w3H4A1nuxY8nvyffFAHiR/Zz8ID/AJiWvegzPD6Z/wCeVV5f2efCSYK6hr2M95oeP/IVe1SAMR6ZU4x3wRmqrnIXB5JGc0AeLN8APCobAv8AW8YBJ86L/wCN1XPwE8NkjF9rO3j5vOi/+N17WVyoUDOQOR9aY0A3ZcYCjAx060AeNL8AvDT/AHb7Wsevmxev/XOp/wDhQHhOMDztS1vP+zNF6/8AXOvV7+9jtgY4fmkAO70FcxqmoSAs0j+V1yCff0oA4mf4EeEI87dQ13jP/LeE/wDtOq//AAo3wmysF1DW1YZwTLER/wCi67i01WCRgrsXTkgkYq9JdpnKoCnPHXtQB4lrXwn0bT3IW41NgO5kTn6fJWXH8PdDbgzannp/rE4/8cr3uaaCZTFdRoyN0bHSuM8UW0cJItlEYPO8dG4/SgDzt/h94bjQbrrVGfptWSP/AOIqE+BPDiklrjVAB282PP8A6BW29wYSFkjOeuc5BNNkMc6AoQHPrQBmW/gXwmwHm3Gs8nHyzRcf+Q60IPhp4SmBYXurlc4ys0f6/u6FjZAeeRz9KuWczQssy5BB+bHf60AI/wAI/DRXdFf6oynpmWP0/wBymD4RaATzeaoBxj97H/8AEV1Gn3ZmCjgE4OO1aCXI+UEA7gBmgDz+6+Ffh+GMMt5qfbrJH/8AEVRHw30Pfj7TqWPaRP8A4ivRLlk2KGUlcD8KqRNEMkRjtnPWgDi7X4ZaFLIA13qQHtImf/QKvr8JNBOP9M1PkD+OP/4iupgS3R1K7gQwx/KtAzhFDc8Ad6AOBX4TaLuw91qQ9xJH/wDEVDN8MNAjBP2vUsDG4mWPj/xyu6kuCwMrthEAJ/OubvNRlnnPRIjwi9/qaAORk8DaGSVhm1IMDyzyJjH/AHxWbP4S0tG2pJek9MmRf/ia7JoWlAzk56gVXkgUSYZhk0AcS/hizDMBJccdTuX/AOJq7p3gmC9lVI/tjEkDCkZ/9BrtdM0+O6fAVSq/ekI4/wDr100F1b2CiLT/AJcn5pCOSaAOctfg1pXlA3N1qRcjkRyIAPzSpV+D3h4tg3Wrj/trH6/9c662zv3kwgdy5GetU9S1JrdiscjGbGTzwtAHN3fwj8NQKV+16uZf7vmx8fX93VGP4Y+GjJslu9VT382PGf8AvitQ6hPuJaeQuepJpf7UlPMuyVf9oYNAAPgz4elXNvfaoR3BljyP/HKgk+DWioMG81LIzz5iEH/xzitvTNaRJcpJJbN1yTuX6V3NpMt9DvjADhTvAOQeKAPJo/hJoJJD3Wq5GeBJH/8AEVPJ8HvD6kYvNV2kZz5kf/xFel3lsXy8Y/eDOR6jFRQsJIyMHIOf0oA81m+EGgpCzC71TII6yx9/+AU60+D/AIemOGvdU4XJxLH1/wC+K9EuSTbH6qc+tRWchjlJU4O08UAcRcfCTQNOtXv7e71RpbaMzqsksZXcoyAcJyMiudMg3hQCDXsOrsRol8WPH2aQ4H+4a8la3jkYPGcgdfanpYBIbpojtZWeMnkHtVtYUZiYCeBuIB5qsqhWwRu96nttyzeYhAbFICtCXMjZXLDsaRy7nDEn64rVE0Jk3TqI88bqivLN4x50QLwnowoArKAmSxHmY4qIlyPm6mrFlA0ztI+QijkmozlxhRhc0AOjtGkjJiBY9/aiFWtXWYk5VsYpYDLE52vs4pkhZyRkkk0Ad0LR7nQ2v7fcyKPnVecVxccRurlvKGB15Ndb8PNajgWfTZuYpxt5+lYviXSpNG1R/LciN+Ub2oAxZEMb4Ktj6U+MAIXAOB14okupM/Pgg+tEcmVPJCn2oAsW6LczL8oUk4Ne/eCdIitNCg8qJQWAJIHXivHvAegTeINZiQIRaod0h6dO1fR9naxWdtHBCuI0AAFAFaONkbkH09Ktqfl5496c+D1zULtsXnp60ATH6jP14ppPGOarrcrkbjzUomUA5NADyTgnBOB2/lTgQB3+lQG4QdBk01ZGY5NAFk5PPFLjBqNTkeoxUi46A8ZoAbwOp6d/SlGSSKDimSSbFOTjigBl5LsjOcA/WvI/HfiUQu9tAw3Z+9nv9K73xHqQs7N5SQSeAK8B8SXi3N4z8B+4oAz55HmuN0kgAY/eNVJxmTYXDDPWnlhtw2T7UpEKqrAtkdqAK0YkVztOK0tLjM92pblc/N71DOm6JBAMq3U96u6Ri2uQGUuDwVFAFfVAlzdSSRoEjGF6/rWaxYRbBn61u6vEIwFC4ycgVmLG29cY6flQA+3jhlgcyPiUfdB71AUK/MASO+KX5Y5NzdqSad1PyE7WPTNADoZf34yAE64xRNdAu37pAM+lMQwkF5NwwM7fU1Ew8wM4HyigCRXDs2Bjg/yr1n9nu98jWL2FnIWRVAX1PP8AhXlESokeTnBU/wAq9H+BbEa3dlWwSo4xn1oA981ebzoYgckqMcUVRUsy/OxOOCcc5ooAknwGPPeoYQN5OexApLlzjBJznvVeB8SDJHHU0Aapk8xmAOOAD+K1VJAAB5+7TomGzcOeEI9+oqs7kIM9gOT7GgCORx1DdAv8yKqINzYHOBx+dSuxcsOBjP44an4Chtv8IbmgAbbEjdOMjj61i6xqUdlEwU88hUFSavf4zFCcbi2T7YzXJ6ojSKPMYgZIJHagDP1HVpZi6QuY1IPCnk/jWOZTM7YJ3Huec+uauzQqHBCgqemarshX7p+YY+goAiQSquFU49TV6yvXRVR33IGC5ByV46/SoiGn4AOVI4x1qAW0kY+ZenXnFAG7cKGhGH+hA61zVxJKo2lldc42t3rTsZXgyrjfAfQ/d+lVrizIdsBZI25XBoA5XU9PnfMtuFKngx55/Csd/NDgSQlcdecEV1F4kinIDYByMVnSsZxiXJAyfcUAUgwiI+YHcOB1yKnhYMOAAVPUdKhNuyTROBvTPI7io50CsAjMCegoA2ILkwsphxkY6d614rtHVW29McenNcgGlt5I2HBA5962IJkkQlW2seMHpQBrTTZQ4GCcdT71Wdo1CDqx5P51EfMZJMHGOhz2zVGWS4DAAA4P1oA2Le4xzjBU4x+NPuZkZeTjoOOnWssJKYZCepPI/EVJc5WFSzYHJI70AR6nduyeVEo29z+NZKsmcFskfhSX918hSHkk/kKWzt8L5k3/AAFe9AEqJJK4VSwTuQOKmfTIAR9onVsHiNT/ADNQSXBkcIW2ovUj+VOiVmjOwnGc5PegC+giUnMm1BwEUYFWYlhcZYsFHVycAVTtYlMYMzCNFOck81Hd3MU0gRJAtunAA/ioA0I9QiZnitg4C8GTu1UJdshc5cDk8mrVilvbxGWSTgEZ4qGSWCSRyzhQx4460AUCmPnD8duKY8bYGwqfYdauGNHwFlQk9Ae9OFq4fACtj0oAz0G1irAjNb+hanJZ3KKjny2O3aT61QEJHzHOD2NOKATDaCDnigD0m0vYtQiLxtideq9COOtRuMTbkwGJwwx1OOtcnps0ttOsm5gQcAj6d660P58azR4HK59jQBVusGzcHsF+neq0B2luhwpHNT3IYRuTjYQuMcY5qvDwHJxnFAEt/KD4f1FG4P2aUfhsNeVQgoQY2yD2r0vU1P8AZd4qnJ8iQfmprzVYVDgO+D3AqvsoCZR1YjGSQOetWICY3VjyO4NQgiNijsWUcggZNWIlzIA5IG3POakCK7iWaUKrZHXg1NaXj2+Yid0HcGmBlEg5+XBxzzVdUInYKC+eg96AN8rDcae6Wm1S2CR1zWEQYHKvwx4HFWl0+5tEWeSQRqw4GetQrPE8mZRuIOOlADcp5R3HL9iahYt17k+9ak62EiDyyRJTZ9PEYQpIANvegClaztBcI6cMCD1r0iS3j8S6CmxgLhB3Oa85ktcHmVQwIzXceBEWK7TdMWU9Rk0AcTqtpPBMY5YyChxwKdo+m3OpXKwW0btk9hkV9BLoOnag+Ggjcnqa2tJ8P6bpS4tLeNWPVscmgDH8C6Kuh2CR+WPNbl2A6muwzkc8fhTFUK7EHg4wMDC//rpzEYwMdaAGMQOpHrVW4cuNoPFTuu7uCPrUOwdufpQBXWPgDGRilC9M1OVpNtADAATz2qQDHpQAFHFNduOPzoAmBBySOetSBumaotIc9SaWN5GbAB3D24FAFuRwoPfPpVVmMj89KeYnPJ7VG48tGI4NAHnHxU1hbO3EAVWJ7ZrxlZzcSFm5Jr2Px5op1BsiMyN25rj7HwVdNgyKE/DmgDkZUbhQPy6mnG3eNTJs+X3FeoR/D9xbG4K5I5K+tcxrOlXe/Y0TLGvAHpQBz+kRiUvDwHYZU4710vhTQp7y/YvGyrHwxK9TVGw0xRqEENvIGcnMjAcD2r1hdV0zQtDLysCwXoAMk0AcD4o0wWi+aI8ntxXEX0axtuxtY9j61t6/rt9qd2XQExDlUHaoLa5jk2C+gHHOMcmgDnicMQwOSfWnJCXk5Q4x2rori40ztC2c8cnpVaXUbRIyYoSr9M0AYbRbjtUZA7561NCi20TmX5s9gKe14fMLKBjsKZdyxu4DD5sdaAK6v5m4ZGACQMdK9P8AgVAX1e5C4y2B7968xKw5zH1IJ6V7H+zdb+drN25UFEGST9KAPaPsmwNGqEsvBNFbMKK93ccZwcY70UAcbNnBySfeqzEZU471POwLZAIH86rv0Uj6mgDQjI8pj0+T+TVVuWIUhQOh4NWU+aBxgjhqqsMySMw+XqPy70AM2nB9W3Z+mM1XvpSmUzjqT+Iq2F+QsxIHUn6rWDLK0zhmRkY4yucn8aAKV243Y4A/+tWNeRvOP3YZiCDk9KsaheR2ocPh5uDsHT8TXN6jqdwS0cjLsbBCjgfSgB13PFbkrPJu2/woMms6XU0ORbQhHHQvzms+/k2SY3AqewFUnMj8qjLycE0AaTajcSMA0jLjg44qrcXLM213fkevaqD+cXJfAIPXOc0saAuN7tu9QOlAD3uHBJDFRngE0qX00B/dPgE5wejVV+XzMOxwOh9BSeWNhyzAZ70AWxqb3GUDlXHVD0//AFVH9oGxvNjwwPUVRl02aQiSBwG9T3qSESSgRyMiyA8SZ4P1oAviUSqnlP8ANjnPFSt9nnwLiLLr0YcE1n3FtNGhHlkE+p6/SoIJJoSVkO4jtQBotaQOW+chjzjrTUtivK8ryDxSxsHcFeCT09avS7R5adGPJP8ASgCNgEtXJJJAIH04qoAu04LYzzmrN0Qtuo5AP68VTGGg68ls49aALtogfcN2flNRaihY7STgZ60lucjBP1z9KmnA4RuFxwDz2oAyPkiQlVVeevU0Ix2vIc8AnJpt6Qp5ABFVbh2a2UPwM/KBQA+OaJVHyhn65J71L50jBsvtUc/hVBcgoo5Hqe1QXERcbPMwgPUHr70AWLq+8wjC4jUZA7n61JYksQSOM8CqdtZozAlyTnBX1rTjiSNsbnb2BxQBNdXGeCSFQ/nVWSbadxY9OQRRcqhzt6nsT0NM+zrvTPK/XvQBPFLuUF6sxyFfmRiH6YBqp5IG0klcCn4YIX3DB4IFAGpDfSNkSKswz16MKu2giuJP3bZxz5ZGDXPrNsYkgjjj61ft5tuMnPfI4oA6COMxjIyw4zmtXRZhHMynmNsZB/nWVY3yOAl0S2OkgHQ+h/xrViUxyxlQvOCrdjQBoXC/uJUbH3QR+Z5rPtxtEoI5I6+9ad2Q9sXVuNmDjsc1mLxuJ6Y5oAbqL40q8ZeD5Eh6f7JrzFdszFs7WPrXpeqZOj35AOfIk7/7JrzGFWaT5gc5qn8KAtxWUxIY429c5rTC27hPNm2uBjK1nGd0s2V2OM9AM/pToOYt2PmNSBoutlCifeYkZABxT475NhSGBE/2z1rMl27o/VRgiolLbyTkJ0xQBZeSS6cedIWHbmomtyGxuyPpTYkCjcec+tWoiC4O2gC7Y2lnHG00zM0ijIj9ax726kmkLkYj7AdquFgsrv1JHAqqQsmQ3GeRQBWfO3Oetbnhi7EN6gkBwxwCtZTRhsKOvTNaOlwqL+AISX3A8fWgD6N8O2Iiso5d5JcA81uhvwrP0WUPpsAHZQOavdv50APUjPvTER926XbuxjahJUD8ep96cM8HA6/pSNwO3PXmgBrR5PQFfcd6jKDAx/Kn7sbiSPbHFQSXAHAHWgAfAz0qNpeuMVE8rEZAJ+lR/Medv0oAmMmR3+lJ97ngZ74/lTQrd80sSpFGqIMKPlCigC1CijkgZp+0Y4zj6UyN8Y9aesw+fd0B4/z+dAByF71laxdra2ryPx1ArSkuF28dBXEeN5ZGh/dbmGMYFAHPX3iIQyMxfd9aoHxxOPkhVd3r71yGqz3a70aNl56msW2F1LdjbuAB755oA9k0/wAc+RZMbxTJJjgdq5WfxTeeJtS+wrbiMEnBUVm2FtLKyecflHUVd1jUBpQ8vToVhkdBmUdTQBLHqdr4euPJCCe4I+cntT3tP+EoZSGCYOdoNcXtV5fMmYuc7iSepq/aatPanfAxQKcAetAHTv4JlhlLx7toHQVi6rpU1uWV0PPR61j4yvBbfeyQKoXmurqNkqS/u5eeaAOVl2xttbdu6c1FIQ0Q+vPfirN3DIgIdSQf4vWqjpsUYyFHtQAmzc3yNgD2qOSPPO4kn8KUOcgg4NMbP4UAKAVU57A49a+gP2abMxWl1cug/ejhu9fPw/eYGOSMfWvqL4WWg0XQbOEoFfad2D3NAHotqAst3ITjL9e+KKp3l2EsCqnBdu3XqKKAOYnb5doHRiTkfnVGU/OvG4ZFXrlVyNjgt/EMH86oygE5znJ/GgDQib9yx6dR+lRxnftyNpbBIPXFSQf8exxkcg80iJtUDAyMH6UAVrt8RBE6nFcprGoLBE8VsTuPLyD+lb+syskDRxkbyPmPcDNcVqTKW4G4KMYHc0AZF1KZASD2zn1rLnMT53DPGQM8LVm4lO52Ye1Unhdt0gwkfUs/AoAqXMxRQqhVcfxYzkfWsy6eRj1cg9qvTzWIjyJDNzg7eB+tUXvsrLGkUC5OUIBZl/E9aAK6SkfeJGRwKkiikZjty2fzrNnmlJbEh3Dqo4qksztIV3tkDA+Y0AdCsMvmAMuWz6d6QJJ8wkBJzyuK55bh4pwSzE9iTmr7yYjDgnLds0Aawjk4J57EVC1t5j4XIY9jwKzkuTsJZiW6denvVy2vJVjwzAjoSwoAsQTOifZ5iWi3ZGeSD7e1F3CDhQDkZ6d6uyNDc20GFMcg53LzmoB50cv7hlfuN1AE1nB/onmzYyp4Hc0RIzy7zKMsehHOaitt+6VZm+8M8HnNW0Q74hxk9z2oAZcREuI2OVwDj04qu0eCoCkrgCrcmcluyn060ze2eo6DAAoAitIWDqDliMZ5x61YuIPNZfmAIAz71JBu65HYfSl2liG68ccUAZctqk0gyp3jgH1rK1CFgwBUjFdjDGjoAePUiquqabHPGGZsA+g5oA4q4BEOxR82QeKZFFMW24wD1J6VqT2sUG4PuY4+T0qK6lBiQQqEyME9aAJPs7CICEAEDLEnvSxuqxs8kikHP51mea/mcbunGehouyQ6jpuXJHagCzlNpxKuO5p0b2yAYmGQe9ZuMRPnsfXrUSyLIQWHXpQBtkGVt6yhiT0BqVIpQACPlHOTWUqKMjGNvQ5q1G0qt+7ZljGOM8mgC7Ez7uAFXoMir0axtw64PZhVKC6JkImVHUHO7OCKuxmGUsVmCkc7WOP16UAOUMpOCWXpx1rf0G+AlWC45jbuTytYKny22FH9eeM/SrsS7mG84b1Hb60Ad08ai2mXgjacH1GR0rK2hY5Ae3pV/TJHlsNkh/eIhz7iqLHFu/GSB69s0AM1PA0W+97eTBH+6a80tS+85XOO5r0bUWJ0m9GR/qJOnb5TXm9o9wYFWUJG/O4IcjP1NU/hQFoAPllI54IFLCPLlAfBXHSkgXy8k/dPUU5XU53A9DUgKqKCzsNxJ/ACgODEE2j5SarM+TkHHHfvQu5vu9/4vSgCwZQpQBMH8aUyMASB1pIYi4xJtDetaelWUdxcxxFhhuvFAGZHk4GGO7jFILaUyFiuBXpsPhi2SP8AdgeZjpXBakstneOjdjyKAMxQ3m/PwOo6V1Hgi0WbVFc846Y5rAK+aN2cMe1d18OIPIJnlXGeASKAPYtCRkswGyK0nBAyDj2qpppXyQF54zS3UskaMyZz70Ac94y8ZQ+F7QzXA3E8Knc1z3hf4kDWZNk0YiLeg4rz/wCI9vqWueJdkyuUQBVB5FdP4I8GNZiOadhk4OBxigD1q023EYckkVObPC/SuJ1/xrYeGUEBcSzdgpHFYS/FYzcRRgeqk/8A16APTJI9gwozSRgkZI/HFYHh3xZaartWRhHKR0zXUooI+UZ/WgCuxP5+lVyCSMkj6d6uSdeBub0oWMlv3gXbQBCqPj6mpPKYDJyae8iJhQc96cpZhkAhRQBUuIXaIgbue9cxqsHBWQEe/XiuzZ8D5gQPpVDUbKG8iITAk7Ef4UAeSao9lbSlbuLeh6ntV3SdG07UY9+nNGxA+6DyKxfiRp17azMoVzn0FYnwylvIfEEYHmJhuQ2QDQB38GgSRTEOnH06VmePfDzppkdzGCXQ8/TivZYoYZ41LxqG+lc5480n7dok0cLbWAyMfyoA+dItz7gQQBSg5+UngUNbywySI2QynB7VRklfcec0Aa+cMSMFT1pjoj8g49BWbHcSMMA4HU81Kt0AASeRQBazNChWQbkY097QTgCN9oA5BpYZWuIS3O1T0NV5pcuAg4HFAEUtm8Y2txz1FX4dMka3DdcjtT9KlzdrHKPNj6bTXo1tplvLZ7rZdo29MUAec+GNIkvfElraFCwLHcPbGa+obOxZQmxNq4GOOtec/DDwsZvEct3KhwAQh7D1r21oYzcpEg4VecdqAMC/3LIiP/CM4opNakDahLsx8uEz9KKAMu52BGZABhsZ/wDrVnSk85x9av3EeHLKARnJ2nIFZspO7qM/SgDVsT/oxzkDipMAoxY/Lt5qPT8mwIYDqOBwKW7Pl2smOeKAOc1ORCGUnDHPOa5eWIyMxwdq9WJwq/jXRXSAB5ro+XAeQ/dvYVxHiW9eYhEG2AdI1PU+p9aAKeo31vbSMLVBOzf8tG6A+wrmNRuZpmZpZCc8j0H4VeeOR2O7CJ1GRjFVZUgBLAl2PBJ4AoAx5pQwUKpyeo9DTNjP82MHvntV91/d77facdcDnFQPIyyYcAcZDdqAKjwedIQ0gzjjjpUJtkGMuxIOMgVoMjcYXIByfpSYc7/LhO3OeR09qAM690x4Y1mdyUJwBx/KljQ7FAJ46A1elglbaxjbH0OcVFdxGOHzEDYzjBoASK1do9/yMxO3aOv5ULFIGAkV8J14qCC6MMiE5L9QSc5ray88AuY2OwjDZHegCJboBEVQQQuFB7Cnfa2MaBQNp5JNQzzYKhgC3U8UkOx4mUH73TPegB6Xe2XkZfGM+laem3HmtkH5lHrWE9sV78A9RV7TyYpXLDGRQBqu+Sc5NRqmZiu39agWQ7lYE4HarHAPU4oAkyQSdp4P51IH6YJ5qFWJVueeO/vSjkHg+vSgCwrsrcfUinM5aIqec1DEp3qPxx6VYAy3A+lAGTrduz2jybWOwZ471zEocjaFYqQCBjOK7vUXZbKUKeCv4GuKS5cJlSVP9KAI7eB3KEq5C9cCk1qKSGZPLiL7lBGO1WhfSGPZE+FPzN65pu/zI8Fxvj5OT1FAGS9tctHjnOMsD1qS2s5duAu1Ack+laEIEs4ZpCFPQVNKzSXGFGAvRR396AKB3gkLEdv949R70+MOv8JLA9fWrkK/ug77sdMA9akZmGNg2qOAKAKjHYCB/Eev9KUOGAXIGDU84jYqu0HuWHGKRbZRGQpBdjnDdvxoAvabeSQ4E2JYOmxu3uD2ro7OCGTabZy+48g9U9jXJRK8XMikDpx0rf0OU2kwlwd56jPVaAOu0tyLlemwgrj8KY67BICvHT2qaAxyvHLatujPbptPpTrld6OTnPUgdqAMnUFY6feoOphfH/fJrz0DaGxnivVbS3+0X0ETA7ZWEZ988f1rz7XLFrC/mgI4DEAg5BH1707K1wM7eWAxzSLuLkYIxx/9epIww5z+dMCN5nDHOKQEUsZ3Hvx0xTYX2MF6L3qaO0lzvlKoO+7FSu9pxgFmHXHAoAZI7JMMdBz0qeyv3gdXhGGB5NSRT29wRFPH5adC47Cpp9OhQP8A2bKs8Q5BA5oA7PR/FSFEacjgYP5VzGvhJL15gT5bHI5zisZUuFULtIbuOa1bXTr2aLzFQ46HNAFK0s5rq4QQsCpOB7V61odolnbQiZRtHT3rntA0iDS7J7y9bkc7R61D/wAJIG1BZZw2xD+7j4/WgD2zR0LQqxGFwCvFT37hImCfeIrK8L61FqNmCSoYDOB2qHUNXsrcyma4XIb7uepoAwruxS2ea+vhnbk4715vq/j3ULieSO1JhtvugV6jqd5Ff6eWUYTb0r5/1cr/AGtcgZ27zigCa9bzyZZCzux5ZjVZbcxjzFkG7sKmxvhjAJ9+DXReE/C9xrl0rAbYVPLE0AO8LT3DzQkKd+4Dn619B6esosofNHzbecdjXP6D4StLExmCHfIB1NdV9kmhQBxmgCCSZI2xjPeqhlaV9oJz/dz0qecDuMN/OmWa5m6fKBn8aALcMaxgFsF/WpN3oeOmBSYx0o6dsDNAC7s9efrVO7h4Lx9R29Ktk59TQoycH8jQBzOqafFqVpJHcrl15Vu5rH8P6LBaXKu8K7weOORXVX8ew4QjPbNcXpurC38Um3uMtHxnn7vFAHoUDqseG+UjjArG8Tatb2tm26RRwetZPjXXFWIx2MgEoH414zqOo6leXBS/aQgHv0oAj1zUI5byfylGXP3vasXZuRmVuT0FW70qu3cq4JznHaqoI83Ea5A5oASC2csRt5PGc0TwrFHt6k1Z8wgFlJGOvNSgpLBmQfQ0AZ0EzxBgnDNx+FPEoYHPDD1p8kKqvynP0qp5RVmyeOxyKANDTJkjvQ5yea9V8OatFPAsEYIkkO0CvGoPkYngAV6V8LLRr7V1mbd5cQDdOpoA+gvBNklvatJgghQM/Xr/ACrdDBBPckjgfyrnNKvWjjaJc4wasaver9njtk/iOW/woAyrp/MZpiBuZix/GimXIAU44JwOec4ooAryMXTKBQOdwXjH1rPYDdnHPvVi4nZ3BbaCOOAB/wDrqJ1+fAGD0NAGpp4P2Y8cetQ6lgwMpO1B1JNTWRzauByc9qzNbdpIXhi6/wARPQUActq93LeSLHCf3S8KnYe5rnrpEgOBhm/vkfyrV1BxDGY4jg/xMOtZhjE0ZYtyvV24AoA525G+VlI45AY1ny2sroflVYh0duBV291SCAlLSMTMTnzn+6MegrnL2ea4k3TyNKc5A6D8qAJpLm0gkBDNPIvTy+B+dQvcvLCTBHChB6NyfpVKTaGJYbfYVDKxdsjnjtQBO91diXDzHp1HFRByXcPIxLDB+ao5D8n7zt0qqzsvzkjaeMYoAuQyzxjarnb0JzU0ktz9kldGyueO+DWaJnK5/gPAAq2kqtbGOUFOcE0AVxdTZXfGGGM59a0tN1FGVYD+7DNn2BrNu0EeAD8h7miBAitIOnbNAG1fPHcSFQqg9CyU+GJFxKGUKowoPrXPkskyFDg+xwakF8yrtchhnvxQB0FtGZflI5J3DmrcUQG84JOO9ZGm6gsdxE7cknBHeuhVQzS7cnjNAFcIvl8YA71LgFRz29aFRVXcR8p4GKYnysQB8vcE9KAJFAXBzg+tOBGM9AenvUbHPuaVV4I7UAWUbbuw34Gpo9yqOzVTaRdgZeVoiuWdsLjr1J6e9AC+IruOHTuCfMIxt9a4Tf8AKQzhFJ6Zqz49vGFysMcwZD3Q8ZrnLYFgAxwoPGTQB0NmyCZSwLA9fSrAuIlnkUQh89+1Ztq8iwmMkHacipxnzWIPBHegCX7Z5KKgiG7171atbxYmVpLaNmwfkJ61Sl2KynaTxjBNRxj52Zj/AAmgDVF5HcSZ8gxKvO1D0qT7TBJtdZSsvQKy9vWsu1YBy+AVVTSx5ILsAoI4A6mgDXS23BpEMcgHUA85+lI1vLAS8wKgD5eOtY7AsVI9Og4xWgl7cRKi+cxjXgJJ8w/+tQBdt5HJ+QcD7zHmtCFUY+YU2sTjKH+lVrS5tZFxODEx6FRlSff0q20TRqrxKskbH76c4oA6HwtK1tckP80LcEjpmtpxsWTkEBuD61z+jO0Z5X5WHQ9K3rTMtjKcfMjYx7UAT6MuddsFC5DXEf4DcKh+KXh4pqgu0TZG/XjvV3w8ofXNMAwCLqI/+PCvTfiNoq6noJlAOQMtt9e1PoB87QaQk5XamEHU07+wUikkcMW2qSBWlp1zKlwbVOdpIIrrrfRvtVvhfldlOeaQHiF883nMH3Y7Zz0pohZ1UxggdK9A8V6LbaXErN87+tckt2wdUhi5J44oAkttIeW0BciMD7xPpWjY2UFnH5sbBmXqPWq1/deZEkDH5h940221mCxXCIJHx1NAGz9ugkHmC3VGA+8/Sq41ZnvIYo3IjJ52dM596wZ7971y8p2oeiitPwssRvSxOdq5ANAHc+IJhc6ZFDZL91Qzeh4rz29aRrxjyG7+letaDos15p5knGC5OOe2a5rUvDW7XvJVWVEOWOO1AHS+B4mt/DbzOxEzK2COo4rzlLqeXVJEuWYnfyGJr0tDPb2XlW0e3y1PB47VxM1okplu3G2buMUAQeIvErQJ9nsuOAGx24riGYEmQ5Zz1Jq3fBnkZhu6+lNhgZ0yVx7gUAWdDtpL+9jhjj5Y4AHevovwb4fWzsobdEAcgbyPWvP/AIS6CDuv7iLp8seRivdLCFbOy3DiRueaALFrBb2kaZUF8flUxmSZgpVSDwfasn7V5hOOvenhyYmxxjnrQA7UtISeN3tSC3XFc/ADHOUYFT0IrpbK68pTvzk9PequuWwdRdoOTw2KAM88UmfbmmxyK6DJP1p5GOnSgBAfSnLwe2BSEhc5Irl/G3iqHRNOcI4MzjCjvQBgeMPE4t9ZFvA+7a3zYNccdXQ+JEJzIZgQWB+7xXJ32ovc3clx5n7yY5Y56VLo+5dRgD5Z3bAoAseLJbuHUUljmbb2IOc02HxKuxYryANnALYrV8cWi20ERYHeDnFcVMGbDFQfb0oA6W706z1NfNs5QrgZK1nyacsRZpJEQjrk9ay7aaaKQPGxCg8471rXIjuIBcykg45X3oAzZAkOQTuBOeKeJ4pVVAu0AdRVeY+WCxOVPQelVhIex4FAF9ZFG4A8VWkw3T+dMdyV+U8/Wlh55PQfrQA9Igy9fmr3j4P6HJb6IZyDvn+b5h0XFeQ+FtOfVtbt7VMgZySBnNfXGh6UmmaRFAq5kYAdPuj0oAx/J+yqW2nG0ge9VY2MkhZwMmtPxIwjdIIxllUlj9RWXDngAcY/KgBt6wGAM4oqK9f5uBwPQ9KKAKDMMvuz6A+op8S/JnOQOBQyksduPXmljx5fBGAeaAL9kStrI/JOenvWXqBCxuCTuPJIrRRvLsc85ZqzH+dmZgD+PAFAHG30SxNNPKxCjkD0+tcdq2sS3chjRQsHAAHH410niu7aVzbWykxA5IXv7muOeBEm8yd95A+6OlAFR7bzC/lk9cFPSqclpOA6PGQqevGPetlZImJe1BRsfMo6n6VLbxmUSRSvu3JlXY0Acm9kQ3zTrnr8ozSrbwAH77EdRnFaU0Dw/I6kE/rUMUTI33RtbgE96AIrAQvIUkjVQ3AOOc1WaEK/yCMKSeo6VPIu2T5toYHu2OPamzFJUM4ljYA7WUHke+KACJreGYGZFf1XtinXIs4mDwgyRMc/P29jTFjgJV2nUBjwMc0SmNpQvnL1AI7GgDTtksL23e3aNfPzuTIrLvbaONVt2QoQckDv71KY2F2fmCuhG3YeMUmrpMZY5V+Yjq2eooApTaczrvRuAMEntVSWDyw25QzfWrkjuDsV8buWA6ZpNjKrAqCvQ5oApwRksucLg8e3vXWaXOzQnec54+orAS0JlG3OP5V0VlblIQoB2t+hoAsSnamFPXt7VADtxyKmmU4yRz6+lViDyfwoAlJwc9B3qRff0qAEk9+B1NOJABx6d6AEk+ZjknB/Oq8jeVljnavp3qXDZHY+maiu1Oxy2SMUAcLrfmT3yyAZUkg//Xp1tpqPwzsT14raubTEIbaSAevqKpwweVIqlyRnOPxoAt2dnAMI+9vQ55JrSitoJMgRBiOD6ioLSJ2uEYFc9Dk9KngRk1BwsqKOmQelAFa4t7dlz/ADj3NQRQQuAqqQPrzTJDkOvmDbu45qzpds1zOgV0GT8vPWgAFpAiAZYc8570klopbd5uAOikVPexv9q2oCR0J9ac6CLDSD5yMD2oArLZSZbY6txnb0NNhtZImLzAqo6D1q1Am+F2JOS2CSP0qZFckpyV/TFAFLjdwQVHPFaGn3j2rtsben9xun/wCuoZokZ9oG0evSnQ2rEgwnd7HigDutJZL2386LGVGMHgg+lW9C2wM8Kn90xPB7VzOnSS2bAj5ZB/Cehrq7MpOq3EWCd2GAPSgDX8P4i8R6aT0W5jPP++K93aJGSS1kyY5FOCe+a8K09S2rWRY4IlQj/voV7Ppl017ZbRtEkKgdfmz2/Sn0A8l8Q+GRpOvM8SHDE4OOPrVLWtYj0qzdtw8wg4API969I8dQtf6O80AKzRqSxHt2x+dfN2u6pJcSvFKDuTI59aQFHV9am1KQidy4B4BqGxnS1DO+zzGHyg4JHvVdHjhwzoS7dB6fWqmJJpmOeT3NACySsZWJIJY96fNYSyRCZk2Kf4iMVZsoIYszXZ3qnRRTrzVTeDbgJCPupQBTijCqdpz+Fb/g+zlutTWOJG+bgkdqqaVpz33K4RfU8V6v8PdKtLRk4BnLfe/CgDv9NtRBawRjI2qB+lWXs4Hcu8aFsYzikRsOQcEdqnQ5OKAKV7p8U0RXAQngkVwXjLw3LDZ501NwPUgc16Nv3Dk89/T8KUxhlwRuB5NAHztd6BeLDuljYN/dAzx61HpGmSmXM6kxofmyK+hjYW7DJRTWbeeH7KYqfLVRnJx3oAt+CtP22lrGU2/7I7V0+qykSiNT8q8cVQ8ORZu12ZAUGtS7tCZHdhwT1FAGagO/cnO6pySq/OuOeKsW8SIS+etOYgxsAMk0AUNwbaAenpWpbqJrGRWG5scA96zQh37lHPX6VftZCGU4zng0Acrua2nZSBwehFTtcgpxnNTa5aMJ2cLgZ4NYWpO9vp9w6H94EbGfpQBkeKfF1nokD7pEe4/hiVsnPv6V4h4g1i71i6lnuGJJPC8/KKxL2a4uNQmknkZpSxySc01pmVShPXuKALFgqNdBCxYk5ArotHuohfm4cqqxDOD6iud0jEXnzkZKrx7GpoZgVAVcZPJz1oA727ePxHY7mx5mcD3FcTqNjPaRn7QNmDwPUVsTXEttZwGGXZx2OO1LDeQ6pYm2vl3XY5RqAObtQHzIzYRRnb2pqXxNyWblDwRT7qCaGTymXaoOPrUUiKCfLwQe5oAlvoGYCWL5om6Y7VVCYXBB645zVqV2isI/KY4JOSKrpP5wAkGGU8GgBxjAG5s4FNV1I+Q9euaf5aHjOCfyrf8ABXhyTWtaihRf3SkFzjjFAHrHwB8J4ZtWuUXH8II5HpXuDuqF5pCdkS//AKzWNoMUWm6Zb2Noqg4wSBik8SXwSNbKLOTguR6elAGJcztc3c0zg/NnH9KWE4BY1CoABAznB5pSSI9qnnFAEE3zSNnnnp3ooYEtkAEgY/CigCnBGeQXJJO4Z7e1W2XoO/161HGoOMcA1YKgDJPtQAyfmFVHPOaxNbkMcDQQELIfvnstdAoXYXbOFH+NcvqrNK7c43cnigDl9TjXyx5JAXktjq3FcxPaiQMUOADyT3rupYTkiNRk+tcdrN3BaysLVRJPu4OfkX6etAGQ/wDozBwojweZW4xUSalAJWYIZ3B+YY2qfpVOdprqUm4YsQSAzd6rSWyrukEpyuOO9AGtc3gvISE+QrwCBzn39qxZElbOWZtnPJ6e9TpJGsrEbg+PnBHWr9va211bs0snlzgAFSeST7UAc3MgKEnO7uc1CrSRsTGcZHNa17ZG2CjIdf4SO/1qkLZnOYiBng5OKAKgZ5HBPOWFQ3gZLkHcAMHnsKtXCYcK4+aM4BHQ0l9DiBN4ODzmgCtYTkMXkLZXkMDxXWeGrNdX065eaVVnjB6nC49TXIQI6W1yAV3Hkd6t6OLhoihdgr8EDv7GgDRvIJrC6QyrHIrDBAOankuIJosKpR+u1ulYuqRXETwyAs0QPzZPAFSq5kX5sbR096ANCKXe6rHnI9PWujgJfy8fdA5Oe9clb745GkjAIPBWugsbk+QCB+HpQBblO75jwCeKrOADj17etOMu5RnjHFRFsHPp3oAcCRg9KccEAAjnpURORz3pwbIHpQAvUc+tVL8jyCDgCrLMcHHbnmsrUJD5JXgketAEdzcRRWzZy2Bn61hPqeUDKeG9KluWHltuLc9Dnoa5+NvL3g8kt37UAbFncyfaYysh+9+dXf3iX8rnceDlT71naIofUEd1JVTjb/hXU6tAI3jOTmRAzcdM9qAMKKGFWZ3JyWJ3MeKvxpCbY3EPysOBg8VlXOJZCqZYA4B7Yq/EiR6cYmVtzEHigBY3k8wEsWUrkkNUsdzIzFs5A6BuaZagRoRECScj8Ks22xnP2iMiIDOQOT7UAWo7vaitcW8YTGcodpqUXaSjbG6xL/dYYA/H1rHuZGllzINhzxnoKMFVABB3HkYoA1WVxg5yp/iHKmtC1LZVjtrEsJntCXRiHPGByB+FbOn3cZY/al5PJaMcj6igDWicONjAEk9D/IVraLKILpdhxE5IZc5rOghWRfMhkjkBP3unH+NWLVDFMu35gWJyeMUAdppybdTtVJ6TKPwyK9Gsrh7K6EysMdGA7ivPdGK3E9ruJykqA+vUV3+Nxwcc84pgaWourKZYyDHKOeK+e/iX4daz1J723XMUhJOB0r3KKYqGikyUPT2rM1nTI9QtJIZFRvlOM84pAfL8zZIPXApkpO3g+9dD4m0STSr9kcHZnismSFdg3MvI6UAR2JDZVgGBGelT2VrCJS9wDsXnHrUlqiRW5Ynew4z61FJKZlAOARQBbjvXnmSOEFI9wAVa7jR9UdL2CFHK7B1zXB6WoilLnqvSpY7plvS4JzmgD2/SfE1mwImnCleME9au3OvBoJXhxt/lXhguSz5jdsDk4Ndfo2qtDpzRud4kGACaAPR9BuzdFWeb5x95e5966ZcYyB714o2sXVteQum6Pbx8p611+j+MWdtlyhIUD5s0Ad4SMjgDPviq1wVYbWAJ+mazbXXrW4LbWdiXAA6gcdRV7HmOMHg85xQBs+GSpumwxzg8EYro5EDRsuAQ3rXL2wNrIs0RO4cnHQj0rpIJhKokDAowGPY96AKEsJiTaeM9+uKZFCVAYAnPGcVfuzHFGZX5C8geprAe7kkmEu4ocbflOBjOen+e9AGw0SkkFcFutOgtwjbm6CoNI1AzSmCZcPjKt2P41oXS/wCiygD+E0AZkwjuAzyj5PuqBXGeJLRktLqPbnKnA9RW/FPvjXByB29Ks3dqmqWxCgCdR3/iFAHxzrNo9nqU6MrLkk1SKr1OTXrXxD8KFLmRxHtYH0rze7tjbjYU+bPpQBE3y2CpGT8xzj0qO1UtIvpnripolEi+W7cn0PSmpE6krnA+tAGhqMkf7lH6diOlU5UeGVZVk78EGrmpBHitzHxsAzzwTVHL7j5mdh7UAJNdNK377cx6AimzQ5UYPUUzYA+eo7VPApc+X/G/Q+lADHO20WPGcZzj61VKjoOD6VcRPLLIRkE4zSw2rXE4jiQtKxwAKAJtH0yfVbqK2gB8xj+VfQPhHw/D4f06KJApuSBvfGc+1ZXw68KDRbFbi6RDdyc89RXcAeX87/XNAGlFdixg8yQr5rDCgdhWQhaWYySNuJPzE/55pHlMrbmbOOgqeNSFOVoAFXO7J52kGmNwjH06GrVtHvJz0wRTL/CjagGT1oAoDeThQCx/ACipNywID1ZucUUAVLCYSxAj7wGD7GrbknYPfPFZljiOdV6ByBitkJulI7dOaAKWosY7NYgTknJ479q5+bYImlncRhT8xbufaty4xcPIW4jAP4YrhfEN+88+AgFupwqHv7/WgDP1jVHuMxqPLtgc4HU+5NcxeLE6Nx84+76Cr95cEnKj5QcAetU3RpxgR4z1xwAaAOdug7H5mz3qvKQhjKvkjBP+Fb8mmsGw7rzwGHr6VlCGKJw20uemG7H1oAWzMVxcF3PzrgquM5+tR6pFKJvNjG8FyWYevtVi3LRBzHGN7jA2jpVkwNLbnzH2Se/egDOUSSQhPlKk9zk0ps0OR5qqQeSB2pyxFCpL4PTJ/rVjymdlRVXf6A8mgChLpkgRHkUmM/KrAdaW6sVbaoY/Lxzj/P4Vr6XMQ7xSBgoBC7vWq9/YTNMxiiZFTn17daAMO3sUWQkSEksQCR0FXdPiEbkxNvXdjIGDmo5opVVWcMr59OtaGl6bdkG68oiMj6CgDO1SbfG0A+bJ+bFZLIVkHOGHY9q7CXSEgtIrqdh5kpJVe4HqawL/AEotKWUlT1UetABHMsqK0QGMcgVrWafuEKjGTuIrN0jSZ3UPGOA3zDtiugmi8tNoXHFAFXb6/WmsMDIqYp17GmnocYH1oAhLY49OacD1GelIV+Y5/KkC8Nnr0zQBMOQDtbriqs1mHkweFbjrVqPGPUjip0AZhg85OPagDH/sdHGGXIrLuPDMbXDb1ARjkEGu2CDGN3XrnvVK/hJkVwOnA9BQBz0OhRrcwCMusaH8GNamp27Tu3kkkEYAPatK2ZYYAXRpGb7w9qUyM9u6rCFVjwQORnoDQByFzpkqNENy/MnmHA9e1LewT74ooR9wD8T6VdvA8V6+/JGMAA9KkgbMyySruIO4c9KAKhjlggUJD8x4Jx0+lQi7lU7SpYjv71fu7wO+CeckYB4H0qmsmTgEFe2aAGNLHLGvmkKOecYNKJFVQYQTkcmgLu5JyR0BFLFEjBgAVH8RHcUASW8W4bnAwPersfDhmxjHHNMS13KoT5l6DjpQ+5MK+QBweOtAF+K4mgKyRkoDxgkHd+FdLok6X0iqBtnU8p2+oriHlGQi9T0z0rd0FzEwk6MCTn0oA9N8OkpfxKRgFwcfiK9DXPbnPU54+leaeGbsXd7Dt+WRWXPvz1r0eN1YjOQw/SgB8qkjcAAeoNLbMJAysOQOacVygx061VRvKnyM+/tQBjeJvDcGs25V1CydmzXiviTw5d6VdMHjPlDgN2r6ShjW5gVlIB6Vl6xpUdxE0d3AHUjrjNAHzRL0VAMADnNV1jZn3L+NeoeKvAMuDNpQ3L1Kd64a60u6s32T27xt3yKAIbONWjMWAZCOF4GaYLNvOKNx3z1qWG1dCSc7sYyOtTwxScOwbKnjOTmgAsLNYjtds7z970ralhhVUFtIzbOTRbhDbN5g/edKhFsY5laJsKRyD3oAsTXreTDK3LPjIIwRSRXZErAH5WHT1qusMs7qm0u2egFdZ4d8JSXRWW5GF68igDV8FWpkKyvnywc4xk16DaIWbef9Wv61V0nS1toVVRsiHU4xV6STOEjHHTFAAbnZKNmd2egFdJo8Xk6dGrYGSTgDGMmsextkicSy8sOOegrQtp5J7lUT7gOT9KALmqWrXdrsQgMCGH4VzUsEsT+VIjK3QDHX8q7CigDH0fTpIpfPn4bHyr3/ABrVlkEeC33e59KczKoyxAHqaiFzbu2wTRFjxjcKAMe/sYmYyWpwT1AqiBIkgIO116GtS7tpYpGdOV68VnSgk5YH6jrQAtxbWeuRGC/QJOBgOO9eW+Nfh5JbF5I4y8f8LL0r2CG3jubTf0kHeoYbua3Uxyp5sPcMM0AfJ+oaVc2LMAhAz1xWcWOwbh8wPFfV2q+GtD1uNsgW8p64FcHr/wAGzKoOnzKwHNAHiSKjRFXcjHPSobiB1UOxJU9MV31/8LNctyQsZdf92oU+H2tYVWjIA9RQBxrWxa3D4qOKFmfKKcgcHvXrmj/DuTy8XbM2R0VTXWaP8Pre1XdHaGRwODItAHiujeE9Q1QI0URVM4LvgV6p4S8FWWjKsroJ7s9WPb6V38Ph+SJAG2xIB+X5VYS1ihT5OcdWagDNWMom5169/Sqk7vKxCj5Qau3jCRyucJ/OqkVzFIv7kEoCVyyleQfQ449+hoAWCPDZY9PxqwmGPr1zTAewA5p6EIN3GR60AX4tsSM5JHynA/Csy4kBYu/L8gdqWS5LblXBwp4FU0DSngYOOSegoAbIJJTgMVb3XNFZmu6/Z6NER5iyzE4OTwOaKANK3iHng8kDJ9MGrwPl28jgM21SMA96LaPb5j8HAwDUd1IttpNzISDx8vbmgDndTvlgiSBHBfOXIrh9VEjSN94ANkDHJrWLefN5k3JPIGeT70zUGDRLMcBl4464oA5kqm8KBzjOe+adc5jX5f8AXsvJ/hH/ANelvtxYkAEAZHY4qvHN5QJvXKJ2B6t9KAGRXPBSTDRjvjkVDPBaCcuqFyByTwD/APXrStLKTULjFnbk26ndu9au3nh1JVIkeVc8lV7/AEoA403SLIXVVVRkcdfpWfLfDcUYljnGTxit/V9AggmDWsrSQgZ54P0IrnrhfMLqkSgk88UAQtebWJLN8vTHNLHqdzES+4IGJwcD8qhMLk7TtVehB61HHYu8hR2OB2oA0DcPcx7xLJG2NpPrTra5nZmhaZyemG9ams7NrVS0kSMuPuMeSKsrZ2k0RubJzHKjAsrUAUoYPtU7h5HEsHBU+taMl5LBEtsXk2gAkDsa2dOtLW1szqLSq9w5+6/J+v0rHhRLy8mkEq7VztHv60AM1HU5FkjDkOFXC5Haqsc6z/65SRn+Gor+aOZ3Q4aReFYVTk8xW+U/LQB0WnTAJJ5TkAHhcVNcOZF3kDceDWZpG1ossT15arsxwMADaOg9KAI2A6Zx+tRkcn1pWyT8x/8ArVHkhyFHy45yaAEaMc0EcnPP1p2fTJNNAAb/AOvQAseBzzmp17VCFJOAcH1zT1Pr075oAuxTc4IBPvUd/clIz5aA4OeaIzlcg/kahuQFjYtjpx70AV2v7hfnzknoNowPatHRZp7m9hXOVZhv9MVhW9wCAM9Dk5rZk1CG302W3ssCR8Zk7jPWgDK8QW8g1SZkmjMRkIVgO1Ymr6o8TeXGAyk88YrQd8s6sSVH/jtZUm2XzU2DHFAEUVyJk3OoDE9jVuEByqhSMnHNUre0aOYAlsDuRWmkISICRyNx/GgCR4gSRGvyk/eqcJnjbgnjp1+tQJ5KrkkgDirEM8UIIySRyCRnNAF2IS2HBwJCOoOQB/jVeZnkyT8gxk544qJ545FYsSHz1U8flSBXf58+aBx8p6fWgBYbXzJASreuQMfpW0sJghRFG4sSSVqlYAEgMA7D73atNkDMgTCkZJPt9aAOg8G3Rj1m1AI5kUHH1FexI6SAbuCTgY614RbXTWCPfQKjSWymZd3RioyAcfSsw/GjxB0FlpgwQT8j/l9+n0A+jsMOB6Z6VGULFsqRxz6V89L8bvESj/jx0r/viT/4upk+OPiHJ/4l+kdP+ecn/wAXSA+gtOn+zSgSZ8o9a6qONJ4QQBJEfxIr5PPxv8Qf9A/SP+/cn/xdWrH4++J7Nv3NjpBU9VaOQj/0OgD6auvD8TjdavsJ/hasHVPCxmU+faJKPUDJrw8ftFeKj/zDdEPP/PKX/wCOVp6F8cPHOs3iW2n6LpE0jHBxDKQvuf3lAHYXXgewZuI5IjnOBxVRvAtqWykz/wDAua7nS9e1prNX1+DS/tBH3II3wPzY0+bW8KW+x2Y5wMoeT+BoA88l8BM3Ec/U55Bq5aeAVV0NxMz4/hBOK7pNZkVR/oloD7Kev508a5ckAJBAAfRTx+tAGVYeFbeAK6QooHOWzWvFa29rjd+8b07VLHd3ErHzEUc8Ed6kRDnJC9KAK9w7yAbiFQc7RT4kHUdPWnzQqwJkLYHPyntUocLGoCKcdz6UAOs7cyysjH+LPX1rVmkt9Mg6fM3Qd2NZceoNbj5I48+pBzVC9uluCZZmZySAAPfjj0oAs3V7csTIJWGeycYqTQ9Ume6FtcNuDZ2k9QaoLFGWQksSuRzipIoY0njmTIZGDA/SgDa17eumuxbJzjrjHvXKpGcBy3zfyrfvLuS7hEciqEzn5RVJrZSQdzA+gI/woAv6VqTJGsd4wZTwG9PrVu9smmaNoJdqbgzAKGDrg/Lk9OcHI5496w3iVdoAYjPPPSrMU7RIFikdV9AaANC4UafaMykeYeFFYaSyyyIZ9xVHDjaxXkfQ8j2PBqxMguD+9dnA5+Y9/WmNCgHUj24oAvQi0uBgtsY+o4rSt7Qwn93NkVzbhFGAc54IpvnMhwpb656UAdiN+eduKTbu4eNce/NcqmrTRghJGwKmi1efqZT9CB/hQB0ioFPyIo+nFIxKDdJIqLXPnUpJTgzsB6Lgf0qKYfaOZZJHx0y1AGvPqNmgwzmX3HNYmo6mJV2xKqxjjjqaabSFwcmQewP/ANaq0umKOUZz9cUAU5JWPH6CoixPJb8jTpYGiPIaowV44J/GgBySOARuB54+lSBZZB3PfNUdZk1BNPaXQ1tmuAP9XOpYH6YIrxLXfif4ptZ3try1tbd1OCqxup/nQB7rcXdrZI73U6cKflU5J49K898V/EWOKJ4LLC54wpyTXj994z1O/YidwNwOdpNYrag7/MVyT78/nQBvazrN1qMzPK5HP3QeKKwornzJQrLgHuDRQB9oGMiJY/mUsdzGsDxrM0NisQICxkEj1+tdPEN9wD0C5Jz6VxHimVrk3PIKg4+tAHOkqsqPtPPQ064EZBN0CkQ6HpuPpWVNqH2dwjKTKBlV7L6E1lXN9cXJBuGHB43Hk/hQAzUr9I9ySt86nCIOw96x1u4nuB5y+Yq/dyc4pdSiRpfMxJIe+eKz5gxXaSEGOi0Advo+q29kjP8AawVIO2JOtVrnxTcvMBBD5aIPvv1/CuMWN4Y2kAMXue9DXT3EoUtkIuPrQB0Wo6+Z5S6RhpV/1ijoRWPf3Xmv50SJGjDJUdVNVorSaQs4GEA6txitGytkTakzbUx85QZzQBgXbXJkDgKqDuOp96a9w8eJtwZugx6101xZW+DIAWj6Bj/XFVp0tPJ2LFGmerqvSgDnxqt3znD8855x64q7ZzBtiyQSEZyCDjPt9KiufIDBR09QuAfetPT7H7RGjKflHTigCTT7h90qtF8pGNpP3PpVSO1l+1MIlbpnC9x710MEAmmQMgj2cByMZqlJvSaRjkFT2GKAMSSH94cDac85659Kh8vD4BO736VsTN56ncoBB7VCiYDOBkYwMjrQBJa4jtVRQSc81aUbhhs4BqC3hdVDH5QeQKtAhRgLlQM8UAQSZBO0kVEWAzxgD2qw/UEL9feoSeCSPwFAAx6fNwKQ9SRyf1pAenH4UpA445PfNAD1XuaMHP0py98Ej8akjGV46j8KAI4y2TjPqap6vLL9jJUE7TmtGJSV+ZNvNSvCssTxH+LigDz/AO3v5hRiF56irtvO7Bm52jrVS8tDbag6SDIHHPStvTdKlvCnk/Mh+9njBoAbaHe7uVZg64x61TitXF2wXmIjk+ldRBpL27IkxZMDJIP861rrwizaTPeQSARFckHvQByUNtbiRVmm3noNvan3Fqss5K7BGo6Z+771WFq9rdyyTTBldPlVhjBpLCKZiftBURZ+8x7+1AEg8uID92GJ9aaDC7A3EmxTyStSXtibdNwU/MMCRulZDMN5Em4jt7UAOeVDIxjU7egB449amilYvkyEbRgEHGKZb23mnAXBI9a1BpTxIso8vZ12980AX7e/2oocKTjnaMNWiJt6KExwDuzwfyrn96Lnd1+nNWATB5J5G7ncG7+lAG1cpjRLzBGPIkx/3ya8jPBbnI9PSvVDfJcaffLIu11tZcMOh+Q9fevK+cnPOOpqugDuhp8X3sd8VEeAM/yp8Q+Y/SpAPTNPjQucKuSemKksrSW7uY4IULyOdqqoya91+H3wvi05Uv8AX/nm4McPYfWgDivAPw1vteZLq/ja1sO5fgsPYV7zomkaboNottpVukQAxvx8xPuauZG0JGoWNeAoHAqaKBnPANAEJJb61LHC7dB371cS1UDB61fgtsoWIAFAGZHZ/wDPQFsdsVfhgC5BUYHqKnQAfd/GmTzpAheVgoHc4AoAmXAB2/nTHlRcktxXDeJPiVomkbo1lM0v92MZx+Nefap8XbydmFhaLH6M5zQB7lLe4UBFJHrVSS8IJZyF4wctXznd+P8AxBOTvuggJ6BaxrvXtTujmW7l59GIoA+l5dXtUOJLuJfT5qibxBpYUg30A/4HXy/LPc9XnlYn1Y03dIVbMj/maAPp9/EekbR5eowD330ieJLFmUR6jbP64evl0iQ4/eN+ZppEkbZ3v+DGgD62tddt8gtIki+zVrxappbuDJcBQevIr40EtwoyJ5QO3zmpPtF3sAFzMeM/ePSgD7RudY0aOBgk8JbHGDzWBJqMWwyK42/3ga+RJby8H/L1Nj/eNes/CqW+1LQbq1uJTsbiN2NAHpOo+NNL08HzryLcOSM81zlz8WdKUNsEr49K8t8Q+Ftasr5zd28k0eeHTkYrC+zlGbcpVu4IoA9Ym+MEKn9zYyH/AHhVG5+MN0w/cWMYP+0K84lSLylMQIPcEVCyjbgDkUAdre/FHWrgYQJF/uis5vHWus+ftDn8a5tVjKkKfmPqKc3yIAfxOKAOvsviRrcL5Zg4FdRo/wAXUVl/tCBh2JFeShyFzg4+lRBNz8c0AfU3h/xpoutRqbe7jDn+AnBrpVdXwYmBUjsa+NYVkjfdE7Iw5yK7nwp8SdQ0jbDd5uIQMDJ5FAH0fLHvUjFZtxaBWyg/CsXwr44sNdCqrbJD2NdmsPmYyMAjrQBzDK0b8MRiud8Z+ErDxVYuJFSK+Vf3cq9/rXbXtsMk55rLKFCTk/j2oA+U/Efhy+0C/a3vomQgnBxwRWCRgf8A16+ude0Wy8R2Js9QXDYOyUAZU4r5y8ceD7zwzfmKbLwtykoHBFAHL2uPtC/j39qKW3H+kKDnv/KigD7fnP2fT5ZOjkYBNee69dx21nJyHmfO1e2fU13Piq5W00hpJMhVHTPU+leManfNPJK8jHcTnp+lAHN6lcTyuuZBjOTt6n61DHMWHmclhxk+lOvl2T/NtCtz9afZQyM6Y+WNuMnvQBLEvnQF4sMPUmqX9mSs4yh8v+90wK6mxsY7edFJDsPftU9wVW4dCpMI/hx+tAHNJZxSyMlzKZ41GFA421H9ijgdRHEwVvTtWheWbtMzW6nHVTTfLaJQryYm6Y6gfSgCsz20SgMDJL2XsDTJrlZgxcFHXjao4NVJ5juZXjy2eWPr9KpPNNtPlozYPJI/lQB0ujalaWVnKLxNzOflDH5R+FZ2rXEEsDCPCSE5UYyMVmBjOAS6REcHceAKbchUVYkbJU5LY5NAFd5ordC00JkPXrgV0mjXC2MFvMYWYzEEqw+4Kh0HT7RvJkmCsGfo5+77kVp6jP5t5ICp2xnHsR2I9qANbVtXtcFY4EB4wwGT+NYGq6o8OxnjRgRkKi53VXZo2Z5mPGcc8bqp39zHLt4J29fcUAWH1BRjMMZU+nB/GpJpLVREmx9rc49/es5CwRriQYhH3V9KpwXZe5ckhkIzxQBtyMhO0E7AKijkGCAaopKzu55Bbp9KsQKT6ggcigCRpGzz29KjZiGGeVPfNOCHdkjp2pGGcfWgAUnDEHpQ2Mjnj1pwHXPT8qCNxHJz9aAFUg4xipl6cEVEvsKkQcjHagCzFyME9KcFBkByCKgV9vRc9sih5GzhCRigDK8WQ28ZiuXYhTwwUVQ0rVI4XWSOYpF/tHtXT3sUVxYSJcHgrnnsa8s16xkguzEzkKeVI6Ee1AHpkOrxyKWeYOARgg/fHpV7U9fuXgihWXECj7qGvMtNmb7NHb4OEHFbNnMqqwlG0jqc0AdDfOs9gpmjVoAceZjkGs24hjjSOQMZAP4M9BWJLf3NvI7wyNJHnAU8rj6VPaykAPvaRPvOe+PQUAadrfPIrx3KM8THoT92oZ7KATb3IYHkAelC3ENzhlj2t2Un+dXLexaXLsDIuMkKDz9aACxe2jlUbRs7hjjn61evJDBHvG3yzwMc8elUGO6UbUVewGOKmRJMYAIXPORwaAKBKySlsEfXpTzIUjUZBUjA4rRmtI2ty3yxuOMDis6e0njUMqlscZFAEsLEaXdkYBeNgc+mDXAEA9OK7yZgtlKgzu8pgecdq4QgngH/AOtT6AKq5rR0fTrjUb1Le1jaSV+Bt5qLTbGe+uo7e0iaWZzhVUZr6U+GvgyDwxp8c91Gr6nImXOM7D6UgIPAPw/sfDUMV5dos2pEcFhwldqXaRsE8ntSYMh+c5yatQ25bB5AHegAtYQW5Gcda0AuMbQMVHGoQgKPrmo7zULbT4Wmu5lijAzljigC7wmSeTipEu0iiP2hlReuWbFeTeJ/ixZ2m+LSU8+XpvPSvLdb8Xa1rMjNc3cix/3EbAoA+gPE/j7SNIhcQzrLKB0BzXivi3x7qmuyNFFK1vb+inBNchguclyx9zmnpGfMJIPAzzQBXaJ3Bd2JYnqeTSxAgr/OgMSxJHFWdyxwLnBJP5UAV52XdgdT3NC7SM9u+aHwzZUH6VNErFtpX73QCgCFZN8oXgr2qJ1fJxmrr26WwLXB2uei9DUdtLksR94dBQA0RFbcSStgdh61GFMzqFBPbillkaRiZOo7UlvcSRFgoVQR+NAE88IiHlkZYDPFVWkJUIqgVesbO+u5SLaJ2LdTXeeFfAE8s6zXaH1+btQBxWj+GrzUZFJXEZNe4+DtDj0fT40VQpx3rZ0zQ7ayjUJGMitQQ9PSgCtMiSJiRVYdwwzXLa54Psb8l0RUf1ArtFtwwGMketI1qcHbj6GgDwfXPBtxaynyskE4HBNYV5pVzbJteIZ7kCvoye0V1xIvasDU/D6TKcLmgD5/eLacMpXB61HM4BGxiR7ivSfEvhkxqdkecmvPtSsHtJCjDnHNADY2WUMhXDkcEVCQ0bH171DDI/nrtGcHrWxd2czQi72qsPTdnvQBRU/ITj61ETnjbWtaW0V5ZMFbEi8njtWfMFjdkVgR60AJZ3dxZTLLaSsjLyMGvWvAfxUmyljrBHYLJXkAXaGPXjioUDYyRg54oA+xrG5hv7dWVg6MMhgc1VvbfBYd/wCdfO/gvxxf+H5liklaS17qxzive9B1+z161SW2lVmx070ARhCJMj8sVQ1fS7PXNMe01GMOjDAbHKn1rcnjw+5eOuaocdhz7UAfNPjXwlceGdb8twXt3JMcgHBH+NFfRupWFpq9qLXUIldAcqSOQaKAKXxS1IFfssbAiPg+xryUSZb5nJwevWuz8YXQmvbnzGx5jHk1ytnb/Z7nMpVmJ6joB9PWgBk1gS0UjYOO3dfrWjBbsYwCFU/3jwKnuivlMqZ34+UL3rM83anz53Dpu6UAaMijKqU25OAQat/aobS3ZJod4B+8TzWIb9/9Wqny/wC8x6fSqUJAnfdI7rnkZ6mgDbu79LtNsSGJFGDxWK9sHO6GVmI6+3vUk1zOSFRCR0ORxUqW5EBlmU4xghexoAymtpopg8hV17Z5zUMrFll35VWxn0/Cte0lARo2yEAJJYdKp3tmk0GTO4jUklsUAY8sEb42S8d/amPD5DeYFJDdGI6/Sp5FghPlwhpQBzzjB9aqRyyzyvHuIVRnAOQBQBqaH5glG0ANJ0DCt3W7h7SdSQuEQbjiqml2vlJNeTNGI41+UZ4J9qkjtv7TOyQsNxyWxwBQBzWsapJIGaCIYJwGPUfhTbFQFzeOd7fw9z71Yv7VbeaT7Phm3Y3kZFUGibczcl88mgCzfXUcgeBcqidB61BpjRiBg6DIPDdyKhlhYspI+bvznit7S7OBrU78ZzkEdcUAVLKLN18uSo61psgKbgQe3B/SrUdvGihVXYeuPWmvhckAAk+nB96AKL59MVGqe9WHU4+tRhcZA/8A10ANA4HQ9jSOPlHGfpT8HJ/uj17UP2HJB6YoARV3fSpIxz0OaSMYbHrUgBBHtigBcA8dvTFCJyO2akQDPHX+dSxjjkA8c4oArXEQZCAwPHTvWBfadFeQbZVIKnr3FdgkSuAMD1yBSmwTeQApJOfm6H2oA8reyuLO9bPMI53CpY5XYhh86k969Dn0QukjOgDgECuJu7CexuGEilYickCgCG4AlCyQgKg4YetLFEQBLFuUNzs7A+1SwQpIsqxnemM7RxilijkhyXBZey/3KAIshpB5qlHHUrWzpepyW87IZQY5BtOTipv7GfULaWfT2VpY1y0eeSPXFYJtp45B5sTA45OOKAOnS5CfNFbI8ikgFvmDVDJdTTsTuO3sD0+lUobmS2wVUeWRjDDtUk9zHPBmLbtXsByaAJyCoUyk7ewXrVk3ReaKNGCxKnT/ABrIFysMZJc5H94foKc9/lEES7WKcsRjNAFrU5ojazrsXeVb5h64rhLeEyOFjQszHAUc5NdXISIJCRk7WJz9K7D4N+DhdznWtQUG2i/1SMOretVbS4HX/CfwWmg2I1G/QNezjKqV+4Pxr0KPLSk45INM3FzyMdgPStPTrUs4GPmI6VIFe0tS5Bq8UEQwf8+1XpIVtQEHMhHNcB8RvGUPh638qIh7twdq+lAE/jHxfZeHLZg5ElwR8qAjNeC+I/El94guzJdSMsWfljB4FUtSvrnV72S5u5C7tzyeBVaBAWAY8E4oABGm0fNx+tLGifMshyjeoqdbctkcevWoXwp2kZx6UASSRKsQaMjI64pEnUQSFuTjHNReSXjJRyR6VB5DAYYkc5wTQBPGVmXaOCemKfcEwlUIzxzVe2+SZSw79K2dTsYjIty7lY2UcetAGdb/ADyqAOCatySrbXu7uBVbzxx9nUIFPfvVeQH5TjGeMDtQA+4uPtUxebcWPeoD+7fC59jStmP5T+laeg6PPqVwECnaCOaAIba1mvnCpHlumcV2nhjwI11h7sE89hxXY+F/CkduitIgJxzXc21skEQVQABQBjaJ4dtdOiAWJenUit5UC4Cr8p/SnBcj0qXYdpwBuxxn196AGoh49qmCYGDTkGFGQM45xSn6/jQAYH8I+lBxj3pfccmkwck+tADWRW6iqktuVJKnI9PSroHHf1pSB0x1oAwrq0jnUh1BNcF4q8Lq6s6IvPXivULi3XBIxiqN3bCVWVh1oA+aNYsJLGRl28Z4Iqos9w9uIjIzQ5ztz0r1bxn4a3pI6p69K8pvIJbKZo9pFAE1jeCzaQYJDDGKquQx39M0kTKzqZQSM84ouxHuJhzt9DQBMpBgOAetEcbu4VRnHepQwGkEhQG3Dn2oN0yQLFCu0Hqe5oAjdcEk1o+Hdeu9Cvkmt3bZnlc8GswM5X5hnNPdfl5A6UAfSfg7xNa+IrJWQgShfmUnkVoSQsuCOn0r5s8Ka/c+H9WWeF2EX8S9iK+i/DetWuv6WlxbuCSOQexoAkAbeMYB96KtSRZZduAenWigDyTXn3XJlZh1ygI4HvWbcF/sou1aNo87WJ+9u+lW/FMwjlkypGMADtXGTXphLK5yZOVHbNAHTLqgi2/KN4GQD1rPvple4ZmkBRhuAA4zWGLjfIGDZPqTWhDteBklkDhugz90+tAD4285gu8hT3I6fWrlktquoxLfyHYo3uI+cjtiqVuwR2DMpbOAp6fSrLGNsO/yMp+6PWgDZn1G1ZnEcbLGP9Wrdfqaq2SXd1MRCpKp8zA9MetU1nhjlUjy2frg/wBahuNYlt2YCdVV8giPsKAL16kFireY7MznIA5rHv7ppUVR98tjavQelbel6Ymowedaz7ufnD/eHritmTRNPsDGXduFzuAzg/XpQBy8OmFoj5qb5lGDUY0hVn8kBQ7kbVHXJq/e3srvtgwkSfKSDliPU1f0iKNUnupJFkuRxGg5OMevagDXudCgs9IijvCHdVGVz37Vl6jcfY7byogE3jHy/wCelUzdXF67q8hbAyo3HFV9bnFrYozkknqx6kUAVJmFzcRrEo8pSFkx0+tUrprEzOiK24HapFRQarEiuYQSpT5s1jpqUnnELGuN3GBmgDTSFTPti5YHJPtXRWVsxJOflIGF9K5zTp3SdWUqd3ciuqsXygV25x94daAJpUxjK5fuapyoQ3FWmQs/DtnioZUJyepyPpQBScnPXGaiIIGeTVoofTn0pu08AjkYoAr7cY64o28DnOMZqUAZ47Hv9aUJ93gfh9aAIkXaefbmnqDz68dKUA5xj/OacqtjA6j/ABoAkixkDsB2qeNM8dB3FQr8ox0qZCOx5zz+dAFmBMA44ParSpu29vX3qkp25yPmAq3A+eM80Aa0LxeSAVySce9Mk0yC58xZIlYN1DDJqINtAyAec1ajmI3Hjpjk0AcLq/hSazuPtGnxsI88xjkH6VkCIxy5fDJuyAeCD716vHNLtOfmWuH8aaeJ5TPbgJKB91f4qAKWng2t4HjuMHoQvcHtVvUbWGJvKeZFD/OpPOPauOW+I++SrKMbTwa1rWRb5Mbj5q8gnuKAM7UFMauWchlbkHofpVayncuwiQAnjeeQPet6WyW6fNwMoQcEHOfwq94US3s7qVDbxKSP9ceflPqKAOffQbk/vLiVxv8Au46N9KSfTJ4QCEZwACRjt9a9MtNWhNqtoIITEmccfMPcVi6vcb7aRFyxKfdHagDlNHja+1WytX2hZ5khK98swH9a+j7K2isbOCytY1WKFQvHHNfOPhdmXxZowOATewnnj+MV9M2kW8gdu9U17qAns4gRvPNdLpqLaWpupfvsMKDWTaxBpUVQAufTPFaV7cxCUmRtsEC5OemBUgYfjDXYPDPh241O+Yec42wx55JNfK2sanc61qMt5duzF2JwTnHtXR/FTxfL4q11/LaQWUJKxoTwK42MkrjpigCVW25U5x0pj7VOAfzoKEkimOh25PagCSOcxDIOexpC4c7lyB6k1G4GBn8qilmU7UXigCxGXXcSfpin29x5m4Tjp3qu37sghs+tO+Td94kUAXreAvcxFACm4VpeI5g08UQHCqOlY1hcyW8m5ScVaurkTSBj1+tAESop3Nnt0psrbkwODSzSEjCce1KiMVG4Ek+hoAfpVjLqF4kScnvXt3hHw/8AZoUZ1GAOuK5/4Y6CXTz5FHJ4r1qOFYkCqMYoAgjVEIQcHHp1qzx2Ax6mmuMrg9uaRTjigCVODz1NSjp7VEjADAGByacjZ6gUATD8RQOTSdc0dR3oAUfzpMYJ9aTdg59elL360AA5o7dTSZ4/GlPWgAPSqlwhLcdCOcVb+lNYBsd6AMbUbYXERXaD9a8k8c6EyBmij5+gr22aPByB1rl/FunC4spCq/NigD5reJoZSJMrinJPCTgt+damvadJDeSZBAzWGISsnHf3oA22iiXS9yMXOefaqibXUEHntTo5hHbNG5LZ561DFLkN8uARx7UAWE2khQfmpJ2PIyfSrGl2oWJruU/IvABPWq91KpYlevXrQBXVGDgSHkjpXV/DrxJLoGrxpLIRaSNhh2rm4wXAZhk+tREYwc4I6UAfXGnSx3caSxncjjcpFFeffBbxIt7afYbuT97CuFDdwKKAOI8ZXaK7ZwQVByPX0rzm7laSbcW59R2re8Zagz3jxRuDGjEGuWjky7LtGcd6ANHeXxxluBxxV62DAchgO+D1rNilk+6TlRyMDpWrbxARq8zlQOQO5oAti2klU+Urrt9OpqMzzrn5nQYwARzRJOcjZMUH90HvU72ayyCSKZkiP32k5wfagCTSraWeSMiMMztt3HpXoOk+F9HcFr9TNKV3bEbAB9Ca4qK8jt4Y4RIWgVsgrwfrmu6Mlu1kn2djGmAS2fmoAdO2l2RMFtCI1HBweBWPqbNfwpCWaK3A+XBxv+tVdYu4o3fC733AufamJ4gspyqTxguVLAH+ED+tAGZc6a4UlWAVDhix4+gpl0otkhjgkKA/Nkmrf2+HV7pIVQQwqQSoHLH/AOvVLXUjS9V4kY7icA849PxoAj0u82XpIiG6IHdsH61F4guxdI8Kg/MR25B9K1dFgS0jmlmBBfh09a0te0bT5rD7bCjKzIBhDgk49KAPO4IIorR/MlPzcBV9arxwu8imNSMn5QfWty1spYTFFKiEMCQGPK/WrVtbIWJYg4/iHrQAadpqLCHnbMp6hOgFXo2WJiVHzDv6VVieO3uWWFyyEcmrzwKpLbsDH5igC1at5pPXgZH51I6KqYBz3/Wm6cQobaMnHOambgHPTnnFAFSQc9P85qIqNpx2H9asSr97HbJ/lUZ/i/E0AQsCPw6fnSOoxzjj/GpmHBx74/IGlZcg9Oc0AViAQSRk89ac65yGGRnNS7cAn689e1DJg+5z+eKAGgEuRj1//VUgyeh55oRegB57flUmNxHYH+eKAAdSM/UVZiwvoCR/SmRR55J6n9atIi4BPBwOcdeKAH5OeeQT1z0qYFiMjnP+FQLwFOAQcVOHCIvfkUAXLa48v5MfM2OKS9sV1KMRQqBKxwAOpJ4FVGXDbs5woq7b5aJdnB7HNAHmvibwy6rK8Iy8efmH8Vcvo93NbXOMDcpwUPavb72GK5Qxuu0lcceteYeJvD01pftPAm5hxxySKALFjzdI4bcTyqDkCtWeG2nnVrUFWUYIY1j6DNCkMpuMpMF+VfSoPt7LOpLtkn5ivSgC9Fc+SxRCu4ZGG6ioNfvp4AbeyyYFUAyrgs3Hc96SMW9xubzcAdMdc+hqlqEixBQVIAwAQeDQBB4USaXxjohdSwN7DkHj+MV9X26CKEYIyepJr5W8JOW8baFztBv4AAOR/rFr6oCiNcrz6Zqn8K/rsBctZSm5uOOM1538XPFTabpTWNtKRc3Aw2Oymu4DiOEs3AxnrXzj4/1E6p4su33744iUX0qQOZjX5fmwSeaasoEoj3JvIyEJ5/KpEQbcgYPpUSQrFK7quHlbczE57YGPwoAtoAVLHGKjdtpIABJ9aIgxYjqaikDFyCMN70AV7tFK7lbOT0qKONWUjO33NXjCFVScYPamSwERiQf6odfagBsKHBUYb0pYIGBZlHPoaFkKbWGFU9KsRTSEkYBHtQAkQ2btw68596Ch3qV6Vc0+Br24ZCBwM1HKgWZkJ2lTgigASPcemPetDTIWu7qNFHyA81BGqxxjPJNdP4Cs/tWorgAgHpQB7J4QsVs9KjXaAcVtt05FR2cQht0QADAqRSGXKkEUARlDzjj9aQqc81LgiTIOc9Qf6UpQE0AViCOnNSIQSM8U1iFYjPPWgDnnpQBOucc07d2FNX9aPpQA5TycZpT0x2pOe5petACe+MGjnPHNKOeetB9MigBQQOlGOMdKCOP/AK1IDjHr6UAI6gjFU7qASwsrDrV7B5/OopBlTQB4h8Q9JMUjtGQvWvM3jdFPPNey/EuAsrMc9D0rxtWxcMrg7c4oAIlDR5fqenNNCkOQzYUfnVqRQFxGMg9DimtDsAMgPPagCe4M01six/6sDoKoopYhJFIJ6HFW45CsmVYipHuncj5BlR1xQBAgIYLHkg96QoAR3NTmZt4IAHXpSkDYGPU+lAF/wtqc2ka1HNC+0lSD78GisyPAuFOCf/1UUAUvEE3zN5ZLYOSx6mseO4kkcfLjJxWrq0ZkZwec1z8DuJCobPP4UAbiNsk37unQVoRsZCjykMB/BntWKDmQg4xW1okILeZIMgEFQe5oA2NO05Z33SxsVJ+VB/WtuYRR7YUUO23DgdAPal+1mGNEjXaWGXIH3eOBVaSQrEUdAGcff70AY+o2s8eWgDNATgP6Gtiw1w2OnmG9j+XgBj1NQw3Miw+W0imJeMHvWVrdk008k0cwKgdzkA+gFAFq/wBTN1vHEaOMbs9vpUNvpMxiF0Z1HO0Acsfw9Kr6ToNzf7pWcKi8Mzn+VegaZoh/stAQfLXq3QjFAGDoOkmW4ngglDXOzKlhx+FaeqW50O0aSWUNcEZdSASPpXTxTR28Ra0WKOQ4MjgDIFcX4vvofNjdSZpwNo9CPU0AO07ZPabpGlDON4J6Z9q1Jr3YsUcUG63xlnz37muYsfEaxweVcxb1TkAcc1onVoZbRUEJDNyCfSgDN1+H7Wxlg4GeC3BPvWbBFeRXBQA7CueDWzJeo8KIuN4yPm/pVzTYUCFpSWY87iP0oA51A9tIofJJOSO5rookeaFGIIyuAtO+xLLPlhuJOc10FvZbIUG3avJ/GgChbx+XA7dCeOnSo5G59DzWrcRIY2VDkD1+lUjEM9cnPBx04oApSjGRxk5/lTCMux9SRx9KsyIWJA5//VTRHjnHf6Y4oAiCnP8AL8qa/JPp/wDWqYKTjp26/Q0uASPwz+VAFbBLhc8YBH16UbRxjGOOD9KkKtwR1GMDtjpinogCD8McUAMjBwpPqKeiZK8cHH8qcgA4+mfzqRMADA7j8eaACEEYJHPFTRcuyjII2k8e5oUYAOMcf1qXdtyWXGTzj60ARvlQMDjAz9aXqQwbp/jVjywwJ69f50CBSD2YZNADTk57Z7/jVi3LcBT65pUt3bIbBLZHHpUkdvJuIyFU/wAX4UAPa2kkO5eSCT7CodSSG3thKIhLcc8NWnJeQ28GxizrjkDr+dYN7MfLkLSlbVuAy9QT0FAHnGuQoL0yzELIedifzNZpnjb5QeAea6HV7NmLAoyvzjPVhXIzwPHOQq5IODz1oAsM6ozhGJQ8jFRyXUhDxPhoyARxWfLfIGdRjCnAqaeZ2mCnO0gYIoA2PBjLH4z0EKuV/tC3yD2/eLzX1a2SSAduentXyp4OVv8AhNNAJyf9Pt/x/eLX1WsbGQjGT65p9AMzxLdjTfDt3OWAIQgE+pFfMfmtNPJPI2WkJY17x8ZbxrXwu0SnBkIH614NAmCOuMUgHqcU7ZuyTjApqqS2ByKe5IJB7UARSSLFKjqcA0sysziTggmopIHmTcVPB6irVt8rIkn3G6mgBk8ZMSsrZPpS2iOYHib5Q/TNT3sLQnMR3RdjVZTIUVyxOD3oAp3EDxSbZDyOlWYMYBUHjrWpexDUbVJ4lHmxjDACstQyjnII7UAdF4XjhfUVZsjPy1W8Q2iwarMobIzmofDd48er26dUZwCK6/x/obR3kVxGMRyqPwoA46Rj+7HRAM13HwpIbUDkd+tcffwmKKND94jmui+HFyLfVlTsSKAPfgPlzTtuMUyE7olYdxmnFmHPX2oAaTg80/coVmJ4xzTj+9X5V57/AFqZIVjj3ScY6UAU2GRnHzEdahBO4ilnWK6EkbgsjDBwcd6kIX68UAKv+ead3pFJxz+FOz/KgAGDnvS565zSD+dB6jvQAo6+tHUZpAeM5xQOaADNLjB9/rQDignBzQAfjTX9c9BTwenpTZeFNAHnPxCTdbue2DXh0sP+lsVbvXu3jhx9ncE9ia8PmUfbJSCevSgCfSovNulUgFM8mpNWdXuSsY+VeFrQ0O0IhmuF644FEViscL3V6wB/hX1oAwWTABB5pFbbnPepZsTOWA79BT2tnIDHAXvmgCEE5UgZqfBMYZ2C+3rSIVQbUcng5quPTJIIzzQBPC6mZVA49aKbAFEqMc5NFAFLUBtc8HniuYulK3JxgAnJNdTqyEM+c4yQO1c3cxFpRtBwCMj2oAuaehaYySDKZwB6mumtbxVTIULtPGB0Nc5EpLlACB2Fb2k2LynzZsiFO/8AhQB3Ok6ZcazaxXDEIwGGOcE/hT5dHigDJcB8R9Nx5zWZo2tTwhxaRnyoxg7/AOI1r6nq1va2S3+pZd+DHEv/AC09j9KAMPVdEmeLdbvDFGvPzHv7VV0nTbcMxuLnft/hH8Rrmdc8R3N7fPI8gihP3IweEHpTtN1MKwIYMF9fWgDt2t3tHR4JCF7A/NgVsW+uSQ6fMs4WQYyWBxiuKXVTPGNxPHbvUbyXLqwwyq/HPTFAGxc62UQpHysnUt/hWBqV0JJy5O9SMZFZl7cJHJ5KO0hHUgYp8EsQtggGZc8jNACK5ll3uSI+hz3rRbUobY7Ryyjg1nS7yrbVYN2GKpyJPI+1oyWPoKANWG8E03mOeN3GD0rp7DU47ZAjOCDxXIWlpcYB2BMjGWOK1LCyUgLkyODnjpQB19re/vN0aZZv+WjdB+FbpuZJolG/kD6VkWdk00S+UDleOnFaZiKBUfGf6+lADI3fftJ4PHP0pxXOOmc9qVFPmAHkZ6/hVhk5B/hwM+lAFDy8EHoeO/tTduCAM4JGauAcgYB6VGUIC8cjGMUAVUXJBwe3b600LjHHYVa8v5lI4HHA+tMKHgE+nb3oAqxplxnA6YzzjmpCAQoA+6MAHqeTUnlnBwvHXOenNOEXp9P1oAgCYyDgD/69PVcj25P61OYxg568/jSrGA7EkkHPXoPpQBGY/lOR6mnMu523HrnOPwqdlCoSxznNRowySy8HOM/SgCVR5Yz2OauRqrjPBz1/KqAmG0A9BzRFMUUt2PbrmgDajEYPJG71H0qnczjeAXCLnKkHORWY1+VI3Ek8YPpUE8plwd2A3X60AJeSyxK535DH72MjFZRutrI3mOVYYI6A1d+0tC4IwSvG1hkGsa9RN/mIzKCc4HIFAD7x47mSNoHYE/w9siud8YQos4aGExGRc4Uk/WtzTZEtzJKpEjqMAdBUE9g13ayTNuyx4GM8elAHl9zbMsZKHnPTOcVJFP5V4rOcggAg9K39c0cWTrGMyIzAll+XFZNxaxCSZZVYgfckH+FAHVeBHjm8XaEuQGGoW+Of+mi19jfYQlshIG489Oa+J/hmsY+Ifh1X3Kf7StgPQ5lWvu6fDSwxgYGc4xT6AeAftBkwS2VoB/CWOa8bh5YoBzjvXrX7REwl8SQqq9ExXlEK8/0pATWykYAPNQXWVl4GB60+MkDAzn1pd5faj9OxxQAy2aVXwrYHf0qfYiklmBPoKgkeRH2hSF9aidST94jvxQBoWrrHIY5T+6boG9adqNr9lVMEMj8gjpVEuRhmXK1vaCtvqOLd22nsCeKAMi2ujbXCsv8Aq/4l9ak1iJGCzRALE3PArc/4Q2eaSRY5owCeOasDwteW0f2e5RmjIyZcjC+3rQBx8MyWrxvHncp3Aiu/TXH1zSBaSgl9oCsRnpXKal4fubc/IN6+3Wuh+Hdu0100M64Zfug0ASW2iSXtnu2HcBgnHesKzlbTdTXIMZR+fevTIb1LbU3t0+RM/Mtc9440aNohe2vUnJANAHq/hi+F5pMMm7PFbSyY9CTXnvwyvluNFWMMdycGu4hkydvegC2krGUdAB1xV24mWaDBQHHWqUaqp5OTTfNKytszt9KAGyjg+WMewpi7gBwDzz/jQzsWI/Km/NnGaAJR6UtRAZySR9KeM96AHfhQ5IUkAsQPujvQKUdenFADfQnjilHfOKU/lQOuRQADtijPPPSlIPGeaOv1oAB0qK7aQQnySit6uCf61L+ZqpqT7YG20AedeOZWFswLKzY5wMCvIx+8vCvUsccCvSvGTNMxjGMn0qp4S8IwM5vdRk8tByoY0AYFo/8AZunN5mN7fdGK53U7qa5lHmkqPSvTL3Q7Oe7MrToIE5z61yfiKLT5pttu4DLxkdKAOVg+UtsPPrT1eQ5DHPbFTXEHkodjBjjk5qpbthzuJzQBNbQSzzEIMmpHgeAjchLEduabHNJG/wC7cqPapvNklQYkYY75oArRmV5gT154oqXzQJVGSTzz60UAW9fihWZgucseSKzLDRWuWIijdjnrivU4/Adxeak88qubZTuzj73oK6/R/BSRTofLZfQY6UAePad4WlJczx7QpwM9Sa6nTPB1xNFsiYo7HkEcfSvWD4YXe4EeAe4FbFho/kqAkZIx1NAHnGneAQkQSUfKOSF6E1ei8GWr3KC7tVlh6bW7e9eo21lIFwVHPc1djsVwC4UEelAHjd18KtHuLlzNYoUY5HtUa/A7RZ1JiWeFj/ErcD8K9vEMSc7RkdzQ8wGcDp3oA8DvvgfcxjGk3rFx0aVcAVkyfCPxFb3EatK11GQQxTp+tfRbXZzjpTPtBLDP6UAfMF38KdZjuSF06WXJwSSDkfhWnZ/DPULaBS1mqO3OCnSvo1rkYOapzzhjmgDxuz8C7BtvZjtPVYohx7ZPWoZvAdqZCWuJiOi8BeK9cnkByMA+9ULgK3JAJ7cUAecQeANKRt7xtI3+0x5rWi8PaZp8bLbW0QZlwTjmuhmDBm2n5TxiqE6McegOaAMS6tFSI+UAqrzgd/asqaLuynNdDcRMWB4+n4VSltznpwfXpQBiiPIHyt64qbYWwGHPHWr32dupyOmKVYSMDbxxQBnGLBHrxULRY6/njrzWq8WGOcDpz+NQSwuYCqP5cmfvFc9+eKAKPlnjAxgZ/Wk8s5OOwyfzrQeFduQTx2x059aa8f3gQe9AFAx5BwpJ570LGTuGPX61c8ng44PNKYwA3oM9aAKxiODkDPJqOQEE9s9vwrRCBV7Afn2qOWAsu4DJ4/lQBkzMNwU9D1x9Kg34HUgcVoNZneB360i2BbHHORQBnoWPOc5pFkEaKufYtWh/Zm7hhhe3qafLowcgKSBxgUAYksikDaSwI5pI4pniYoGwa6SDQlDENg8cZrcsdJSMKBz1GCKAODh02+uo12xcj7rMP0Naen+Dry5DC5ZEDZzz09q9Ct9MEZJQAk9sYrRt7ZTzt6HrQBxFt4GtrREIcPgfN8uc+1atj4d06NgjqQpOR7GuwW3LKAfxx0xTTp6sNyk7j7UAYd1oOj3kDQXlhBMh7lcEfQ1wfiP4LWVzK8ug3TQd/Kc7h+Br1yOzKjbgk8YqUWzK7bOPUUAfPOkeAtR0Lxv4fkkRGt4tRt3aTHpIua+n7y58maR2yoROD61mPaqQjyKGKMH57EciqHi288vT7mTJAVTn3p30sB8+fFbUP7Q8TyHJIX361yKAZ/DvVnV52udTnlyWyx6mqiEl/m4pASRNtY9xQ8gEgIRfypoBZgB2pCpcE5wfWgB0ly0mAUBHTgU9bKWZAYgSe4FRGORwBGQMdanhlmgH+tKEnHBoAjWIIDHcsfpUYuFtZ1a2RgwPBrZhnsZmQXH3/wC/irE2nWjDdZTpJIf0oAmvtVuRp8U9vJ5cwHzYpum+Nbtj5V6RInTpWaI54VdblDtPfrWezxISV27h7UAd5PqMD24nhHI5KmtbwjrejzyjftguzwM8A155p+spHbPFMgYHgH0rOcZuBLGxXB3AigD1TxaJIWM8EWZO5HcVz8niAPaG3uvlOOhqhZ+MHGIr7Lx9Aalv7nRLm0eaRC0vGNpxigDU+HGrm11eSLcEt2/KvZY5QFDJznnjvXzcl/DbSr9jOzPOc17X4C1NtT0cb33OmATQB16OSAaeTyMVFGvAAqZVHHHNACY/OlAyf6U4dOaXAA5GKAGgD04pevQUp5pOh78UAHvilHWk+vWjoetAC9sjpR1NB70gzk0AOFLntTC3agke4oAJHVELHtXIeItYMIYBlOfuqe3+NaniTUUtrVxntzXjXiLWy0/ysT6UAbI1Gwlu2e9ch88c1heJfEEksrQWpPlJwMGsC8uVmAkIIbHaqoYynk496ANCa9u5rUMZWaPoR6VmOxPUkGpJZHRQgb5PSolfcSXIIFACqGYhe5q4ukTBGkI2xjuTwKr3Uj3TKUQJgcEUi3srRG3uJGKtwMnpQBYS1iVcvOpPoDVcvHtMYbA7mo4I2S5KMTg9+1SHT5DJkFcEdc8UAMgiDzgB1x70VOLZI2X96rP6A0UAfYFtYlbfHvnbjpVqC2KyKXU4B79v8a0wgBBOMjjNRhTuGcdeaAKs8Y3MAOM+tWoYguKikjBnDADj9KtdOlACH5QMUxn4PNObmoyOP8aAI3c+5zmqzDk88VZccE5NQsuDQBC2fXmoyDz74qcg54qFgeg6cUAVpCzAdagYHjGef8atuMAHDdunWotp6tn6enNAFYxE5yPwqCWInt68VcZeckHODio3Q47d+TQBnSw5zyOpxVdoBznB7mtN1Jz7ZqCSFyQVxgHoeh4oAyZLYduR7/Sq72qjaCuc9q2JYyZSNhxxyeh4qFkAIUjPSgDGa1HYccVG1uAFxnBxn861jCT2weP51G0OByMgDp360AZTwKc8cgc/nURtlCYx/nNanlkLwuD/APXpJIgvG3sR9OaAMs24KkYPfIpGgA3EL61ptDyfTnj8qbJDkHI6560AZghGDxk8/wAqeIAT93nPTHtV/wAg7QMd+fyoSIZGehxzjpxQBQ8oAjIwM9fwpBEDg9Mkcj6VoiIFQCMjI6ikFuQwOOuKAM8WyNgFcjjFWI7EEfKB2/nVyK3JA4+Qf41cEYUdun9aAMxNOAIBwDjrirUVjEH+YFsZPPSr4jODjPenrGQDnPf8KAIPssZOfLB69qsRWyAjAH49uKmVCT68nvU2wleOTx+dAEQULjI6nGD34qRMAg4IHpQsZbbjvilCEEH0waALEJI259BxVyHDplT09KqREYJZ8AdTn3qxHICcISQM8CgCyseTx1z/AFp7oSzcDqaVCC688k1KRl3PvQBRuhttnZCeAf5Vxvi6Uy6Fc43Z8s9K7fUE8yzmG5gPLPTvx1rjL+PztLmQn+EjgUAfNLqzTSBcE7jg1GIyH+Y/MOtXboeVqcykfxmklhBbeozkZoApjCLk0ElgMHipHA8slh0qC2cSFwufxoAWRmK7E6+1QmQImCdzjtVpYMnIzuxURjCSZKjnvQAyGV5Sf4R0yKlV/IHDEkfrUUis52LgAHOaROhyefQ0AX31e4ZBG43BxgcZx9ax5N7Mxzg1c2FTuByKkQqHyyg0AZ0bF2AJ+tTmVwcDOOlSyxKmWRMZqHy3lG1OGHP1oAR2bG1h9DU+cQhDwGGaswWFxcxFlib5OpxRe2MkMQebAJHyqOtAFcwqEDq2QK9j+CazNp1wzriIkbT3NeX+D9Ll1bUY4DE3lE/MccYr6T0DSrfStPigtkVVA7DFAGgq4xjrS4paO2KAGpIHBwCMEryMdKeOT15pCMDmkoAXOeBTcHOSaU8deKTcCTQAo60HqT2oyPX9aCR1x0oAAvb+dIeh6UhbAJ5NNMiqMMe/BoAjYnqeKiubnyoy/JIpt7cpDEXbpXnfinxh9lZo4iNxGMA5oAzPHWvO7PGqt3FecuZp5MmNmJ9q077Xri8ny8akA55FQLqk3mfKEUewoAjTTbll+ZSinnmnC3ijGXkyR2FNvr+eQBWkb6CqqwO6bmJxjk0ASzNH2Xmofl/u/hUbHOAp3AdaDkLubgdh60ATRu4TBI2/TmoZlwS3Jx7UscgH3hgCpI1XYZQ2TnoaAEindgqtwvfipGeF8LvkGBg0pKyJvI59qozAldyHtyMUAWhGqXC7SWB9aKfp8gR13KH/AB9qKAPtwIWlySSAfwP/AOqngAH8c18WH9qrxueuleGuP+nef/49R/w1V43/AOgX4b/8B5//AI9QB9pEfMeBzT6+Kv8Ahqnxvkn+y/Df/gPP/wDHqX/hqvxv/wBArw3/AOA8/wD8eoA+0edxGMAAc+tNIyvfHtXxef2qfG5IP9l+G/8AwHn/APj1I37VHjcjA0zw4Ppbz/8Ax6gD7OccHPvUbL8zZFfGp/ao8bn/AJhXhv8A8B5//j1N/wCGpvG3/QL8N/8AgPP/APHqAPskr1H6Y9qhdPm3H2B9K+PP+GpfG3/QL8Ocf9O8/wD8epn/AA1F41x/yDPDv/gPP/8AHqAPsTB7+3So9oz6HH9a+P8A/hqHxocf8Svw5x/07zf/AB6m/wDDT/jT/oF+Hf8AwHn/APjtAH17KNqseTgHAAyTULqdvKnBz+HFfI//AA094z5/4lnh3n/p3m/+O01v2m/GTZzpnh7n/phN/wDHaAPrdk555Az/ACqMpkHvnv8AhXyWf2mfGJOTpnh7P/XCb/47Tf8Ahpbxhj/kGeH/APvxN/8AHaAPq91JwB2A/lURThcrgkAn86+U/wDhpTxh/wBA3w/nj/lhN/8AHab/AMNI+L/+gboH/fib/wCO0AfU5XC7iAFGP50jwlVx+n418rn9o/xcRj+zdAx/1wm9f+utJ/w0b4u76doJ4xzBN/8AHaAPqGceW6Kq7i5I9sA//qpWiyGwO55r5e/4aO8W4IGmeHwD2EE3/wAdpv8Aw0X4tzn+zdB/78Tf/HaAPqJ7cHJ6sM4/KogFeSVI2VpI8bh1AyOK+Yv+Gi/FvP8AxLdB5/6YTemP+etIP2i/FgHGm6AO/FvL/wDHaAPqBI1YLnIOR/KkSHnOM/dPXNfL4/aJ8Wj/AJh2hdQf9RN2/wC2tA/aJ8WA8aboPp/qZv8A47QB9RLDhh1OQD+tL5OAOMgdPzr5d/4aL8Wcf8S3QeP+mE3/AMdo/wCGivFn/QO0H/vxN6/9daAPqYJglf7o5/OpUi++Tgn5uSfocV8qD9ovxaGJGnaDyMH9xN/8dp5/aO8XY/5BugD/ALYTf/HaAPq/y/mOB1yKVEDPtAO7r+lfKA/aQ8Xg5/s3QCf+uE3/AMdpf+GkvF/GdN0A4wf9RN/8doA+s1Q54xjIwM+1ORX4BIyCOfUV8lj9pPxgCpGm6AMf9MJv/jtIn7SPi5MY0zw/kdzBMe+f+etAH10qEAfLjp/OnCIkk57Gvkj/AIaY8Y4/5Bnh7/wHm/8AjtOH7TXjIAj+zPD3OetvN/8AHaAPq24RyxABzycVbgj2qSRj9a+Rh+0z4wzk6V4dP/bvN/8AHaf/AMNPeM8g/wBmeHeD/wA+83/x2gD7FgyXQHGMjvzU4UNnI6kHivjVP2oPGikFdL8OZGMf6NN/8dp3/DUfjXGP7M8Of+A83/x2gD7EvV/0OYY/gIrkghaGRCAOozXz74V/aO8Xa74o0bSbvTtAS2v7yG1kaOCYMqySKpKkykZwe4NfRlvCWeXgEcnNAHzl4msmttcukPXdmqTsqoAFwxHJruPixpxtdciuGwFlXsPSuJZ9wK44x2oAo7k2spbPvUEaqrkipjECckYoMQHLHkdKAEVx2GD7VWmVt+AflqWTcpAXHuc0mN7cnFAEHTIJwTUiwAR53VK8SFshiVpsIYOV/gJoANu1MA9amiRNgYkbjUtpZvPNsUZHrXXaH4PhmKtcSHH05GaAOM+aS3cKBuzxx2pbO3kZ1G0g5r2rT/B+lW9qzKFJ7sx5rHv9K02N2VX6cjAoAfolin9jvFEAZ3H3veufTwZq9xeSS3EYMceWJz1HpVm3vp4LnydORy/ckHArrfDfiW8nma2uNjkDqKAOf+G90+pa9cW/9n+RbW+VDkYJNevhQAMdqwdL1OyUM5jjh55YcZq5ca9plum5rmP6ZFAGmRz3pG49a5aXxzpIuBEkoZj6dqfeeK7OKMuJU6Z60AdMJF6MR09aRmUH29q8P8T+Mrq7nK2kpSMHgiu0+GniKXVbVre7IaaPv60Ad0WHHvRnnGOnrRnnpxQemaAE3Ypkkyg7TnJGenH507aSO2PemPGxHBFADCWc/LwOn0psULPtYnHPIYc1IH2KcgCnearR5zx70AYvipQdIkZNwYDgV4RqttcG4MkyMT1FfRcywyxfviClcXr2p6LbpKssQZlHBAoA8Y3uN2I+2Oa07PSory0LJIqTLzjNSarcxXc7/ZlCxnkDpT/D1n507LI7Rr/EfagDHvf3ZWLb8y9Wx1oiif7K4Y5PYe1dqkVhqMDLp8Mks0B2tuHWtnw34HN/N9quT5aAcJjHNAHlawLFGXkzu7KKAzbdzKAg6Zrt/F3hx7DUTGisy+uOK5a7jEUmGwVXotAGa4LL06+lMG5V9jxVtczHdjoeFAp4hxJvmJA9KAKsbbXCsODStCRgnkGrC7GlZlXDe4yKpyhmYFSc59KALFvGqugXvyaKbEDDcqJTkEZB/CigDwyiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA6T4a/8AJRvCv/YVtf8A0ctfoNoaJLM6Nxle/avz4+G3HxE8LEDJ/tW14/7bLX39pc7R3aPJhcHBQHPH1oA574y+HjfeGhd26Dzbb72RzjNfO6zsjkbTnmvs68t47qOe2lVWjnjIAPTpXyd4v0p9H8SXto4CmJyAPWgDnlLyj5aR1eQ4BBIoYvF8x79KbbZl3hFYkc8UAVxnJyx4qa3t3cMSR04NRkNvKkY9qmVXA4Bx3AoAekLxwEHnPJIp1ukbA+YcKKs2W9SRtJUjBB6Vcj0V9rOxWNTyATQBVstU+yS4gi3YPeui0jVLy/nCW+5Dn5vasvT9Iea52qCw6cV11zHa+HNNORm4cc57UAT694hj0m1jhUNLOw5+aqfhJYta1L967DvjPSvPtR1Ga8nZu2a6v4aI6akkwdto6jNAHpPiWwS0snttIgVLmQY345/OuL8O2lxo97dfaSWmcfePb1r1t5bZwJs/MO57VwnjMG2tpZlKB5M49aAOE8SazN5DQQSsp3cmuWknnZhvmdl+tWZTLJFISvR+aW20uaY5UgZ6A0AVYTkk8lx0NXIrmZikcyu6N/Fn7tXbi2g0yJGf57huqjpWVc3DtJ0wD2HagB9yAr7UDYJ611Hw51Eadr0e9sK/y/nXO28f2lUjDHzM4AzXeeGvAFxeLDdSzeVGp3AjqaAPXi64DZGMZpFfeu7oKzVheFFiZs7BgE81oW3+rX9aAJgfUcClB+lJzyOM0Z9aAEkQOpBA9K4rxRqslpLHa2z/ALw/OR9O1duucZ5rzzxaEPiCPywDJg5A7UAJb63cz6bISjZj4zXOa1pR/s5ppC7GX5jkdK07OZ0mkRBkMeR2rvYLOK60oJKqMCuMjmgDwvT7SDJY9F9RXV6Kliqb1Q7/AEx1q8nhKWK5uflLRsx2mmWmmNZzvE6FVHIY0Ab+kRFJN1nHHGr/AHsKOa6ZI5Ios5Cey1wwvv7PBl80eSn3iD0q1b+N7a+2wRbiD/EBQBa8W6TdavpsqxSbJCOD3NeOXeiX1k0n2lGLg4yR1r3uC7ZoVDqGDdCKrX9vayIFuYixxxxmgDxGyjjs7UyTJukbopHSs2VmnYtggV7p/wAIvY38e5W2/Va5LXvCps2YworDrnPagDz6JwYFSRQqqfvDqaiiWOcmOM7MnqTV6/spopiMcVkvbSJ1BB60ASC3drld53bcgUVf0+25BdwHbtn2ooA+e6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDpPht/wAlF8K8Z/4mtr/6OWvvSPkbj35H0r4K+G5x8RPCx/6itr0/67LX3sjdiBntj0oA6i0m+06dHMp/eJwcV4r8btKzqCahGAPMGHx616jot39nuHhkI8qT+dc38SLE3ukSrtztBxigD5y3+XCdxDE9qWC7lTm3VVJ4pJ4SszKw6cUpkSABVHzkdaAJ5LkxANJCrSHkn0pn9pScFEVTVSRmfbuFXLGz81l3sqJ1JNAFrTfNmkaWVtsa8/Wqt1eT3t3tiLYzhQD1q3qk8caLZxg4Hcd62vCllZWim6uPmcDIHpQBqaQ8egWHmzAvMRna3Y1yOv6tPqk7ySnBJwFzwBV/xNqX2h5dv3c/KK5qIh1beec0AVkzv5B9K6Dw3qjaXMWUEk8bayEDo4aNQ7HgVu6ZpaWi/a75gxYZC0AdppniWaCM3GpfLF2TPeud8day+pJDLCMRsTgA1gazeSXMrfOFjXsPWppl83SoSGzszQBXsZ9qyiQDkdqsGV5bYNGTuTvWfbyAOcjJIwc1LBKYzt6pnBFAEpl+0RlZDlhzz1qJ7YsA25cUXCeXIRjaD0x6V13gDw4dZulknB8pD09aADwd4Ymv5o5FVljGMuRXt2lWEsdqkKJkKOK0dC0a2tLdAI1WNQMCtZpNq4TAHtQBitpErgsynPpmq/2V7clW6HtW95mDySfxp7mKYbJFDf0oA53II96OgzVvUbB7cmSM7ov5VmGSVgdke7HYdaAJ3kEaMSenOM15dfzG5124uS3CnC4Paus8T6rHa2BKv80owg7153DONxUt8pOSTQB1OntFNC+Fwc/e9aTVtcutGNpFbI0sCjLqBz1rEtL6aS7EEDHZ6eprv9A0v5TLfKHkYcg0AS22uR3ENq6RYSQfNnjbR4gQNZiaFFfHJwMmm+IbGKLTmNviLbzgVhWWq3CIsaBnXvnmgBLObT9RDWd5ZFfM4JA606bwPpmnqZrQsrdgTxW9bRiWFZIoFWQ85Iq+LeSSMCYhsjkUAcpaxSiNNu8qmfxrXiBubcGZSjLwCe9a1vaiI7QBsqZokJAKgrQBiLchImEbLnp9K5+8W+mmfb91e5HWuo/saJJmk3HZnO3NKTCpZCoDNwBQB5Vr9k7gSYBYdgK5doZHGXXHbFeteILJIYiwTHNctpmmmV285Mr1BoA5CytHF4vmLwQSM/SivR7PRIjeKrLng8fhRQB8VUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHR/Dfj4ieFv8AsK2v/o5a+9EOBgYHsO9fBfw3GfiH4XH/AFFbX/0ctfdqv5Tc7voewoAWYnzODtVSDkVPdEXtkyONx24x+FVpnDH5efx6VNaNkkr1I5NAHgni3TZLHUJBs+Ung1zipu+8Pm9a9h+IOl+dCZo1JYDpXks0TiQhs7iei0AJEixxh2GT2GKAzTTqG6+gFRu2HA59KnQrFH5xzycCgCPcHmLseRx0rT0uVn8x2J8tRWTAAQ3qTxV66LWlgkS/ec5Yj0oAr3QWSQ5JAPIFV/JU58w8D070M58oA4yOntU9jFl98hyg5xQBq6SlraW7zzoxbtVI3Et/d7mBCD7op0l39oYqqHylHTPWnW8qw3A4Bz0FAGfqNsUZW/hbqRS282bcxL0B71ua4sI01Ai4c9ya5iHJkwDt+tAFoxkHIAKjk+oplwQZlKYCnFT2oDXIjL/e4602SLYWjduVPGKAJEO87ZBnA4r3H4UWqjTFx0LeleM6VaveXMSR9R3r6F8C2n2CzghJ+brQB1sx2KFXpVY59cGrFzknkVBtBYdM9M+1AA1AwCexpVGeKVlwQOAKAJ4SJYmjk5BFc1qCvZzyf3RzW+hw4xWV4lQSOV6blxmgDw/xlqp1DVZJB8qxnaoXv71jBxJF8oww5J9ava3o8sOrXELEqS25feq9vp10dwl79TjHFAHT+Bkj+1iVmG4DgV6RdXnl27bMA4615HYpcWigW4YOOd3rXVafqkjWqiZSzL1zQBoX8VxfIPNmAB+6PWrOh6LNbzq/Aixgg96uaUIrt1kCYAHSt1RtGMce1ADVjUckfSpCc0maQnnA6UAL2xSZwOtJgjvQeB7CgBDyeeapNZb7kSueFOQPeruO9L3oAydWtvtcRRQu8HoRWFHpq27hpDlyOgrdunU35VGw+Ofes66mVpUiU/OeDnrQBPpFuJbgy+nHNFadhF5IReSxHJ7CigD87qKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDo/hv/wAlD8L5/wCgra/+jlr7uuF3JySD0HevhH4bkD4ieFien9q2v/o5a+8RhnBX0yeOooAzwwU88HoeKtWb/Oe3XvRcRbn3IQSOCO4qKLKyHI6DNADtXsVurRhjnH41494n0drOV2jX9K9utmEsSnk8YrG8RaNFqFtIB97FAHz8kROTJnNOb96gjwcVu69o8tncMmw9etZGTGPujI55oAkgto4U8xztHb1zVOaYyyNuPynoKkZt8WJCeeRS29uJJQucqeuaAI7O1aV9xz5Y6mnzyqA0UXyrnGT3qa7uAgNvBgIOCfWoLS0W5lVVP4GgCWzRoyzOCFHX3qO2zcXm1QcZ4HtVq+Koxt42DqnBI9fSrWhxxwsZ5QASMDigA1+dHijiiXJUcn3rnvmY4xzV+6f99ISeCetVwFMq4HHrigBLOMfaYznGDyTV67UfaXBAzjI96f8AZjJ80JyPQ1ahsmlm3S9sUAdV8LNPim1AmZVOBnFe3xWBtGikRTtNeffCTRJDe/anjCwqvOehr1jz9+9ABsHSgCO4TeAyjIqDy8Cr0aLjK8k9aScpBFvlwFFAFEdeKQrkgetQSamm/CoCp745q3aTxTrhSMjtQAiR45I4qrf2T3T7kHatJFYE7gNo5qPzlLko/CelAHmvinRkEgnkiPnJwRXOxaZNOxkiwVBwVavX9T08ajAzJzKOcHvXnurXbaQ+0x7TnldpFAEVvpqHjYV4x06Vf07SIyxzyvpim6drEV5Eo+6x7ZrbsSojwMZoAlt4EhXEahQKmGfXFGO4ORR0x3oAXt1xQPY849KARRnigAxwKMDvzSmk/EUAMKgsGIG4cA+lKxAGeaU4xzTWOVIGKAMe82rcNIQS+DxUOmWQmcXEyfMR371sw2qvKGYZ4PWpTtCgYAAoAiVdj4J4HSio7h1JHPIooA/OuiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA6H4eHHj/wyfTU7b/0atfdVtcEqRxgdQf6V8K/Dv8A5KB4Zzn/AJClr0/66rX2/t2P38sHgdMUAa8bbs7du0gEY6n1zTjbhyWTHIqnbzkD5iCpq/A25htOOPz9qAKMTtA/zZ960UQTRZU9ajaMSLhwAf5Ulsz2rLn5lz27CgDC8SaELvJ8skkfeGMV5bq/hueC4Z2BKr0wK+hUiWZS8ah1b73PSs2/0KK8VtignHTFAHzlNpjqQSG54xinmJooCkUZ3t8ua9b1Tw1LFITHGGx2IxXPz6IYiztbsJDwTigDgv7NkKbnwDj86mgtjboWK/NjjFdTLpitKXlYgf3emKhewTJZj+7FAHGxxOkpMmSCe1TzeYJUUA7a6cWMLKGUZ5xT5rGB0UICZKAOdfTi4BjO49KltdGlcjeuAK6Ozsdnyqpye9dJo/h66u2HlQsw/SgDlrLTUQ7ETLmu18M+BnvnSS6GyAHJNdbo/hWysGE2oMpl/uA5rojPvAitkAToAKAIreCCxtEtLBdsa9x1NNncW/7uLLSt19qsXIFnbhicyscAVmQP/pSyMN3PNAG7p8ckdsom+/Wb4lLhYj/BW0jB0DDoRUdxHFcI0MuDxyPSgDjARj+lWtLLG9RY+SahvbZre+FrG28uflI9Peui021hsEUysn2hupz+lAF+WLfCyA4yMZrlJ/tFldEBSwJ+bmuv4NYOtFZJvl6gYJxQAunXaSnCna/oaqa7olrriMrgR3K9Pes9lKOGU4YV0W0XdlHNFxIo5x1oA8mvfD9zo960sgPlg9K6DTrxJIlZhsHTnv712ckkVxCYNRjDp0BxzWBd+E23+dpc+9AP9WTzQAsGGXKnINSnI7Y71W8uWzAWeN0wOcin/aEYHaRnFAE59hilGT9PWqMt0EH3hUB1HGNpDk9qANIrg5/i6ZpJHCDNZ8d+zykbCPbFXEjLqC2RnmgBwbcOacF56mpooGcDYpPvVhbcd8k0AV4lJbjsKp3MvlqBnnuK0LiVYTsBy/NZYhaVtzmgCuoZ3B596K0YgsbAcCigD846KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDT8L3L2XiXSbqP78F3DKuPVXBH8q+yvBnjjT/EkCwzN5N2AAVf+Kvi/REMms2CKMlriMD/voV6NF9qsJg8TOkingjg0AfWrwGIcZIPIyc0+3lKtz1xXh/hT4rXunqsGrx+fD039wK9a8O+KdF19Va2nRJGHKE4OaAN+G5BIycjvxVgsHHykZ96oPbEAFSCp6Ec0xJWVuTz6UAa9rO9rKGj+7nBHrW7bSwXwzCfLmHJWuXhuQRtbipweQ8bbWHQigDpZYVZSl3HuHQOOtU5dFil5t5VIPZhmobDW5VJjvY96joy9fxrWhktLkAxuAfTODQBzF54U84ndbpn1Q1k3HgVnUrGpUHqDXoyxuvSU49xmnYkx94flQB5jF8PrngZQDPc1pW/gFRzPMqgdwM13JDfxTYHsMVE81sn35QT9c0AYNn4a0uwIYo08grVAl2bLaIRJ22jFE+qQorCJSSOhxVCXWLlztRQlAFr7AQxedwPcmrEdxbW67YPnb2rAnle4bMrMx7ZpkLyRNuTjFAGvdK8nMrZYnp6CqEjeSM8cdaha4nkLbjgHvUbA7uST2zQBKmpXETggttz0BrbgeO+jEi7tx4IzzXPhR1PSprK4a0nSRc7ScMPagDdOmWpcSHcXXgHPIqGWGGEGRxgDuTWgVMkqsv3GGc1zWu3r3V4beL/VRnGR3oAS41KWSTELME+tSQz+auJPv1Qji24LH8KmXOTxj0NAE8sRB+fgU63vWsWJX5l7ioHeQgDfx6EVHtaQHOB+FAG1HfWd6BvzFJ644qzHaMvNtMv1BrnRFtHHFKjyxENFMyn0FAHVDeV23EQcd+M1Vk03TZGy0Kgn6iqdvqtwgAk2yD6YNWxqsD8SRkfrQBWl8PadMpALAegao08MWkf+rcj0zWgLuwbqQv4UpubIYIkHHXrQBUXQreP5mlP1xUgtLSEfIhkb1NWXvLNF/wBYM/TNU5NXjiULEpkbH32wP5UAPktjJG3nBVgxyG6VmXeoJzHajIHBeoby9uLtsSPhPQdKpSSrECqDmgCRFCSb5HJJz15zUD3AHC4wagEzM/XmkS3d13HhcdTQAeazSdcj3oqte3+m6Woe9uo1HTG7migD8/KKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigC7ozMusWLR/fE8ZX67hXpdtqsxULewrMh/i4yBRRQBfhs4L1MwJgns3HNRjTr2ymL2jtGw6bXxzRRQB0nh74j+IdHdFuGNxCvBRmFey+DfGOn+LISiwvBdrwykZH50UUAb08DW78/d9RUlvKwYYHFFFAGggLLkUoJU9Me9FFAE6yzDpJIMf7VP8ANlb70j/99UUUAIXc92I+tRtyQMc59aKKAEYEHODjHPNGCRxRRQBQ1vUV0q2tp3ieUTXUVoFUgYMhI3c+mK0ChVmHocUUUAIVJ/8A10mCOccHpRRQA0kDJIwKUJzjs1FFAGxY30smgNI8flTqCm3dnp71jRw7V3EAluc0UUACKT1FP25JIz9PSiigBcH047HNABODiiigAKtnBFAQht3bFFFACnPpzSEHr2xRRQAHIOMYpvO/aB70UUAQrvYsQSVUldvTBHenMDjL9B6UUUAVp7ggbFXqKgSF5mGAOe9FFAEOq6lZaBbme8yzYOFCk5OK8l13xp4g12cppqraWY4yG5PvRRQByN00YuQ+p3E93MScgk4BooooA//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph and CT scans demonstrate bilateral nodules and masses, most prominent at the bases.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_20_25926=[""].join("\n");
var outline_f25_20_25926=null;
var title_f25_20_25927="Acquired C1 inhibitor deficiency: Management and prognosis";
var content_f25_20_25927=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acquired C1 inhibitor deficiency: Management and prognosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/20/25927/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/20/25927/contributors\">",
"     Marco Cicardi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/20/25927/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/20/25927/contributors\">",
"     Sarbjit Saini, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/20/25927/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/20/25927/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/20/25927/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquired deficiency of C1 inhibitor, also called acquired angioedema (AAE), is a rare syndrome of recurrent episodes of angioedema, without urticaria, which is associated with B cell lymphoproliferative disorders in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25927/abstract/1\">",
"     1",
"    </a>",
"    ]. Angioedema typically affects the skin or mucosal tissues of the upper respiratory and gastrointestinal tracts. The swelling is self-limited, although laryngeal involvement may cause fatal asphyxiation. Clinically, this disorder is very similar to hereditary angioedema (HAE), although AAE develops in older patients and is associated with underlying disease, whereas HAE presents in younger patients who are otherwise healthy.",
"   </p>",
"   <p>",
"    This topic review will discuss the management and prognosis of acquired C1 inhibitor deficiency. The clinical manifestations, epidemiology, pathogenesis, and diagnosis of this disorder are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/12/26824?source=see_link\">",
"     \"Acquired C1 inhibitor deficiency: Clinical manifestations, epidemiology, pathogenesis, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hereditary angioedema, which is caused by mutations in the gene for C1-INH, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33864?source=see_link\">",
"     \"Hereditary angioedema: Pathogenesis and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19272?source=see_link\">",
"     \"Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33657?source=see_link\">",
"     \"Hereditary angioedema: Treatment of acute attacks\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29658?source=see_link\">",
"     \"Hereditary angioedema: Prevention of attacks\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ACUTE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of a patient with AAE involves several components.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Educating the patient about the potential characteristics of angioedema attacks and ensuring that the patient understands there is a real risk of fatal asphyxiation with attacks involving the upper airway.",
"     </li>",
"     <li>",
"      Providing the patient with written instructions about treatment of acute attacks, which can be given to other providers in the emergency setting.",
"     </li>",
"     <li>",
"      Management of associated diseases, if present, or monitoring for the development of an associated disease.",
"     </li>",
"     <li>",
"      Evaluating the need for prophylaxis to prevent angioedema attacks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Patient education about laryngeal edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with AAE must understand what steps to take to get prompt and appropriate treatment in case of angioedema involving the upper airway. Patients should",
"    <strong>",
"     not",
"    </strong>",
"    attempt to manage early laryngeal attacks at home. Instead, they should be taken by ambulance to the nearest emergency department. If therapy is available for self injection it can be initiated, but should not substitute for obtaining emergency care nor delay the acquisition of emergency care.",
"   </p>",
"   <p>",
"    AAE is a rare disorder, and few emergency department providers are familiar with the treatment. Patients can be equipped with a document that briefly explains the patient's diagnosis, outlines the indicated treatment for acute attacks, and provides contact information for the supervising clinician (",
"    <a class=\"graphic graphic_form graphicRef57664 \" href=\"UTD.htm?0/32/517\">",
"     form 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Laryngeal attacks are the most dangerous type of attack in acquired angioedema because edema can lead to fatal airway obstruction. Upper airway angioedema usually progresses over hours, although it can occur precipitously. Intubation may become very difficult due to distortion of the anatomy of the upper airway.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Airway management in laryngeal edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment and protection of the upper airway is the first and most important management issue in the patient with an acute attack involving any part of the airway, because none of the available therapies, including C1-inhibitor replacement (C1INHRP),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/36/4675?source=see_link\">",
"     icatibant",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/23/23923?source=see_link\">",
"     ecallantide",
"    </a>",
"    , can be considered universally effective in all cases. In addition, these agents take time to work, and the patient's airway must be protected in the interim.",
"   </p>",
"   <p>",
"    Intubation should be performed immediately if stridor or signs of respiratory arrest are present. A clinician trained in difficult airway management should be summoned if possible, because failed attempts can lead to fatal obstruction. Emergent cricothyroidotomy may be required in rare cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18552?source=see_link\">",
"     \"The difficult airway in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4905?source=see_link\">",
"     \"Emergent surgical cricothyrotomy (cricothyroidotomy)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once the patient is assessed and either intubated or deemed stable, additional therapies can be considered. Transfer to the intensive care unit should be arranged. Frequent and meticulous monitoring of airway status should continue throughout the course of the attack until complete resolution, and patients should not be discharged until all airway symptoms have resolved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Pharmacologic treatment of acute attacks",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of acquired angioedema (AAE) is extrapolated from that of hereditary angioedema (HAE). No controlled studies have been performed in patients with AAE and no therapies are specifically registered for treatment of this condition. Based on clinical experience, there appears to be some differences in the response of these two disorders to the available therapies, as discussed in this section. The safety, efficacy, and administration of each agent (in HAE) are reviewed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33657?source=see_link\">",
"     \"Hereditary angioedema: Treatment of acute attacks\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     C1 inhibitor concentrate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most widely used therapy for acute laryngeal edema is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/57/23444?source=see_link\">",
"     C1 inhibitor concentrate",
"    </a>",
"    (C1INHRP). C1INHRP became available in the United States in 2009, but has been available in Europe for decades. Clinical experience indicates that C1INHRP is effective in the majority of patients with AAE.",
"   </p>",
"   <p>",
"    An initial dose of 20",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    is suggested, based on data in patients with HAE. The dosing, administration, and adverse effects of C1INHRP are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33657?source=see_link&amp;anchor=H2#H2\">",
"     \"Hereditary angioedema: Treatment of acute attacks\", section on 'Medication options'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3419210\">",
"    <span class=\"h4\">",
"     Resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small percentage of patients with AAE become less responsive to C1INHRP over time, requiring higher doses to control symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25927/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. As an example, one of our patients required multiple infusions totaling 12,000 units of C1INHRP (the usual initial dose is 1000 units) over a period of two hours to control laryngeal edema. If a patient with AAE fails to improve after an initial dose of C1INHRP, we would suggest administering one of the newer agents discussed below as the next intervention. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Ecallantide'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H20\">",
"     'Icatibant'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The mechanism by which resistance to C1INHRP develops appears to involve extremely rapid catabolism of the inhibitor protein, although this has not been formally demonstrated. In blood samples collected from the patient described above, no significant increase of C1-INH function could be detected at any point during the multiple infusions, while C1-INH antigen normalized due to the increase in cleaved C1-INH. These data suggest that the infused C1-INH was rapidly bound by the autoantibodies and converted in its cleaved inactive form upon interaction with target proteases. The patient described above had very high levels of anti-C1-INH antibodies.",
"   </p>",
"   <p>",
"    The newer therapies for bradykinin-mediated angioedema,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/23/23923?source=see_link\">",
"     ecallantide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/36/4675?source=see_link\">",
"     icatibant",
"    </a>",
"    , offer alternatives for the treatment of patients who become resistant to C1INHRP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Ecallantide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/23/23923?source=see_link\">",
"     Ecallantide",
"    </a>",
"    (Kalbitor&reg;) is an inhibitor of plasma kallikrein. Kallikrein is the enzyme that releases bradykinin, the mediator of angioedema, from high molecular weight kininogen. Ecallantide is approved by US FDA for acute angioedema attacks in patients with HAE [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25927/abstract/4\">",
"     4",
"    </a>",
"    ]. It is only available in the US (at the time of this update).",
"   </p>",
"   <p>",
"    During the first open label trial we used this drug in two patients with AAE, one of them resistant to C1-INHRP, and observed a prompt resolution of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25927/abstract/5\">",
"     5",
"    </a>",
"    ]. Both patients developed a relapse of angioedema within 12 hours, but the symptoms were mild and resolved spontaneously without need for further treatment.",
"   </p>",
"   <p>",
"    The dosing, administration, and adverse effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/23/23923?source=see_link\">",
"     ecallantide",
"    </a>",
"    are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33657?source=see_link&amp;anchor=H7#H7\">",
"     \"Hereditary angioedema: Treatment of acute attacks\", section on 'Kallikrein inhibitor (US only)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Icatibant",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/36/4675?source=see_link\">",
"     Icatibant",
"    </a>",
"    (Firazyr&reg;) is an antagonist of the B2 bradykinin receptor. This drug has been approved in Europe by the European Medicines Agency (EMA) for treatment of acute attacks of HAE (the same indication as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/23/23923?source=see_link\">",
"     ecallantide",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25927/abstract/6\">",
"     6",
"    </a>",
"    ]. It became available in the United States in 2011.",
"   </p>",
"   <p>",
"    The author has successfully used",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/36/4675?source=see_link\">",
"     icatibant",
"    </a>",
"    to treat several AAE patients who presented with angioedema, including laryngeal edema, some of whom were not responsive to C1-INH [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25927/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The dosing, administration, and adverse effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/36/4675?source=see_link\">",
"     icatibant",
"    </a>",
"    are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33657?source=see_link&amp;anchor=H2297196#H2297196\">",
"     \"Hereditary angioedema: Treatment of acute attacks\", section on 'Bradykinin B2 receptor antagonist'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Plasma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma has been used in the treatment of acute laryngeal attacks and severe abdominal attacks in both AAE and HAE, although the efficacy has not been formally investigated. Where available,",
"    <span class=\"nowrap\">",
"     solvent/detergent",
"    </span>",
"    treated plasma",
"    <span class=\"nowrap\">",
"     (S/D",
"    </span>",
"    plasma) is preferred. If not available, fresh frozen plasma (FFP) may be given. Plasma contains an array of complement components, including C1 inhibitor.",
"   </p>",
"   <p>",
"    Two units is the usual initial dose for treatment of angioedema. This dose can be repeated every two to four hours until there is clinical improvement. Once the attack begins to subside, further plasma is not usually required. If a patient has comorbid conditions that increase the risk for volume overload, then dosing of 10 to 15 mL per kg body weight is recommended instead, with monitoring of volume status and cardiopulmonary function.",
"   </p>",
"   <p>",
"    The administration, infection risks, and adverse effects of plasma are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33657?source=see_link&amp;anchor=H18#H18\">",
"     \"Hereditary angioedema: Treatment of acute attacks\", section on 'Plasma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Antihistamines, glucocorticoids and epinephrine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our and others' experience support the view that antihistamines, corticosteroids, and epinephrine are NOT effective in acute treatment of AAE [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25927/abstract/9\">",
"     9",
"    </a>",
"    ]. There are no trials that directly evaluate the use of these therapies in HAE or AAE. We strongly recommend NOT relying on these drugs to treat angioedema in patients with C1-INH deficiency. In one review of 22 patients, investigators concluded that \"in the acute setting, high dose corticosteroids with or without subcutaneous epinephrine seem to be effective, depending on the severity of symptoms\" [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25927/abstract/10\">",
"     10",
"    </a>",
"    ]. However, they did not provide the data to support statement, and this conclusion is not consistent with our clinical experience. On the other hand, the harm of administering antihistamines, glucocorticoids, and intramuscular epinephrine is probably minimal, and these therapies should be considered if there is any uncertainty about the patient's diagnosis, because allergic forms of angioedema do respond to these therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     LONG-TERM MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term management includes treatment of any associated diseases, monitoring for development of lymphoproliferative disorders, and in some cases, prophylaxis to prevent recurrent angioedema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22581856\">",
"    <span class=\"h2\">",
"     Avoidance of medications that may exacerbate symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications that can increase the frequency",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severity of attacks in AAE include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Estrogen-containing medications, such as hormone replacement therapy and contraceptives [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25927/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       Tamoxifen",
"      </a>",
"      , a selective estrogen receptor modulator (SERM) that has mixed",
"      <span class=\"nowrap\">",
"       agonist/antagonist",
"      </span>",
"      actions on the estrogen receptor. In one reported case, a patient with HAE who developed increased episodes on tamoxifen was successfully treated with the aromatase inhibitor",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/26/36261?source=see_link\">",
"       letrozole",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25927/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Angiotensin-converting enzyme (ACE) inhibitors [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25927/abstract/13\">",
"       13",
"      </a>",
"      ]. In contrast, the experience of the author is that angiotensin II receptor blockers (ARBs) are well-tolerated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Treatment of associated disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of the associated disease in patients with AAE is usually successful in reducing attacks of angioedema, although the degree of improvement is variable. This may be the best initial approach to management, depending upon the nature of the associated condition.",
"   </p>",
"   <p>",
"    There are scattered reports of partial or complete clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    biochemical remission of AAE upon treatment of different associated diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25927/abstract/14-19\">",
"     14-19",
"    </a>",
"    ]. In patients with AAE and lymphoma, a variety of therapies, including surgery, chemotherapy, and biologic agents as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , have been reported to be helpful in reducing episodes of angioedema [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25927/abstract/18,20-22\">",
"     18,20-22",
"    </a>",
"    ]. Responses to treatment range from partial to complete (and apparently stable) remission.",
"   </p>",
"   <p>",
"    Alterations in complement abnormalities are also variable following treatment for lymphoma in patients with AAE. C1-INH levels, C1q, and C4 levels may normalize in concert or independently. Disappearance of autoantibodies can also occur. We have observed a wide range of changes in complement studies and autoantibody levels in the patients we manage following treatment for lymphoma, although we have not detected a consistent pattern. One of our patients had complete reversal of clinical and complement abnormalities, but persistence of anti-C1-INH autoantibodies. Such findings highlight the uncertainties regarding the pathogenesis of AAE. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/12/26824?source=see_link&amp;anchor=H5#H5\">",
"     \"Acquired C1 inhibitor deficiency: Clinical manifestations, epidemiology, pathogenesis, and diagnosis\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Monitoring MGUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with AAE who are found to have monoclonal gammopathy of uncertain significance (MGUS) must be followed and evaluated regularly, as MGUS can transform to a more serious disorder at a rate of approximately 1 percent per year. It is not known if treatment of MGUS prior to transformation would impact the patient's outcome. The recommendations for monitoring are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/60/4041?source=see_link\">",
"     \"Clinical course and management of monoclonal gammopathy of undetermined significance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Prophylaxis to prevent attacks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic therapy to prevent attacks of angioedema in AAE should be considered in patients who are significantly impaired by recurrent episodes resulting in five or more days of disability per month.",
"   </p>",
"   <p>",
"    The options for prophylactic therapy in patients with AAE are the same as those used in HAE: antifibrinolytic agents, attenuated androgens, or regular infusions of C1-INHRP [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25927/abstract/2,14,23-25\">",
"     2,14,23-25",
"    </a>",
"    ]. However, we have concerns about the use of C1-INHRP for prophylaxis because AAE patients sometimes become resistant to it (possibly due to anti-C1 inhibitor antibodies) and we prefer to reserve it for treating acute attacks. (See",
"    <a class=\"local\" href=\"#H3419210\">",
"     'Resistance'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Thus, it is the author's approach to start with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    (3 grams daily). If the attacks do not decline in number and severity, we then change to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"     danazol",
"    </a>",
"    (600 mg daily, usually as 200 mg three times daily) for one month with subsequent tapering if symptoms subside to the lowest effective dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Antifibrinolytics",
"    </span>",
"    &nbsp;&mdash;&nbsp;TA is well tolerated by most patients with AAE, and reduces the frequency and severity of attacks in the majority of patients. As an example, of 13 patients treated with TA in one series, 8 responded very well, and 4 responded partially [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25927/abstract/2\">",
"     2",
"    </a>",
"    ]. Use of TA for the prevention of angioedema, including dosing and monitoring, is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29658?source=see_link&amp;anchor=H24#H24\">",
"     \"Hereditary angioedema: Prevention of attacks\", section on 'Antifibrinolytics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is still debated whether or not antifibrinolytics carry an increased risk of thrombosis, particularly in patients with associated malignancies. We have not seen this complication in our patients, but the number of individuals treated is sufficiently small that we may not have encountered it yet. Until this question is conclusively answered, we coadminister",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy (with a target INR between 2 and 3) in patients with increased risk of thromboembolism who also need long-term TA for AAE [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25927/abstract/26\">",
"     26",
"    </a>",
"    ]. In the US, there is limited experience with TA because it was not available in oral form until 2009. Experience with the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30311?source=see_link\">",
"     aminocaproic acid",
"    </a>",
"    in AAE is extremely limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3418914\">",
"    <span class=\"h3\">",
"     Androgens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attenuated androgens, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"     danazol",
"    </a>",
"    , stanozolol, and others control symptoms in approximately one-half of patients, in our clinical experience [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25927/abstract/2,14,24,25\">",
"     2,14,24,25",
"    </a>",
"    ]. Those who respond well to this therapy sometimes achieve control of symptoms with very low doses and remain on this agent for years. However, in the remaining patients, androgens either do not work from the outset, or become ineffective after a period of time [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25927/abstract/2\">",
"     2",
"    </a>",
"    ]. Use of androgens for the prevention of angioedema is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29658?source=see_link&amp;anchor=H15#H15\">",
"     \"Hereditary angioedema: Prevention of attacks\", section on 'Attenuated androgens'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no published studies that provide information about the long-term prognosis of patients with AAE. Among the 40 to 50 patients we have followed, six have died (two of lymphoma, one of breast cancer, and three of apparently unrelated causes).",
"   </p>",
"   <p>",
"    The risk of asphyxiation due to upper airway closure remains a real and immediate risk for patients with AAE because of the limited knowledge of this condition on the part of clinicians. We learned of a female patient with known AAE who is in a persistent vegetative state after presenting with \"dysphagia\" to the emergency department of a local hospital. An infusion of 1000 units of C1-INHRP was started, but during administration, the swelling suddenly progressed to airway closure. Attempts at endotracheal intubation failed because of massive laryngeal edema and permanent anoxic brain damage was already established by the time a tracheotomy was performed. We know of several other patients who have died of laryngeal edema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients should be educated about the risk of fatal laryngeal attacks, and instructed on how to proceed should swelling in the throat develop. Because so few clinicians are familiar with this disorder, equipping the patient with information about proper treatment is critical. A printable form is provided (",
"      <a class=\"graphic graphic_form graphicRef57664 \" href=\"UTD.htm?0/32/517\">",
"       form 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Patient education about laryngeal edema'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with laryngeal attacks require immediate assessment of the airway. If respiratory distress or stridor is present, preparations to intubate should be made, because even the first line therapies take approximately 30 minutes or more to begin working. An expert should manage the airway if possible. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Airway management in laryngeal edema'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      First-line therapies for treatment of severe attacks of AAE are:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Purified human C1 inhibitor (C1INHRP) (available in many countries)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/23/23923?source=see_link\">",
"       Ecallantide",
"      </a>",
"      , a kallikrein inhibitor (available in the US)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/36/4675?source=see_link\">",
"       Icatibant",
"      </a>",
"      , a bradykinin B2 receptor antagonist (available in US, Europe and other countries)",
"      <br/>",
"      <br/>",
"      (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Pharmacologic treatment of acute attacks'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with AAE can become resistant to C1INHRP over time. For patients with acute angioedema who do not improve in response to an initial dose of C1INHRP, we suggest administering",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/23/23923?source=see_link\">",
"       ecallantide",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/36/4675?source=see_link\">",
"       icatibant",
"      </a>",
"      instead (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      If an underlying disorder is identified, treatment of that disorder usually reduces the frequency of angioedema episodes. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Treatment of associated disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with ongoing symptoms resulting in five or more days of disability per month, we suggest prophylactic therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The primary agents for prevention of attacks are attenuated androgens or antifibrinolytic agents. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Prophylaxis to prevent attacks'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25927/abstract/1\">",
"      Pappalardo E, Cicardi M, Duponchel C, et al. Frequent de novo mutations and exon deletions in the C1inhibitor gene of patients with angioedema. J Allergy Clin Immunol 2000; 106:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25927/abstract/2\">",
"      Cicardi M, Zingale LC, Pappalardo E, et al. Autoantibodies and lymphoproliferative diseases in acquired C1-inhibitor deficiencies. Medicine (Baltimore) 2003; 82:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25927/abstract/3\">",
"      Cicardi M, Bergamaschini L, Cugno M, et al. Pathogenetic and clinical aspects of C1 inhibitor deficiency. Immunobiology 1998; 199:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25927/abstract/4\">",
"      Schneider L, Lumry W, Vegh A, et al. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor. J Allergy Clin Immunol 2007; 120:416.",
"     </a>",
"    </li>",
"    <li>",
"     Cicardi M, unpublished data.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25927/abstract/6\">",
"      Bork K, Frank J, Grundt B, et al. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J Allergy Clin Immunol 2007; 119:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25927/abstract/7\">",
"      Zanichelli A, Badini M, Nataloni I, et al. Treatment of acquired angioedema with icatibant: a case report. Intern Emerg Med 2011; 6:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25927/abstract/8\">",
"      Zanichelli A, Bova M, Coerezza A, et al. Icatibant treatment for acquired C1-inhibitor deficiency: a real-world observational study. Allergy 2012; 67:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25927/abstract/9\">",
"      Agostoni A, Ayg&ouml;ren-P&uuml;rs&uuml;n E, Binkley KE, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 2004; 114:S51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25927/abstract/10\">",
"      Markovic SN, Inwards DJ, Frigas EA, Phyliky RP. Acquired C1 esterase inhibitor deficiency. Ann Intern Med 2000; 132:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25927/abstract/11\">",
"      Bork K, Fischer B, Dewald G. Recurrent episodes of skin angioedema and severe attacks of abdominal pain induced by oral contraceptives or hormone replacement therapy. Am J Med 2003; 114:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25927/abstract/12\">",
"      Rousset-Jablonski C, Thalabard JC, Gompel A. Tamoxifen contraindicated in women with hereditary angioedema? Ann Oncol 2009; 20:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25927/abstract/13\">",
"      Ricketti AJ, Cleri DJ, Ramos-Bonner LS, Vernaleo JR. Hereditary angioedema presenting in late middle age after angiotensin-converting enzyme inhibitor treatment. Ann Allergy Asthma Immunol 2007; 98:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25927/abstract/14\">",
"      Gelfand JA, Boss GR, Conley CL, et al. Acquired C1 esterase inhibitor deficiency and angioedema: a review. Medicine (Baltimore) 1979; 58:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25927/abstract/15\">",
"      Farkas H, Gyeney L, Majth&eacute;nyi P, et al. Angioedema due to acquired C1-esterase inhibitor deficiency in a patient with Helicobacter pylori infection. Z Gastroenterol 1999; 37:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25927/abstract/16\">",
"      Cicardi M, Frangi D, Bergamaschini L, et al. Acquired C1 inhibitor deficiency with angioedema symptoms in a patient infected with Echinococcus granulosus. Complement 1985; 2:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25927/abstract/17\">",
"      Jung M, Rice L. Unusual autoimmune nonhematologic complications in chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk 2011; 11 Suppl 1:S10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25927/abstract/18\">",
"      Hauptmann G, Petitjean F, Lang JM, Oberling F. Acquired C1 inhibitor deficiency in a case of lymphosarcoma of the spleen. Reversal of complement abnormalities after splenectomy. Clin Exp Immunol 1979; 37:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25927/abstract/19\">",
"      Sz&eacute;plaki G, Varga L, Sz&eacute;pv&ouml;lgyi A, et al. Acquired angioedema associated with primary antiphospholipid syndrome in a patient with antithrombin III deficiency. Int Arch Allergy Immunol 2008; 146:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25927/abstract/20\">",
"      Schreiber AD, Zweiman B, Atkins P, et al. Acquired angioedema with lymphoproliferative disorder: association of C1 inhibitor deficiency with cellular abnormality. Blood 1976; 48:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25927/abstract/21\">",
"      Levi M, Hack CE, van Oers MH. Rituximab-induced elimination of acquired angioedema due to C1-inhibitor deficiency. Am J Med 2006; 119:e3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25927/abstract/22\">",
"      Hassan A, Amarger S, Tridon A, et al. Acquired angioedema responding to rituximab. Acta Derm Venereol 2011; 91:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25927/abstract/23\">",
"      Levi M, Choi G, Picavet C, Hack CE. Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. J Allergy Clin Immunol 2006; 117:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25927/abstract/24\">",
"      Bouillet-Claveyrolas L, Ponard D, Drouet C, Massot C. Clinical and biological distinctions between type I and type II acquired angioedema. Am J Med 2003; 115:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25927/abstract/25\">",
"      Hauptmann G, Mayer S, Lang JM, et al. Treatment of acquired C1-inhibitor deficiency with danazol. Ann Intern Med 1977; 87:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25927/abstract/26\">",
"      Cicardi M, Beretta A, Colombo M, et al. Relevance of lymphoproliferative disorders and of anti-C1 inhibitor autoantibodies in acquired angio-oedema. Clin Exp Immunol 1996; 106:475.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8110 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-0AA24E0359-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_20_25927=[""].join("\n");
var outline_f25_20_25927=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ACUTE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Patient education about laryngeal edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Airway management in laryngeal edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Pharmacologic treatment of acute attacks",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - C1 inhibitor concentrate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3419210\">",
"      Resistance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Ecallantide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Icatibant",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Plasma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Antihistamines, glucocorticoids and epinephrine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      LONG-TERM MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22581856\">",
"      Avoidance of medications that may exacerbate symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Treatment of associated disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Monitoring MGUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Prophylaxis to prevent attacks",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Antifibrinolytics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3418914\">",
"      - Androgens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/8110\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/8110|Form\">",
"      <a href=\"#\" title=\"FORMS\">",
"       FORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?0/32/517\" title=\"form 1\">",
"      AAE emergency care",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/12/26824?source=related_link\">",
"      Acquired C1 inhibitor deficiency: Clinical manifestations, epidemiology, pathogenesis, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/60/4041?source=related_link\">",
"      Clinical course and management of monoclonal gammopathy of undetermined significance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4905?source=related_link\">",
"      Emergent surgical cricothyrotomy (cricothyroidotomy)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19272?source=related_link\">",
"      Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33864?source=related_link\">",
"      Hereditary angioedema: Pathogenesis and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29658?source=related_link\">",
"      Hereditary angioedema: Prevention of attacks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33657?source=related_link\">",
"      Hereditary angioedema: Treatment of acute attacks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18552?source=related_link\">",
"      The difficult airway in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_20_25928="Lateral internal sphincterotomy for management of an anal fissure";
var content_f25_20_25928=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Lateral internal sphincterotomy for management of an anal fissure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/20/25928/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/20/25928/contributors\">",
"     C Neal Ellis, MD, FACS, FASCRS, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/20/25928/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/20/25928/contributors\">",
"     Martin Weiser, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/20/25928/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/20/25928/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/20/25928/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H25641362\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lateral internal sphincterotomy is the gold standard for the operative management of an anal fissure secondary to hypertonicity or hypertrophy of the internal anal sphincter [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25928/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The goal of surgical therapy is to relax the internal anal sphincter, provide symptomatic relief, and heal the fissure.",
"   </p>",
"   <p>",
"    The major operative principles for performing a lateral internal sphincterotomy for the management of an anal fissure will be reviewed here. The clinical presentation, medical management, indications, and an overview of the surgical management for anal fissures are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/24/34181?source=see_link\">",
"     \"Anal fissure: Clinical manifestations, diagnosis, prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H302558412\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;An anal fissure is a tear or ulceration in the lining of the squamous epithelium in the anal canal distal to the mucocutaneous junction (dentate line) that is most often due to local trauma (",
"    <a class=\"graphic graphic_picture graphicRef51583 \" href=\"UTD.htm?34/14/35040\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef68238 \" href=\"UTD.htm?24/47/25332\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef54523 \" href=\"UTD.htm?20/54/21348\">",
"     figure 2",
"    </a>",
"    ). The fissure causes pain during defecation that persists for one to two hours. Hypertrophy and hypertonicity of the internal anal sphincter can be so severe that it causes ischemia, pain, and non-healing of the fissure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25928/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Medical management using topical therapies and dietary measures is the first approach to treating an anal fissure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25928/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. These therapies are directed toward relaxing the internal anal sphincter and subsequently healing the fissure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/1/15384?source=see_link&amp;anchor=H72479764#H72479764\">",
"     \"Anal fissure: Medical and surgical management\", section on 'Medical therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/24/34181?source=see_link\">",
"     \"Anal fissure: Clinical manifestations, diagnosis, prevention\"",
"    </a>",
"    .) Surgery is reserved for patients who fail medical management [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25928/abstract/7-10\">",
"     7-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lateral internal sphincterotomy is the first-line surgical option for all fissures associated with hypertrophy and hypertonicity of the internal anal sphincter [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25928/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. It can be performed using the open or closed approach, depending upon the surgeon&rsquo;s preference. An alternative procedure, the V-Y advancement flap, is generally reserved for recurrent fissures or fissures that are not associated with hypertrophy and hypertonicity of the internal anal sphincter. (See",
"    <a class=\"local\" href=\"#H3495872\">",
"     'Endo-anal V-Y advancement flap'",
"    </a>",
"    below.) Previously described procedures, such as anal dilatation and midline posterior sphincterotomy, are rarely if ever used because of the high rates of incontinence, recurrence, and longer time for wound healing [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25928/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25643490\">",
"    <span class=\"h1\">",
"     KEY OPERATIVE PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lateral internal sphincterotomy involves the complete or partial division of the internal anal sphincter. The goal of surgical therapy is to relax the internal anal sphincter, thereby providing symptomatic relief and healing the fissure.",
"   </p>",
"   <p>",
"    To surgically treat an anal fissure, there are a number of important issues that need to be addressed. These include preoperative antibiotics, type of anesthesia, patient positioning, the operative technique, and postoperative care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25643740\">",
"    <span class=\"h2\">",
"     Preoperative antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous antibiotics are",
"    <strong>",
"     not",
"    </strong>",
"    generally required for patients undergoing a sphincterotomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18806?source=see_link&amp;anchor=H1191970282#H1191970282\">",
"     \"Control measures to prevent surgical site infection following gastrointestinal procedures\", section on 'Colorectal surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25641397\">",
"    <span class=\"h2\">",
"     Type of anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A lateral sphincterotomy can be performed in the surgeon&rsquo;s office using a local anesthetic (0.5 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    ). If a regional or general anesthetic is required, the procedure is performed in an outpatient setting in the operating room. The anesthetic technique used for lateral sphincterotomy should provide maximum patient safety and comfort.",
"   </p>",
"   <p>",
"    The type of anesthesia is determined by both patient and surgeon preference. Data are limited on patient outcomes with different methods of anesthesia in observational studies; randomized trials have not been performed.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective study of 80 patients underwent anorectal surgery with either a local anesthetic (n = 52) or spinal anesthesia (n = 28) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25928/abstract/13\">",
"       13",
"      </a>",
"      ]. The patients treated with a local anesthetic had a significantly shorter recovery time (82 versus 139 minutes), fewer complications (40 versus 75 percent), and lower rates of postoperative urinary retention (9 versus 32 percent).",
"     </li>",
"     <li>",
"      A retrospective review of 298 patients reported a higher rate of local recurrence with a sphincterotomy performed under local anesthesia compared with the procedure performed under a general anesthesia (45 versus 9 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25928/abstract/14\">",
"       14",
"      </a>",
"      ]. The reason for the high rate of recurrence with a local anesthesia is unclear and may be related to the small number of patients (n = 20), or to an incompletely performed sphincterotomy procedure. Other authors have dismissed this high recurrence rate under local anesthesia and have purported the benefits of office-based procedures in this era of reducing healthcare costs [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25928/abstract/15,16\">",
"       15,16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25641404\">",
"    <span class=\"h2\">",
"     Patient positioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;We prefer prone jackknife position for lateral internal sphincterotomy. Alternative positioning options include the lithotomy or lateral decubitus positions, depending upon the preference of the surgeon and patient and upon certain patient characteristics. As an example, morbidly obese patients are typically placed in the lateral decubitus position, since they frequently do not tolerate the prone jack-knife or lithotomy position. The location of the fissure does",
"    <strong>",
"     not",
"    </strong>",
"    influence the choice of patient positioning.",
"   </p>",
"   <p>",
"    Only enough gentle dilation is performed to allow admittance of a medium (0.75 to 1 inch [1.90 to 2.54 cm]) rectal retractor. Anoscopy is not generally performed since an adequate examination can be performed using the rectal retractor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25641411\">",
"    <span class=\"h2\">",
"     Operative technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Either an open or a closed technique can be used for a lateral internal sphincterotomy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the open sphincterotomy technique, the surgeon incises the mucosa to directly expose the internal sphincter muscle and divides it under direct vision. Complete division of the internal sphincter is important, since an incompletely divided internal sphincter has been associated with a marked increase in fissure recurrence. The supporting data are presented below. (See",
"      <a class=\"local\" href=\"#H25641425\">",
"       'Failure to heal, recurrent, or atypical fissures'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In the closed sphincterotomy technique, the mucosa is left intact, and the surgeon, prior to dividing the muscle, passes a blade either directly under the mucosa or into the intersphincteric groove (",
"      <a class=\"graphic graphic_figure graphicRef54523 \" href=\"UTD.htm?20/54/21348\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Regardless of the method chosen, the sphincterotomy is performed on the",
"      <strong>",
"       right",
"      </strong>",
"      side between the anterior and posterior hemorrhoidal columns to avoid confusion if a repeat procedure is required.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The extent of the sphincterotomy remains controversial. There are two approaches that have been described:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One approach is to divide the internal anal sphincter muscle to the level of or just proximal to the dentate line [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25928/abstract/17,18\">",
"       17,18",
"      </a>",
"      ]. This is also referred to as the &ldquo;longer sphincterotomy&rdquo;.",
"     </li>",
"     <li>",
"      Alternatively, the tailored or partial sphincterotomy divides the internal anal sphincter only to the level of the apex of the fissure, preserving more sphincteric muscle [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25928/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]. This is also referred to as the &ldquo;fissure apex sphincterotomy&rdquo;.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The outcomes with these procedures are discussed in the following section.",
"   </p>",
"   <p>",
"    It is important to note that the fissure is",
"    <strong>",
"     not",
"    </strong>",
"    excised and a biopsy is performed only if the fissure has an atypical appearance. (See",
"    <a class=\"local\" href=\"#H25641425\">",
"     'Failure to heal, recurrent, or atypical fissures'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H302558719\">",
"    <span class=\"h2\">",
"     Postoperative care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infiltration of the operative site with a local anesthetic before",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    after the sphincterotomy will provide postoperative pain relief [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25928/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Oral narcotics can be used as primary postoperative analgesia. Nonsteroidal anti-inflammatory drugs, particularly intramuscular or intravenous, improve analgesia, lower narcotic usage, and lower the rate of urinary retention [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25928/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33689?source=see_link\">",
"     \"Infiltration of local anesthetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since a bladder catheter is not typically used, limiting perioperative fluid administration to less than one liter lowers the incidence of postoperative urinary retention [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25928/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. Postoperative instructions include recommendations for sitz baths for comfort, adequate intake of fluid and fiber to avoid constipation, and limited activity for a few days. These instructions are primarily derived from clinical experience, rather than specific data. With appropriate postoperative instruction, a lateral sphincterotomy can be performed with a high degree of patient satisfaction [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25928/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3495567\">",
"    <span class=\"h1\">",
"     RESULTS AND COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two primary outcome measures are healing of the fissure and fecal incontinence. A lateral internal sphincterotomy provides prompt symptomatic relief and heals the fissure in over 95 percent of patients within three weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25928/abstract/20,29-33\">",
"     20,29-33",
"    </a>",
"    ]. The description of the procedures is described in the preceding section (See",
"    <a class=\"local\" href=\"#H25641411\">",
"     'Operative technique'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A number of randomized trials assessed the rates of healing and rates of fecal incontinence following different internal sphincterotomy techniques:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial of 76 patients, patients treated with a sphincterotomy performed to the level of the dentate line (longer sphincterotomy) had more rapid symptomatic relief than those treated with a sphincterotomy to the fissure apex (2.1 versus 4.7 days) and had fewer recurrences at 12 months (0 versus 13.2 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25928/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A meta-analysis of three randomized trials with a total of 320 patients found the longer sphincterotomy (muscle is divided to the level of or just proximal to the dentate line) compared with the partial tailored sphincterotomy (fissure apex sphincterotomy) resulted in a significantly higher rate of healed fissures (odds ratio [OR] 6.7, 95% CI 1.4-33.3) and no difference in the rate of incontinence [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25928/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A meta-analysis of five randomized trials with 299 patients found no significant difference between the",
"      <strong>",
"       open",
"      </strong>",
"      compared with the",
"      <strong>",
"       closed",
"      </strong>",
"      lateral sphincterotomy for rate of healing (OR 1.0, CI 0.40-2.48) or rate of incontinence (OR 0.87, CI 0.41-1.83) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25928/abstract/11\">",
"       11",
"      </a>",
"      ]. In the largest trial (n = 79), the rate of healing at six weeks was 96 percent and new incontinence was diagnosed in five patients (6.8 percent) at 52 weeks for open and closed procedures combined [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25928/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A meta-analysis of three randomized trials with 78 patients found no difference in rate of healing for a",
"      <strong>",
"       lateral",
"      </strong>",
"      sphincterotomy compared with a",
"      <strong>",
"       posterior",
"      </strong>",
"      sphincterotomy [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25928/abstract/11\">",
"       11",
"      </a>",
"      ]. There were too few complications in these trials to determine if incontinence was higher with a posterior sphincterotomy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Retrospective studies have assessed the frequency, type,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    duration of postoperative incontinence following a lateral internal sphincterotomy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective review of 298 patients who underwent a lateral internal sphincterotomy, persistent flatus incontinence was reported in 30 percent and persistent fecal incontinence in 8 percent of patients at five years following the procedure [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25928/abstract/14\">",
"       14",
"      </a>",
"      ]. Only 2.3 percent considered the seepage of stool to be significant. Neither gender nor a previous anorectal surgery was associated with an increased risk of incontinence of any type. The surgical outcomes recorded in a chart review were significantly lower than the incontinence rates reported by patient survey for both flatus incontinence (4.4 versus 31.5 percent) and stool incontinence (2.8 versus 28.7 percent).",
"     </li>",
"     <li>",
"      Low rates of incontinence when chart review is performed were also noted in a retrospective study of 287 patients undergoing a fissure apex tailored lateral internal sphincterotomy [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25928/abstract/19\">",
"       19",
"      </a>",
"      ]. There were low rates of flatus (1.4 percent), minor fecal staining (0.35 percent), and fecal urgency (0.7 percent), and no reports of fecal incontinence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3496754\">",
"    <span class=\"h1\">",
"     ALTERNATIVE PROCEDURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Options for surgical management of anal fissure other than the lateral internal anal sphincterotomy include a V-Y advancement flap and a subcutaneous fissurotomy. These alternative procedures can be used for patients with a high risk of incontinence, recurrent fissures, or fissures that result from causes other than hypertonicity, such as infection, inflammation, or malignancy. (See",
"    <a class=\"local\" href=\"#H25641425\">",
"     'Failure to heal, recurrent, or atypical fissures'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3495872\">",
"    <span class=\"h2\">",
"     Endo-anal V-Y advancement flap",
"    </span>",
"    &nbsp;&mdash;&nbsp;An endo-anal V-Y advancement is an alternative to the lateral internal sphincterotomy and has been suggested for patients at increased risk of fecal incontinence (eg, elderly, multiparous women, recurrent fissures) or those whose fissures are not related to hypertonicity of the sphincter muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25928/abstract/34-38\">",
"     34-38",
"    </a>",
"    ]. These techniques do not divide the internal sphincter and are not associated with increased incontinence (",
"    <a class=\"graphic graphic_figure graphicRef63328 \" href=\"UTD.htm?38/8/39055\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25928/abstract/35,39\">",
"     35,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies have been performed assessing the rate of healing and complications of the V-Y advancement flap:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial of 40 patients with a chronic anal fissure, the rate of healing was higher for patients treated with the lateral sphincterotomy compared with the V-Y advancement flap (100 versus 85 percent), and no patient was incontinent after either procedure [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25928/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective review of 54 consecutive patients who underwent a V-Y advancement flap, wound dehiscences occurred in three (5.6 percent) at eight weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25928/abstract/40\">",
"       40",
"      </a>",
"      ]. Only one patient with a dehiscence required additional surgery. At six months, all but one patient had a healed wound.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The technical aspects of the advancement flap procedure for anal fissure are based upon those used for surgical treatment of an anorectal fistula. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/51/5946?source=see_link&amp;anchor=H22288859#H22288859\">",
"     \"Operative management of anorectal fistulas\", section on 'Advancement flaps'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3497395\">",
"    <span class=\"h2\">",
"     Subcutaneous fissurotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A subcutaneous fissurotomy involves unroofing of the fissure tract. It can be performed to surgically treat an anal fissure that fails to heal or recurs following medical therapy or a lateral internal sphincterotomy. Randomized trials comparing these procedures have not been performed. A prospective observational study evaluated the efficacy of subcutaneous fissurotomy without a lateral sphincterotomy in 109 patients with a chronic anal fissure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25928/abstract/41\">",
"     41",
"    </a>",
"    ]. The rate of healing was 98 percent at 12 months and there was no change in fecal incontinence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25641425\">",
"    <span class=\"h1\">",
"     FAILURE TO HEAL, RECURRENT, OR ATYPICAL FISSURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fissures that fail to heal or recur after lateral internal sphincterotomy have been associated with an incomplete sphincterotomy, sphincter hypertonia, or chronic morphologic changes within the fissure, including fibrosis, a sentinel pile,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    rolled edges [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25928/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. In a review of 51 patients following a lateral internal sphincterotomy, there was a significantly increased risk of fissure recurrence with an incompletely divided internal sphincter compared with a completely divided sphincter (75 versus 10 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25928/abstract/42\">",
"     42",
"    </a>",
"    ]. The defect was evaluated by anal endosonography.",
"   </p>",
"   <p>",
"    Fissures that are persistent, recurrent, or atypical (eg, irregular, off midline, or large) should alert the surgeon to the possibility of a secondary manifestation of a systemic illness, such as Crohn&rsquo;s disease, tuberculosis, HIV infection, adenocarcinoma, metastatic basal cell carcinoma, lymphoma, or leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25928/abstract/45-49\">",
"     45-49",
"    </a>",
"    ]. The patient evaluation should include a thorough history and physical examination focusing on secondary manifestations of a systemic disease, wound cultures to identify a possible pathogen, and an examination under anesthesia with biopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25928/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26246?source=see_link\">",
"     \"Perianal abscess: Clinical manifestations, diagnosis, treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25273?source=see_link\">",
"     \"Perianal complications of Crohn's disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11670?source=see_link\">",
"     \"Evaluation of the HIV-infected patient with anorectal symptoms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/33/1562?source=see_link\">",
"     \"Anal intraepithelial neoplasia: Diagnosis, screening, prevention, and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/24/34181?source=see_link\">",
"     \"Anal fissure: Clinical manifestations, diagnosis, prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39462691\">",
"    <span class=\"h2\">",
"     Medical management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anal fissures related to an underlying disease are initially treated by aggressive medical management of that disease. As an example, medical treatment of patients with Crohn&rsquo;s disease should be optimized, since sphincter preservation is a goal for patients with chronic diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25928/abstract/44\">",
"     44",
"    </a>",
"    ]. Anal fissures are multiple in approximately one-third of patients with Crohn&rsquo;s disease, thereby complicating surgical and medical management. Anal fissures associated with Crohn&rsquo;s disease are usually painless; thus, excessive pain suggests that a rectal abscess may be present [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25928/abstract/50\">",
"     50",
"    </a>",
"    ]. In this setting, an examination under anesthesia should be performed and, if present, the abscess drained. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25273?source=see_link&amp;anchor=H21#H21\">",
"     \"Perianal complications of Crohn's disease\", section on 'Anorectal abscesses'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26246?source=see_link&amp;anchor=H88522783#H88522783\">",
"     \"Perianal abscess: Clinical manifestations, diagnosis, treatment\", section on 'Treatment by site of abscess'",
"    </a>",
"    .) A lateral internal anal sphincterotomy is reserved for patients with minimal active anorectal inflammation who fail all reasonable nonsurgical therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25928/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Conservative management with a high fiber diet and high fluid intake can heal approximately two-thirds of persistent or recurrent fissures that are unrelated to infection, inflammation, or malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25928/abstract/49,51\">",
"     49,51",
"    </a>",
"    ]. The risk of fecal incontinence following a repeat sphincterotomy makes medical management the optimal initial approach. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/1/15384?source=see_link&amp;anchor=H72479764#H72479764\">",
"     \"Anal fissure: Medical and surgical management\", section on 'Medical therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5141245\">",
"    <span class=\"h2\">",
"     Surgical management",
"    </span>",
"    &nbsp;&mdash;&nbsp;A recurrent or persistent anal fissure secondary to a technical complication is most often detected by anal endosonography. Surgical options include completion of an incompletely divided sphincter, a contralateral lateral internal sphincterotomy, a tailored lateral sphincterotomy, an endo-anal V-Y advancement flap if not initially performed, or a subcutaneous fissurotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25928/abstract/35,49,52,53\">",
"     35,49,52,53",
"    </a>",
"    ]. The procedure selected is based upon the results of the ultrasound examination of the internal sphincter. If the internal sphincter is clearly divided to a point proximal to the dentate line, we perform a V-Y flap. If the sphincter is incompletely divided, we attempt to complete the sphincterotomy on the same side or more commonly because of scarring, we perform a sphincterotomy on the contralateral side. (See",
"    <a class=\"local\" href=\"#H3496754\">",
"     'Alternative procedures'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Management of a persistent anal fissure depends upon the degree of symptoms associated with the fissure. The treatment options include [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25928/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For a persistent anal fissure that bleeds with bowel movements but is only minimally painful, nonoperative therapy to allow more time for healing is appropriate. If, however, the fissure does not heal and remains only minimally painful, a subcutaneous fissurectomy alone is performed if the fissure has the chronic morphologic changes described above (fibrosis, a sentinel pile,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      rolled edges). (See",
"      <a class=\"local\" href=\"#H3497395\">",
"       'Subcutaneous fissurotomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25641425\">",
"       'Failure to heal, recurrent, or atypical fissures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For persistent or recurrent fissures that are painful, anal sonography is used to assess the extent of the previous lateral internal sphincterotomy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If the lateral internal sphincterotomy is incomplete, a repeat procedure is performed to complete the sphincterotomy to the level of the dentate line. A subcutaneous fissurectomy can be performed at the surgeon&rsquo;s discretion, based upon the presence or absence of chronic morphologic changes.",
"     </li>",
"     <li>",
"      If the lateral internal anal sphincterotomy is complete, surgical fissurectomy is performed and an endo-anal V-Y advancement flap is used to cover the defect. (See",
"      <a class=\"local\" href=\"#H3495872\">",
"       'Endo-anal V-Y advancement flap'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics&rdquo;. The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/31/44529?source=see_link\">",
"       \"Patient information: Anal fissure (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25643551\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lateral internal sphincterotomy is the gold standard for the operative management of an anal fissure secondary to hypertonicity or hypertrophy of the internal anal sphincter. The goal of surgical therapy is to relax the internal anal sphincter, provide symptomatic relief, and heal the fissure. (See",
"    <a class=\"local\" href=\"#H302558412\">",
"     'Background'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest performing a lateral internal anal sphincterotomy under local anesthesia, if tolerated by the patient (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25641397\">",
"       'Type of anesthesia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend performing a longer lateral internal anal sphincterotomy rather than the tailored or partial sphincterotomy (fissure apex sphincterotomy) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The longer lateral internal anal sphincterotomy results in a higher rate of healed fissures. (See",
"      <a class=\"local\" href=\"#H3495567\">",
"       'Results and complications'",
"      </a>",
"      above.) The procedure can be performed as either an open or a closed technique.",
"     </li>",
"     <li>",
"      An endo-anal V-Y advancement flap is an alternative to the lateral internal sphincterotomy and is suggested for patients at increased risk of fecal incontinence. (See",
"      <a class=\"local\" href=\"#H3496754\">",
"       'Alternative procedures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For fissures that fail to heal, or recur following a lateral internal anal sphincterotomy, anal endoscopy is performed to determine if the sphincterotomy is complete. (See",
"      <a class=\"local\" href=\"#H25641425\">",
"       'Failure to heal, recurrent, or atypical fissures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For fissures that fail to heal or recur following an adequate sphincterotomy, a biopsy of the fissure should be performed to identify any underlying infection, inflammatory process, or malignancy. (See",
"      <a class=\"local\" href=\"#H25641425\">",
"       'Failure to heal, recurrent, or atypical fissures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aggressive and optimal medical management for anal fissures related to a medical disease should be performed prior to operative management (eg, Crohn&rsquo;s disease, HIV, cancer). (See",
"      <a class=\"local\" href=\"#H39462691\">",
"       'Medical management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/1\">",
"      Poh A, Tan KY, Seow-Choen F. Innovations in chronic anal fissure treatment: A systematic review. World J Gastrointest Surg 2010; 2:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/2\">",
"      Perry WB, Dykes SL, Buie WD, et al. Practice parameters for the management of anal fissures (3rd revision). Dis Colon Rectum 2010; 53:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/3\">",
"      Richard CS, Gregoire R, Plewes EA, et al. Internal sphincterotomy is superior to topical nitroglycerin in the treatment of chronic anal fissure: results of a randomized, controlled trial by the Canadian Colorectal Surgical Trials Group. Dis Colon Rectum 2000; 43:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/4\">",
"      Schouten WR, Briel JW, Auwerda JJ. Relationship between anal pressure and anodermal blood flow. The vascular pathogenesis of anal fissures. Dis Colon Rectum 1994; 37:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/5\">",
"      Gosselink MP, Darby M, Zimmerman DD, et al. Treatment of chronic anal fissure by application of L-arginine gel: a phase II study in 15 patients. Dis Colon Rectum 2005; 48:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/6\">",
"      Kua KB, Kocher HM, Kelkar A, Patel AG. Effect of topical glyceryl trinitrate on anodermal blood flow in patients with chronic anal fissures. ANZ J Surg 2001; 71:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/7\">",
"      Evans J, Luck A, Hewett P. Glyceryl trinitrate vs. lateral sphincterotomy for chronic anal fissure: prospective, randomized trial. Dis Colon Rectum 2001; 44:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/8\">",
"      Libertiny G, Knight JS, Farouk R. Randomised trial of topical 0.2% glyceryl trinitrate and lateral internal sphincterotomy for the treatment of patients with chronic anal fissure: long-term follow-up. Eur J Surg 2002; 168:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/9\">",
"      Oettl&eacute; GJ. Glyceryl trinitrate vs. sphincterotomy for treatment of chronic fissure-in-ano: a randomized, controlled trial. Dis Colon Rectum 1997; 40:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/10\">",
"      Mente�� BB, Irk&ouml;r&uuml;c&uuml; O, Akin M, et al. Comparison of botulinum toxin injection and lateral internal sphincterotomy for the treatment of chronic anal fissure. Dis Colon Rectum 2003; 46:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/11\">",
"      Nelson RL. Operative procedures for fissure in ano. Cochrane Database Syst Rev 2010; :CD002199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/12\">",
"      Ram E, Vishne T, Lerner I, Dreznik Z. Anal dilatation versus left lateral sphincterotomy for chronic anal fissure: a prospective randomized study. Tech Coloproctol 2007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/13\">",
"      Fleischer M, Marini CP, Statman R, et al. Local anesthesia is superior to spinal anesthesia for anorectal surgical procedures. Am Surg 1994; 60:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/14\">",
"      Casillas S, Hull TL, Zutshi M, et al. Incontinence after a lateral internal sphincterotomy: are we underestimating it? Dis Colon Rectum 2005; 48:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/15\">",
"      Hananel N, Gordon PH. Lateral internal sphincterotomy for fissure-in-ano--revisited. Dis Colon Rectum 1997; 40:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/16\">",
"      Argov S, Levandovsky O. Open lateral sphincterotomy is still the best treatment for chronic anal fissure. Am J Surg 2000; 179:201.",
"     </a>",
"    </li>",
"    <li>",
"     Keighley MR. Fissure in ano. In: Surgery of the Anus, Rectum and Colon, Keighley MR, Williams NS (Eds) (Eds), WB Saunders, Philadelphia 1993. p.364.",
"    </li>",
"    <li>",
"     Timmcke AE, Hicks TC. Fissure-in-ano. In: Shackleford's Surgery of the Alimentary Tract, Zuidema GD, Condon RE (Eds), WB Saunders, Philadelphia 1996. p.322.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/19\">",
"      Littlejohn DR, Newstead GL. Tailored lateral sphincterotomy for anal fissure. Dis Colon Rectum 1997; 40:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/20\">",
"      Mente�� BB, Ege B, Leventoglu S, et al. Extent of lateral internal sphincterotomy: up to the dentate line or up to the fissure apex? Dis Colon Rectum 2005; 48:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/21\">",
"      Morisaki H, Masuda J, Fukushima K, et al. Wound infiltration with lidocaine prolongs postoperative analgesia after haemorrhoidectomy with spinal anaesthesia. Can J Anaesth 1996; 43:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/22\">",
"      Chester JF, Stanford BJ, Gazet JC. Analgesic benefit of locally injected bupivacaine after hemorrhoidectomy. Dis Colon Rectum 1990; 33:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/23\">",
"      Richman IM. Use of Toradol in anorectal surgery. Dis Colon Rectum 1993; 36:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/24\">",
"      Place RJ, Coloma M, White PF, et al. Ketorolac improves recovery after outpatient anorectal surgery. Dis Colon Rectum 2000; 43:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/25\">",
"      Petros JG, Bradley TM. Factors influencing postoperative urinary retention in patients undergoing surgery for benign anorectal disease. Am J Surg 1990; 159:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/26\">",
"      Zaheer S, Reilly WT, Pemberton JH, Ilstrup D. Urinary retention after operations for benign anorectal diseases. Dis Colon Rectum 1998; 41:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/27\">",
"      Gottesman L, Milsom JW, Mazier WP. The use of anxiolytic and parasympathomimetic agents in the treatment of postoperative urinary retention following anorectal surgery. A prospective, randomized, double-blind study. Dis Colon Rectum 1989; 32:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/28\">",
"      Thompson-Fawcett MW, Cook TA, Baigrie RJ, Mortensen NJ. What patients think of day-surgery proctology. Br J Surg 1998; 85:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/29\">",
"      Nelson R. Operative procedures for fissure in ano. Cochrane Database Syst Rev 2005; :CD002199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/30\">",
"      Jensen SL, Lund F, Nielsen OV, Tange G. Lateral subcutaneous sphincterotomy versus anal dilatation in the treatment of fissure in ano in outpatients: a prospective randomised study. Br Med J (Clin Res Ed) 1984; 289:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/31\">",
"      Saad AM, Omer A. Surgical treatment of chronic fissure-in-ano: a prospective randomised study. East Afr Med J 1992; 69:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/32\">",
"      Wiley M, Day P, Rieger N, et al. Open vs. closed lateral internal sphincterotomy for idiopathic fissure-in-ano: a prospective, randomized, controlled trial. Dis Colon Rectum 2004; 47:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/33\">",
"      Garcea G, Sutton C, Mansoori S, et al. Results following conservative lateral sphincteromy for the treatment of chronic anal fissures. Colorectal Dis 2003; 5:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/34\">",
"      Di Castro A, Biancari F, D'Andrea V, Caviglia A. Fissurectomy with posterior midline sphincterotomy and anoplasty (FPSA) in the management of chronic anal fissures. Surg Today 1997; 27:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/35\">",
"      Leong AF, Seow-Choen F. Lateral sphincterotomy compared with anal advancement flap for chronic anal fissure. Dis Colon Rectum 1995; 38:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/36\">",
"      Nyam DC, Wilson RG, Stewart KJ, et al. Island advancement flaps in the management of anal fissures. Br J Surg 1995; 82:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/37\">",
"      Jonas M, Scholefield JH. Anal Fissure. Gastroenterol Clin North Am 2001; 30:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/38\">",
"      Corby H, Donnelly VS, O'Herlihy C, O'Connell PR. Anal canal pressures are low in women with postpartum anal fissure. Br J Surg 1997; 84:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/39\">",
"      Singh M, Sharma A, Gardiner A, Duthie GS. Early results of a rotational flap to treat chronic anal fissures. Int J Colorectal Dis 2005; 20:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/40\">",
"      Chambers W, Sajal R, Dixon A. V-Y advancement flap as first-line treatment for all chronic anal fissures. Int J Colorectal Dis 2010; 25:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/41\">",
"      Pelta AE, Davis KG, Armstrong DN. Subcutaneous fissurotomy: a novel procedure for chronic fissure-in-ano. a review of 109 cases. Dis Colon Rectum 2007; 50:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/42\">",
"      Garc&iacute;a-Granero E, Sanahuja A, Garc&iacute;a-Armengol J, et al. Anal endosonographic evaluation after closed lateral subcutaneous sphincterotomy. Dis Colon Rectum 1998; 41:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/43\">",
"      Lindsey I, Cunningham C, Jones OM, et al. Fissurectomy-botulinum toxin: a novel sphincter-sparing procedure for medically resistant chronic anal fissure. Dis Colon Rectum 2004; 47:1947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/44\">",
"      Steele SR, Madoff RD. Systematic review: the treatment of anal fissure. Aliment Pharmacol Ther 2006; 24:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/45\">",
"      Smith DL 2nd, Cataldo PA. Perianal lymphoma in a heterosexual and nonimmunocompromised patient: report of a case and review of the literature. Dis Colon Rectum 1999; 42:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/46\">",
"      Tai WC, Hu TH, Lee CH, et al. Ano-perianal tuberculosis: 15 years of clinical experiences in Southern Taiwan. Colorectal Dis 2010; 12:e114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/47\">",
"      Abramowitz L, Benabderrahmane D, Baron G, et al. Systematic evaluation and description of anal pathology in HIV-infected patients during the HAART era. Dis Colon Rectum 2009; 52:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/48\">",
"      Sehdev MK, Dowling MD Jr, Seal SH, Stearns MW Jr. Perianal and anorectal complications in leukemia. Cancer 1973; 31:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/49\">",
"      Lewis TH, Corman ML, Prager ED, Robertson WG. Long-term results of open and closed sphincterotomy for anal fissure. Dis Colon Rectum 1988; 31:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/50\">",
"      Fleshner PR, Schoetz DJ Jr, Roberts PL, et al. Anal fissure in Crohn's disease: a plea for aggressive management. Dis Colon Rectum 1995; 38:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/51\">",
"      Nyam DC, Pemberton JH. Long-term results of lateral internal sphincterotomy for chronic anal fissure with particular reference to incidence of fecal incontinence. Dis Colon Rectum 1999; 42:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/52\">",
"      Brown SR, Taylor A, Adam IJ, Shorthouse AJ. The management of persistent and recurrent chronic anal fissures. Colorectal Dis 2002; 4:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25928/abstract/53\">",
"      Bhardwaj R, Parker MC. Modern perspectives in the treatment of chronic anal fissures. Ann R Coll Surg Engl 2007; 89:472.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14998 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-50DD9E1A11-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_20_25928=[""].join("\n");
var outline_f25_20_25928=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25643551\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25641362\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H302558412\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25643490\">",
"      KEY OPERATIVE PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25643740\">",
"      Preoperative antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25641397\">",
"      Type of anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25641404\">",
"      Patient positioning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25641411\">",
"      Operative technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H302558719\">",
"      Postoperative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3495567\">",
"      RESULTS AND COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3496754\">",
"      ALTERNATIVE PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3495872\">",
"      Endo-anal V-Y advancement flap",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3497395\">",
"      Subcutaneous fissurotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25641425\">",
"      FAILURE TO HEAL, RECURRENT, OR ATYPICAL FISSURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39462691\">",
"      Medical management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5141245\">",
"      Surgical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25643551\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/14998\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/14998|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/47/25332\" title=\"figure 1\">",
"      Anal fissure anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/54/21348\" title=\"figure 2\">",
"      Anal rectal anatomy lateral view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/8/39055\" title=\"figure 3\">",
"      V-Y advancement for anal fissures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/14998|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/14/35040\" title=\"picture 1\">",
"      Chronic anal fissure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/24/34181?source=related_link\">",
"      Anal fissure: Clinical manifestations, diagnosis, prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/1/15384?source=related_link\">",
"      Anal fissure: Medical and surgical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/33/1562?source=related_link\">",
"      Anal intraepithelial neoplasia: Diagnosis, screening, prevention, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18806?source=related_link\">",
"      Control measures to prevent surgical site infection following gastrointestinal procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11670?source=related_link\">",
"      Evaluation of the HIV-infected patient with anorectal symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33689?source=related_link\">",
"      Infiltration of local anesthetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/51/5946?source=related_link\">",
"      Operative management of anorectal fistulas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/31/44529?source=related_link\">",
"      Patient information: Anal fissure (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26246?source=related_link\">",
"      Perianal abscess: Clinical manifestations, diagnosis, treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25273?source=related_link\">",
"      Perianal complications of Crohn's disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_20_25929="Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults";
var content_f25_20_25929=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/20/25929/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/20/25929/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/20/25929/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/20/25929/contributors\">",
"     Pier Mannuccio Mannucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/20/25929/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/20/25929/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/20/25929/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disseminated intravascular coagulation (DIC, also called consumption coagulopathy and defibrination syndrome) is a systemic process producing both thrombosis and hemorrhage. It is initiated by a number of defined disorders and consists of the following components:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Exposure of blood to procoagulants such as tissue factor and cancer procoagulant",
"     </li>",
"     <li>",
"      Formation of fibrin within the circulation",
"     </li>",
"     <li>",
"      Fibrinolysis",
"     </li>",
"     <li>",
"      Depletion of clotting factors",
"     </li>",
"     <li>",
"      End-organ damage",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    DIC is a complication of underlying illness occurring in approximately 1 percent of hospital admissions [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25929/abstract/1\">",
"     1",
"    </a>",
"    ]. Treatment is generally supportive with platelet and clotting factor replacement therapy. In selected conditions, judicious use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    may be of benefit. The key to management of DIC and a favorable prognosis is effective treatment of the underlying disease.",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis, treatment, and prognosis of DIC will be reviewed here [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25929/abstract/2\">",
"     2",
"    </a>",
"    ]. The pathogenesis and etiology of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/56/8073?source=see_link\">",
"     \"Pathogenesis and etiology of disseminated intravascular coagulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The consequences of DIC, which include bleeding and thrombotic manifestations, depend upon its cause and the rapidity with which the initiating event is propagated (",
"    <a class=\"graphic graphic_algorithm graphicRef78959 \" href=\"UTD.htm?32/4/32846\">",
"     algorithm 1",
"    </a>",
"    ). Although there is overlap, two clinical forms have been described: acute and chronic DIC (",
"    <a class=\"graphic graphic_table graphicRef63831 \" href=\"UTD.htm?34/15/35067\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Acute DIC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute DIC develops when blood is exposed to large amounts of tissue factor over a brief period of time, with massive generation of thrombin, resulting in the acute triggering of coagulation. This overwhelms control mechanisms, and compensatory mechanisms do not have sufficient time to recover. The clinical consequence is a profound systemic bleeding diathesis and, due to widespread intravascular fibrin deposition (",
"    <a class=\"graphic graphic_picture graphicRef81610 \" href=\"UTD.htm?4/52/4932\">",
"     picture 1",
"    </a>",
"    ), tissue ischemic injury, and a microangiopathic hemolytic anemia (",
"    <a class=\"graphic graphic_picture graphicRef70851 \" href=\"UTD.htm?37/50/38694\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef50715 \" href=\"UTD.htm?22/13/22739\">",
"     picture 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=see_link&amp;anchor=H7#H7\">",
"     \"Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism\", section on 'Disseminated intravascular coagulation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Common manifestations of acute DIC, in addition to bleeding, include thromboembolism and dysfunction of the kidney, liver, lungs, and central nervous system. In one series of 118 patients with acute DIC, the main clinical manifestations included the following [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25929/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bleeding (64 percent)",
"     </li>",
"     <li>",
"      Renal dysfunction (25 percent)",
"     </li>",
"     <li>",
"      Hepatic dysfunction (19 percent)",
"     </li>",
"     <li>",
"      Respiratory dysfunction (16 percent)",
"     </li>",
"     <li>",
"      Shock (14 percent)",
"     </li>",
"     <li>",
"      Thromboembolism (7 percent)",
"     </li>",
"     <li>",
"      Central nervous system involvement (2 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Petechiae and ecchymoses are common in conjunction with blood oozing from wound sites, intravenous lines, catheters, and, in some cases, mucosal surfaces. The bleeding can be life-threatening if it involves the gastrointestinal tract, lungs, or central nervous system. In patients who develop DIC after surgical procedures, hemorrhage may develop around indwelling lines, catheters, drains, and tracheostomies, and blood may accumulate in serous cavities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Acute renal failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute renal failure occurs in 25 to 40 percent of patients with acute DIC. Two major mechanisms are involved: microthrombosis of afferent arterioles may produce cortical ischemia or necrosis (renal thrombotic microangiopathy), and hypotension",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sepsis can lead to acute tubular necrosis.",
"   </p>",
"   <p>",
"    Endotoxin-induced endothelial injury may predispose to intrarenal thrombus formation by directly promoting platelet aggregation, by diminishing the release of nitric oxide (endothelium-derived relaxing factor), which normally inhibits platelet aggregation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25929/abstract/4\">",
"     4",
"    </a>",
"    ], and by increasing the synthesis of plasminogen activator inhibitor type 1, leading to a reduction in fibrinolytic activity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25929/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4170?source=see_link\">",
"     \"Pathogenesis and etiology of postischemic (ischemic) acute tubular necrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Hepatic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Jaundice is common in patients with DIC and may be due both to liver disease and increased bilirubin production secondary to hemolysis. In addition, hepatocellular injury may be produced by sepsis and hypotension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Pulmonary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary hemorrhage with hemoptysis and dyspnea may result from damage to the pulmonary vascular endothelium. In addition, sepsis, trauma, and amniotic fluid embolism are causes of acute respiratory distress syndrome (ARDS) as well as DIC. Diffuse pulmonary microthrombosis due to DIC can augment the lung injury associated with ARDS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=see_link\">",
"     \"Acute respiratory distress syndrome: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Central nervous system dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of neurologic abnormalities can occur in patients with DIC. These include coma, delirium, and transient focal neurologic symptoms. Microthrombi, hemorrhage, and hypoperfusion all may contribute.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Malignancy and acute DIC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although malignancy more often causes chronic DIC, it can produce acute DIC, particularly in acute promyelocytic leukemia (APL). Among patients with this disorder, DIC is often present at the time of diagnosis or soon after the initiation of cytotoxic chemotherapy. It can cause pulmonary or cerebrovascular hemorrhage in up to 40 percent of patients and some studies report a 10 to 20 percent incidence of early hemorrhagic deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25929/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rapid induction of tumor cell differentiation with all-trans-retinoic acid can lead to prompt improvement in the coagulopathy associated with APL [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25929/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/12/200?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults\", section on 'Disseminated intravascular coagulation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Chronic DIC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compensated or chronic DIC develops when blood is continuously or intermittently exposed to small amounts of tissue factor and compensatory mechanisms in the liver and bone marrow are largely able to replenish the depleted coagulation proteins and platelets, respectively. Under these conditions, the patient is either asymptomatic with increased levels of fibrin degradation products or has manifestations of venous",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    arterial thrombosis. Patients with chronic DIC may also have minor skin and mucosal bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Malignancy and chronic DIC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignancy, particularly solid tumors, is the most common cause of chronic DIC. Venous thromboses commonly present as deep venous thrombosis in the extremities or superficial migratory thrombophlebitis (Trousseau's syndrome), while arterial thromboses can produce digital ischemia, renal infarction, or stroke. Arterial ischemia can also be due to embolization from nonbacterial thrombotic (marantic) endocarditis. This subject is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=see_link\">",
"     \"Hypercoagulable disorders associated with malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laboratory findings used to confirm the diagnosis of DIC are somewhat different in acute and chronic disease (",
"    <a class=\"graphic graphic_table graphicRef63831 \" href=\"UTD.htm?34/15/35067\">",
"     table 1",
"    </a>",
"    ). Other issues that must be addressed are establishing the presence of DIC in patients with liver disease and differentiating DIC from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS), a clinically similar disorder with a different pathogenesis and treatment. These subjects are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Acute DIC",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of acute DIC is suggested by the history (eg, sepsis, trauma, malignancy), clinical presentation, moderate to severe thrombocytopenia",
"    <span class=\"nowrap\">",
"     (&lt;100,000/microL)",
"    </span>",
"    and the presence of microangiopathic changes on the peripheral blood smear (",
"    <a class=\"graphic graphic_picture graphicRef70851 \" href=\"UTD.htm?37/50/38694\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef50715 \" href=\"UTD.htm?22/13/22739\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The diagnosis is confirmed by a variety of laboratory studies that should demonstrate evidence of both increased thrombin generation (eg, decreased fibrinogen) as well as increased fibrinolysis (eg, elevated FDPs and D-dimer) (",
"    <a class=\"graphic graphic_table graphicRef63831 \" href=\"UTD.htm?34/15/35067\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef81428 \" href=\"UTD.htm?30/24/31118\">",
"     figure 1",
"    </a>",
"    ); the degree of abnormality in these findings may correlate with the extensiveness of organ involvement as well as overall mortality (",
"    <a class=\"graphic graphic_algorithm graphicRef78959 \" href=\"UTD.htm?32/4/32846\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25929/abstract/2,3,7-12\">",
"     2,3,7-12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=see_link\">",
"     \"Approach to the adult patient with a bleeding diathesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Fibrin degradation products, D-dimer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinically significant DIC is unlikely if there is no biochemical evidence of accelerated fibrinolysis (",
"    <a class=\"graphic graphic_table graphicRef78455 \" href=\"UTD.htm?16/22/16748\">",
"     table 2",
"    </a>",
"    ). Elevated D-dimer levels, reflecting degradation of cross-linked fibrin, are the most common abnormal parameter in patients with DIC [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25929/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. However, this finding is not specific for DIC, as there are multiple other causes for an elevated D-dimer level (",
"    <a class=\"graphic graphic_table graphicRef60881 \" href=\"UTD.htm?6/49/6940\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Measurement of D-dimer is more specific although somewhat less sensitive than a latex agglutination test for fibrin degradation products [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25929/abstract/13\">",
"     13",
"    </a>",
"    ]. The method of choice is the enzyme-linked immunosorbent assay (ELISA). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=see_link&amp;anchor=H21#H21\">",
"     \"Approach to the adult patient with a bleeding diathesis\", section on 'Tests for fibrinolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Prothrombin time",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolongation of the prothrombin time (PT) reflects reduced activity of the components of the extrinsic and common pathways. These include factors VII, X, V, and prothrombin, which are the most frequently decreased clotting proteins in DIC [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25929/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical use of coagulation tests\", section on 'Prothrombin time'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Activated PTT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The activated partial thromboplastin time (aPTT) measures the intrinsic and common pathways of coagulation. It is sensitive to deficiencies of factors XII, XI, IX and VIII, and less sensitive than the PT to deficiencies of components of the common pathway. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical use of coagulation tests\", section on 'Activated partial thromboplastin time'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Fibrinogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The plasma fibrinogen concentration is usually low in acute decompensated DIC, but may be elevated as an acute phase reactant in certain chronic conditions, including pregnancy. Thus, a plasma fibrinogen of 200",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    although within the normal range, may represent a significant decrease in a patient whose baseline level, because of underlying malignancy, sepsis, or inflammation, should be 800",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Other testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other",
"    studies which may be useful include the thrombin time and reptilase time, which are usually prolonged due to hypofibrinogenemia and the presence of fibrin degradation products. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical use of coagulation tests\", section on 'Thrombin time'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Specific assays can also be used to monitor various coagulation factors. Factors V and VIII, in addition to fibrinogen, are usually significantly depressed. Prothrombin levels may be normal in some patients, particularly those with abruptio placentae [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25929/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29417?source=see_link\">",
"     \"Placental abruption: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute DIC is also characterized by reduced levels of endogenous coagulation inhibitors such as antithrombin (AT), protein C, and protein S [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25929/abstract/16\">",
"     16",
"    </a>",
"    ]. A marked reduction in AT levels at the onset of septic shock may be a sensitive marker of unfavorable prognosis, presumably by permitting persistence of the procoagulant state [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25929/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Another potentially useful marker is measurement of soluble fibrin monomers. One study has shown that levels are elevated in DIC with a high degree of sensitivity and specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25929/abstract/18\">",
"     18",
"    </a>",
"    ]. However, specific assays for soluble fibrin monomers are not generally available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Chronic DIC",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above laboratory studies are variable in chronic DIC because a slower rate of consumption of coagulation factors may be balanced by enhanced synthesis of these proteins (",
"    <a class=\"graphic graphic_table graphicRef63831 \" href=\"UTD.htm?34/15/35067\">",
"     table 1",
"    </a>",
"    ). Thus, the platelet count may be only moderately reduced, plasma fibrinogen is often normal or slightly elevated, and the PT and aPTT may be within normal limits. In such patients, the diagnosis may be largely based upon evidence of microangiopathy on the peripheral blood smear and increased levels of FDPs and particularly, D-dimer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Acute DIC with severe liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe liver disease results in decreased synthesis of coagulation factors and inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25929/abstract/19\">",
"     19",
"    </a>",
"    ], and thrombocytopenia may be induced by hypersplenism secondary to portal hypertension. In addition, liver disease alone may be associated with chronic or intermittent fibrinolysis, fibrinogenolysis, and elevated levels of FDPs. Accordingly, it may be difficult to distinguish the coagulopathy associated with primary severe liver disease from the liver dysfunction often seen in patients with acute DIC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=see_link&amp;anchor=H20#H20\">",
"     \"Endoscopic procedures in patients with disorders of hemostasis\", section on 'Liver failure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33914?source=see_link&amp;anchor=H5858372#H5858372\">",
"     \"Coagulation abnormalities in patients with liver disease\", section on 'Infection and endogenous heparinoids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     DIC versus TTP-HUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of DIC, a thrombotic microangiopathy resulting from activation of the coagulation system, is different from the pathogenesis of another thrombotic microangiopathy, thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS), which results from primary platelet activation, due in many cases to a congenital or acquired defect in ADAMTS13, the von Willebrand factor cleaving protease, or primary endothelial injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=see_link\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Differences in pathogenesis between TTP-HUS and DIC result in coagulation abnormalities that usually permit these disorders to be distinguished [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25929/abstract/20\">",
"     20",
"    </a>",
"    ]. In one comparative study, although the plasma levels of soluble fibrin monomer, thrombin-antithrombin complex, plasmin-plasmin inhibitor complex, and D-dimer were significantly increased in the DIC patients, there were no significant differences in these markers between the DIC patients who survived and those who died. The plasma thrombomodulin (TM) levels in the DIC and TTP patients were significantly higher than those in healthy volunteers; plasma TM levels in the patients who died were significantly higher than those who survived. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/56/8073?source=see_link&amp;anchor=H6#H6\">",
"     \"Pathogenesis and etiology of disseminated intravascular coagulation\", section on 'Thrombotic microangiopathy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29721?source=see_link&amp;anchor=H18#H18\">",
"     \"Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'TTP-HUS versus DIC'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with TTP-HUS present with thrombocytopenia and a microangiopathic blood smear, but usually have normal levels of the coagulation components and little or no prolongation of the PT or aPTT (",
"    <a class=\"graphic graphic_table graphicRef78455 \" href=\"UTD.htm?16/22/16748\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef63416 \" href=\"UTD.htm?20/57/21404\">",
"     table 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25929/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. In addition to the different laboratory findings, TTP-HUS is usually not seen in the typical clinical settings that are associated with DIC (eg, sepsis, trauma, malignancy, and obstetrical complications).",
"   </p>",
"   <p>",
"    Establishing the correct diagnosis is important clinically, because TTP-HUS in adults is initially treated with plasma exchange, which may be life-saving; this is not the modality used to treat DIC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42490?source=see_link\">",
"     \"Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     DIC versus fibrinogenolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary fibrinogenolysis occurs when plasmin is generated in the absence of thrombosis. It is rare and may occur in certain conditions, such as direct infusion of thrombolytic agents and in patients with prostate cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25929/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. It can be distinguished from DIC by the absence of elevated levels of D-dimers.",
"   </p>",
"   <p>",
"    However, when fibrinolysis is prominent, elevated levels of D-dimer and other fibrin degradation products will be present (",
"    <a class=\"graphic graphic_table graphicRef78455 \" href=\"UTD.htm?16/22/16748\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21450?source=see_link&amp;anchor=H26#H26\">",
"     \"Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis\", section on 'Laboratory diagnosis of abnormal fibrinolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     DIC versus heparin-induced thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The appearance of otherwise unexplained thrombocytopenia, thrombosis associated with thrombocytopenia, a platelet count which has fallen 50 percent or more from a prior value, or necrotic skin lesions at",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    injection sites, should raise the possibility of heparin-induced thrombocytopenia (HIT) in any patient begun on heparin therapy within the preceding 5 to 10 days, or in a patient receiving prolonged treatment with low molecular weight heparin.",
"   </p>",
"   <p>",
"    The diagnosis of HIT is initially made on clinical grounds, because the assays with the highest sensitivity and specificity may not be readily available and have a slow turnaround time. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=see_link\">",
"     \"Heparin-induced thrombocytopenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute DIC is a serious complication associated with a high mortality rate, determined in part by the underlying disease. The reported mortality rate ranges from 40 to 80 percent in patients with severe sepsis, trauma, or burns [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25929/abstract/3,26-31\">",
"     3,26-31",
"    </a>",
"    ]. Risk factors for death include increasing age and the severity of the organ dysfunction and hemostatic abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25929/abstract/3\">",
"     3",
"    </a>",
"    ]. It is not clear, however, if the poor outcome in sepsis and trauma reflects the effects of DIC or the consequences of the systemic inflammatory response. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24744?source=see_link\">",
"     \"Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This last observation illustrates the central importance of correction of the underlying disease and initiating factors in any patient with DIC. Hemodynamic support is essential, but many patients do not require specific therapy for the coagulopathy, either because it is of short duration or because it is not severe enough to present a major risk of bleeding or thrombosis.",
"   </p>",
"   <p>",
"    In selected instances, the use of blood component replacement therapy or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    may be of value, although there are no controlled studies demonstrating definitive benefit. Restoration of physiologic levels of antithrombin may be another therapeutic option. In contrast, the administration of antifibrinolytic agents, such as epsilon-aminocaproic acid (EACA) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/52/6982?source=see_link\">",
"     aprotinin",
"    </a>",
"    , is generally CONTRAINDICATED, since blockade of the fibrinolytic system may increase the risk of thrombotic complications [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25929/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Platelet transfusion and fresh frozen plasma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with DIC bleed because of thrombocytopenia and coagulation factor deficiencies. There is no evidence to support the administration of platelets and coagulation factors in patients who are not bleeding or who are not at high risk of bleeding. However, treatment is justified in patients who have serious bleeding, are at high risk for bleeding (eg, after surgery), or require invasive procedures.",
"   </p>",
"   <p>",
"    Patients with marked",
"    <span class=\"nowrap\">",
"     (&lt;20,000/microL)",
"    </span>",
"    or moderate thrombocytopenia",
"    <span class=\"nowrap\">",
"     (&lt;50,000/microL)",
"    </span>",
"    and serious bleeding should be given platelet transfusions (1 to 2 units per 10 kg per day). Such patients typically show a less than expected rise in platelet count, due to ongoing platelet consumption. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37945?source=see_link&amp;anchor=H16695439#H16695439\">",
"     \"Refractoriness to platelet transfusion therapy\", section on 'Etiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20586?source=see_link&amp;anchor=H558395714#H558395714\">",
"     \"Clinical and laboratory aspects of platelet transfusion therapy\", section on 'TTP-HUS, HIT, and DIC'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With respect to replacement therapy, actively bleeding patients with a significantly elevated prothrombin time (INR)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a fibrinogen concentration &lt;50",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    should receive fresh frozen plasma or cryoprecipitate, the latter for fibrinogen replacement. It is preferable to keep the fibrinogen level &gt;100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef69637 \" href=\"UTD.htm?13/38/13932\">",
"     table 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/33/9752?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical use of plasma components\", section on 'Cryoprecipitate'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or other anticoagulants to interrupt the underlying coagulopathy in DIC would appear to be a logical therapeutic approach. However, there are no controlled trials indicating benefit and there is little evidence that the use of heparin improves organ dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25929/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. Additional arguments against the routine use of heparin include potential aggravation of bleeding and the likelihood that it will have reduced effect due to the low levels of AT (",
"    <a class=\"graphic graphic_table graphicRef76966 \" href=\"UTD.htm?43/22/44396\">",
"     table 6",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link&amp;anchor=H2#H2\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\", section on 'Use of heparin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is generally limited to the subset of patients with chronic, compensated (or low-grade) DIC who have predominantly thrombotic manifestations, such as migratory thrombophlebitis and acral ischemia. Heparin may be useful in patients with retained dead fetus and hypofibrinogenemia prior to the induction of labor, excessive bleeding associated with a giant hemangioma, and aortic aneurysm (prior to resection).",
"   </p>",
"   <p>",
"    Low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    may be a useful adjunct in the DIC associated with acute promyelocytic leukemia. However, since the DIC in that situation generally responds to treatment with all-trans retinoic acid, heparin is now rarely indicated. Other settings in which heparin might be used include malignancy and chronic DIC prior to surgery, septic abortion, and mismatched transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25929/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/12/200?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once the clinical decision has been made to employ",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in acute DIC, it is important to be sure that the patient's antithrombin (AT) level is near normal (ie, 80 to 100 percent), so that the biologically important heparin-AT complex can form and inactivate the serine protease procoagulants, particularly thrombin and factor Xa (",
"    <a class=\"graphic graphic_figure graphicRef64839 \" href=\"UTD.htm?35/16/36110\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The usual intravenous bolus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    injection of 5000 to 10,000 units should be avoided. One may start with an IV dose of 500 units per hour, aiming for an aPTT of about 45 sec. If the patient's baseline aPTT is prolonged, the situation is more difficult, and one aims for further slight prolongation of the aPTT. Once there is evidence of heparin effect, replacement therapy with fresh frozen plasma or cryoprecipitate is pursued. In chronic DIC, a continuous infusion can be used, beginning at 500",
"    <span class=\"nowrap\">",
"     units/hour.",
"    </span>",
"    Low molecular weight heparins are also efficacious.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Protein C concentrate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with homozygous protein C deficiency or acquired protein C deficiency (eg, due to meningococcemia) may develop purpura fulminans (retiform purpura) as part of their DIC (",
"    <a class=\"graphic graphic_picture graphicRef61719 \" href=\"UTD.htm?22/56/23426\">",
"     picture 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef74453 \" href=\"UTD.htm?7/14/7397\">",
"     picture 5",
"    </a>",
"    ). Such patients appear to benefit from the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/50/6949?source=see_link\">",
"     protein C concentrate",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25929/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. In one series of 12 patients with purpura fulminans so treated, none died despite a predicted mortality rate of 60 to 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25929/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25609?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment and prevention of meningococcal infection\", section on 'Protein C concentrate'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39608?source=see_link&amp;anchor=H136707379#H136707379\">",
"     \"Approach to the patient with retiform (angulated) purpura\", section on 'Life-threatening emergency (purpura fulminans)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The administration of FFP as a source of protein C is more difficult because of the short half-life of protein C in the plasma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=see_link\">",
"     \"Protein C deficiency\"",
"    </a>",
"    .) There are anecdotal reports that repeated plasma exchange has been helpful in maintaining normal levels of protein C when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/50/6949?source=see_link\">",
"     protein C concentrate",
"    </a>",
"    is not available [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25929/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Antithrombin",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, acute DIC is characterized by reduced levels of endogenous coagulation inhibitors such as antithrombin (AT, formerly known as antithrombin III), protein C, and protein S [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25929/abstract/16\">",
"     16",
"    </a>",
"    ]. A marked reduction in AT levels at the onset of septic shock may be a sensitive marker of unfavorable prognosis, presumably by permitting persistence of the procoagulant state [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25929/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In vitro data suggest that, in addition to anticoagulant properties, AT may decrease the inflammatory response of mononuclear cells and cultured endothelial cells to lipopolysaccharide by decreasing the transcription of genes for mediators such as interleukin-6 and tumor necrosis factor alpha [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25929/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While some clinical studies have suggested that AT therapy is beneficial in patients with severe sepsis or septic shock [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25929/abstract/42,43\">",
"     42,43",
"    </a>",
"    ], a subsequent randomized placebo controlled trial in 2314 patients with sepsis found no benefit in terms of mortality from AT administration, and there was an increased risk of bleeding in those who received both AT and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25929/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29960?source=see_link&amp;anchor=H2552815#H2552815\">",
"     \"Investigational and ineffective therapies for sepsis\", section on 'Ineffective therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Recombinant human factor VIIa",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/42/30373?source=see_link\">",
"     Recombinant human factor VIIa",
"    </a>",
"    has been used as a \"last resort\" in some patients with severe DIC-associated hemorrhage due to obstetric or other causes. However, at this time there is insufficient published data to draw any conclusions on its efficacy or safety in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25929/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/62/994?source=see_link\">",
"       \"Patient information: Disseminated intravascular coagulation (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disseminated intravascular coagulation may be acute or chronic. The diagnosis of DIC is suggested by the history (eg, presence of sepsis, trauma, malignancy), the clinical presentation (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Bleeding'",
"    </a>",
"    above), moderate to severe thrombocytopenia",
"    <span class=\"nowrap\">",
"     (&lt;100,000/microL)",
"    </span>",
"    and the presence of microangiopathic changes on the peripheral blood smear (",
"    <a class=\"graphic graphic_picture graphicRef70851 \" href=\"UTD.htm?37/50/38694\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef50715 \" href=\"UTD.htm?22/13/22739\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute DIC &mdash; the diagnosis of acute DIC is confirmed by demonstrating increased thrombin generation (eg, decreased fibrinogen) and increased fibrinolysis (eg, elevated FDPs and D-dimer); the degree of abnormality in these findings may correlate with the extensiveness of organ involvement (",
"      <a class=\"graphic graphic_table graphicRef63831 \" href=\"UTD.htm?34/15/35067\">",
"       table 1",
"      </a>",
"      ), (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Diagnosis'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Chronic DIC &mdash; The above laboratory studies are variable in chronic DIC because a slower rate of consumption of coagulation factors may be balanced by enhanced synthesis of these proteins. In such patients, the diagnosis may be largely based upon evidence of microangiopathy on the peripheral blood smear and increased levels of FDPs and particularly, D-dimer (",
"      <a class=\"graphic graphic_table graphicRef63831 \" href=\"UTD.htm?34/15/35067\">",
"       table 1",
"      </a>",
"      ), (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Diagnosis'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of the underlying disease (eg, sepsis) is of central importance in controlling acute or chronic DIC. Hemodynamic support is essential. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=see_link&amp;anchor=H3#H3\">",
"     \"Evaluation and management of severe sepsis and septic shock in adults\", section on 'Early management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many patients do not require specific therapy for the coagulopathy associated with DIC, either because it is of short duration or because it is not severe enough to present a major risk of bleeding or thrombosis (see",
"    <a class=\"local\" href=\"#H25\">",
"     'Treatment'",
"    </a>",
"    above). There is no evidence to support the administration of platelets and coagulation factors in patients who are not bleeding or who are not at high risk of bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Supportive modalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations concerning management of the coagulopathy associated with DIC are limited by the absence of controlled trials. We suggest the use of one or more of the following supportive modalities for the symptomatic patient (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment with platelets and coagulation factors is justified in patients who have serious bleeding, are at high risk for bleeding (eg, after surgery), or require invasive procedures. Patients with marked or moderate thrombocytopenia",
"      <span class=\"nowrap\">",
"       (&lt;50,000/microL)",
"      </span>",
"      and serious bleeding should be given platelet transfusions (1 to 2 units per 10 kg per day); (see",
"      <a class=\"local\" href=\"#H27\">",
"       'Platelet transfusion and fresh frozen plasma'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Actively bleeding patients with a significantly elevated prothrombin time (INR)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a fibrinogen concentration &lt;50",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      should receive fresh frozen plasma or cryoprecipitate in order to keep the fibrinogen level &gt;100",
"      <span class=\"nowrap\">",
"       mg/dL.",
"      </span>",
"     </li>",
"     <li>",
"      The administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      is generally limited to the subset of patients with chronic, compensated DIC who have predominantly thrombotic manifestations. It is important to be sure that the patient's antithrombin (AT) level is near normal (ie, 80 to 100 percent) in order for heparin to be effective (see",
"      <a class=\"local\" href=\"#H28\">",
"       'Heparin'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25929/abstract/1\">",
"      Matsuda T. Clinical aspects of DIC--disseminated intravascular coagulation. Pol J Pharmacol 1996; 48:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25929/abstract/2\">",
"      Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol 2009; 145:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25929/abstract/3\">",
"      Siegal T, Seligsohn U, Aghai E, Modan M. Clinical and laboratory aspects of disseminated intravascular coagulation (DIC): a study of 118 cases. Thromb Haemost 1978; 39:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25929/abstract/4\">",
"      Shultz PJ, Raij L. Endogenously synthesized nitric oxide prevents endotoxin-induced glomerular thrombosis. J Clin Invest 1992; 90:1718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25929/abstract/5\">",
"      Keeton M, Eguchi Y, Sawdey M, et al. Cellular localization of type 1 plasminogen activator inhibitor messenger RNA and protein in murine renal tissue. Am J Pathol 1993; 142:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25929/abstract/6\">",
"      Barbui T, Finazzi G, Falanga A. The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia. Blood 1998; 91:3093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25929/abstract/7\">",
"      Yu M, Nardella A, Pechet L. Screening tests of disseminated intravascular coagulation: guidelines for rapid and specific laboratory diagnosis. Crit Care Med 2000; 28:1777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25929/abstract/8\">",
"      Levi M. Current understanding of disseminated intravascular coagulation. Br J Haematol 2004; 124:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25929/abstract/9\">",
"      Taylor FB Jr, Toh CH, Hoots WK, et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001; 86:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25929/abstract/10\">",
"      Bakhtiari K, Meijers JC, de Jonge E, Levi M. Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation. Crit Care Med 2004; 32:2416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25929/abstract/11\">",
"      Gando S, Iba T, Eguchi Y, et al. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med 2006; 34:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25929/abstract/12\">",
"      Gando S, Saitoh D, Ogura H, et al. Natural history of disseminated intravascular coagulation diagnosed based on the newly established diagnostic criteria for critically ill patients: results of a multicenter, prospective survey. Crit Care Med 2008; 36:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25929/abstract/13\">",
"      Carr JM, McKinney M, McDonagh J. Diagnosis of disseminated intravascular coagulation. Role of D-dimer. Am J Clin Pathol 1989; 91:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25929/abstract/14\">",
"      Spero JA, Lewis JH, Hasiba U. Disseminated intravascular coagulation. Findings in 346 patients. Thromb Haemost 1980; 43:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25929/abstract/15\">",
"      Sutton DM, Hauser R, Kulapongs P, Bachmann F. Intravascular coagulation in abruptio placentae. Am J Obstet Gynecol 1971; 109:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25929/abstract/16\">",
"      Fourrier F, Chopin C, Goudemand J, et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992; 101:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25929/abstract/17\">",
"      Mesters RM, Mannucci PM, Coppola R, et al. Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood 1996; 88:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25929/abstract/18\">",
"      Wada H, Wakita Y, Nakase T, et al. Increased plasma-soluble fibrin monomer levels in patients with disseminated intravascular coagulation. Am J Hematol 1996; 51:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25929/abstract/19\">",
"      Stein SF, Harker LA. Kinetic and functional studies of platelets, fibrinogen, and plasminogen in patients with hepatic cirrhosis. J Lab Clin Med 1982; 99:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25929/abstract/20\">",
"      Wada H, Mori Y, Shimura M, et al. Poor outcome in disseminated intravascular coagulation or thrombotic thrombocytopenic purpura patients with severe vascular endothelial cell injuries. Am J Hematol 1998; 58:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25929/abstract/21\">",
"      George JN, Gilcher RO, Smith JW, et al. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: diagnosis and management. J Clin Apher 1998; 13:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25929/abstract/22\">",
"      Neame PB, Hirsh J, Browman G, et al. Thrombotic thrombocytopenic purpura: a syndrome of intravascular platelet consumption. Can Med Assoc J 1976; 114:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25929/abstract/23\">",
"      Lerner RG. The defibrination syndrome. Med Clin North Am 1976; 60:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25929/abstract/24\">",
"      Okajima K, Kohno I, Soe G, et al. Direct evidence for systemic fibrinogenolysis in patients with acquired alpha 2-plasmin inhibitor deficiency. Am J Hematol 1994; 45:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25929/abstract/25\">",
"      Sallah S, Gagnon GA. Reversion of primary hyperfibrinogenolysis in patients with hormone-refractory prostate cancer using docetaxel. Cancer Invest 2000; 18:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25929/abstract/26\">",
"      St&eacute;phan F, Hollande J, Richard O, et al. Thrombocytopenia in a surgical ICU. Chest 1999; 115:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25929/abstract/27\">",
"      Hulka F, Mullins RJ, Frank EH. Blunt brain injury activates the coagulation process. Arch Surg 1996; 131:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25929/abstract/28\">",
"      Selladurai BM, Vickneswaran M, Duraisamy S, Atan M. Coagulopathy in acute head injury--a study of its role as a prognostic indicator. Br J Neurosurg 1997; 11:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25929/abstract/29\">",
"      Olson JD, Kaufman HH, Moake J, et al. The incidence and significance of hemostatic abnormalities in patients with head injuries. Neurosurgery 1989; 24:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25929/abstract/30\">",
"      Gando S, Nanzaki S, Kemmotsu O. Disseminated intravascular coagulation and sustained systemic inflammatory response syndrome predict organ dysfunctions after trauma: application of clinical decision analysis. Ann Surg 1999; 229:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25929/abstract/31\">",
"      Garc&iacute;a-Avello A, Lorente JA, Cesar-Perez J, et al. Degree of hypercoagulability and hyperfibrinolysis is related to organ failure and prognosis after burn trauma. Thromb Res 1998; 89:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25929/abstract/32\">",
"      Ratnoff OD. Epsilon aminocaproic acid--a dangerous weapon. N Engl J Med 1969; 280:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25929/abstract/33\">",
"      Feinstein DI. Diagnosis and management of disseminated intravascular coagulation: the role of heparin therapy. Blood 1982; 60:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25929/abstract/34\">",
"      Feinstein DI. Treatment of disseminated intravascular coagulation. Semin Thromb Hemost 1988; 14:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25929/abstract/35\">",
"      Corrigan JJ Jr, Jordan CM. Heparin therapy in septicemia with disseminated intravascular coagulation. N Engl J Med 1970; 283:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25929/abstract/36\">",
"      Dreyfus M, Magny JF, Bridey F, et al. Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate. N Engl J Med 1991; 325:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25929/abstract/37\">",
"      Smith OP, White B, Vaughan D, et al. Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans. Lancet 1997; 350:1590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25929/abstract/38\">",
"      Rintala E, Sepp&auml;l&auml; OP, Kotilainen P, et al. Protein C in the treatment of coagulopathy in meningococcal disease. Crit Care Med 1998; 26:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25929/abstract/39\">",
"      Hodgson A, Ryan T, Moriarty J, et al. Plasma exchange as a source of protein C for acute onset protein C pathway failure. Br J Haematol 2002; 116:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25929/abstract/40\">",
"      Baker PM, Keeling DM, Murphy M. Plasma exchange as a source of protein C for acute-onset protein C pathway failure. Br J Haematol 2003; 120:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25929/abstract/41\">",
"      Oelschl&auml;ger C, R&ouml;misch J, Staubitz A, et al. Antithrombin III inhibits nuclear factor kappaB activation in human monocytes and vascular endothelial cells. Blood 2002; 99:4015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25929/abstract/42\">",
"      Eisele B, Lamy M, Thijs LG, et al. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med 1998; 24:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25929/abstract/43\">",
"      Baudo F, Caimi TM, de Cataldo F, et al. Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. Intensive Care Med 1998; 24:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25929/abstract/44\">",
"      Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001; 286:1869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25929/abstract/45\">",
"      Franchini M, Manzato F, Salvagno GL, Lippi G. Potential role of recombinant activated factor VII for the treatment of severe bleeding associated with disseminated intravascular coagulation: a systematic review. Blood Coagul Fibrinolysis 2007; 18:589.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1306 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-1A66C01F0E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_20_25929=[""].join("\n");
var outline_f25_20_25929=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Acute DIC",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Bleeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Acute renal failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Hepatic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Central nervous system dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Malignancy and acute DIC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Chronic DIC",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Malignancy and chronic DIC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Acute DIC",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Fibrin degradation products, D-dimer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Prothrombin time",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Activated PTT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Fibrinogen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Other testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Chronic DIC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Acute DIC with severe liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      DIC versus TTP-HUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      DIC versus fibrinogenolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      DIC versus heparin-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Platelet transfusion and fresh frozen plasma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Heparin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Protein C concentrate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Antithrombin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Recombinant human factor VIIa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Supportive modalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/1306\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1306|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?32/4/32846\" title=\"algorithm 1\">",
"      Pathophysiology of DIC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1306|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/24/31118\" title=\"figure 1\">",
"      Regulation of fibrinolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/16/36110\" title=\"figure 2\">",
"      Mechanisms of action of heparin LMW heparin and fondaparinux",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1306|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/52/4932\" title=\"picture 1\">",
"      Genesis of schistocyte",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/50/38694\" title=\"picture 2\">",
"      Schistocytes on peripheral smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/13/22739\" title=\"picture 3\">",
"      Helmet cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/56/23426\" title=\"picture 4\">",
"      Disseminated intravascular coagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/14/7397\" title=\"picture 5\">",
"      Disseminated intravascular coagulation acral purpura",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1306|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/15/35067\" title=\"table 1\">",
"      Acute versus chronic DIC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/22/16748\" title=\"table 2\">",
"      Lab diagnosis fibrinolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/49/6940\" title=\"table 3\">",
"      Causes elevated D-dimer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/57/21404\" title=\"table 4\">",
"      Lab findings TTP HUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/38/13932\" title=\"table 5\">",
"      Use of plasma components",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/22/44396\" title=\"table 6\">",
"      Thrombophilia test interference",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=related_link\">",
"      Acute respiratory distress syndrome: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=related_link\">",
"      Approach to the adult patient with a bleeding diathesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39608?source=related_link\">",
"      Approach to the patient with retiform (angulated) purpura",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=related_link\">",
"      Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20586?source=related_link\">",
"      Clinical and laboratory aspects of platelet transfusion therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/12/200?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=related_link\">",
"      Clinical use of coagulation tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/33/9752?source=related_link\">",
"      Clinical use of plasma components",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33914?source=related_link\">",
"      Coagulation abnormalities in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29721?source=related_link\">",
"      Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=related_link\">",
"      Endoscopic procedures in patients with disorders of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=related_link\">",
"      Evaluation and management of severe sepsis and septic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=related_link\">",
"      Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=related_link\">",
"      Heparin-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=related_link\">",
"      Hypercoagulable disorders associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29960?source=related_link\">",
"      Investigational and ineffective therapies for sepsis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/56/8073?source=related_link\">",
"      Pathogenesis and etiology of disseminated intravascular coagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4170?source=related_link\">",
"      Pathogenesis and etiology of postischemic (ischemic) acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/62/994?source=related_link\">",
"      Patient information: Disseminated intravascular coagulation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29417?source=related_link\">",
"      Placental abruption: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=related_link\">",
"      Protein C deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37945?source=related_link\">",
"      Refractoriness to platelet transfusion therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24744?source=related_link\">",
"      Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=related_link\">",
"      Therapeutic use of heparin and low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21450?source=related_link\">",
"      Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25609?source=related_link\">",
"      Treatment and prevention of meningococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42490?source=related_link\">",
"      Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_20_25930="Diagnosis and treatment of gram-negative bacillary meningitis";
var content_f25_20_25930=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and treatment of gram-negative bacillary meningitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/20/25930/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/20/25930/contributors\">",
"     N Deborah Friedman, MPH, MBBS, FRACP, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/20/25930/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/20/25930/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/20/25930/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/20/25930/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/20/25930/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/20/25930/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 23, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gram-negative bacilli are an important cause of nosocomial meningitis, accounting for 33 percent of 197 episodes in the same report [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/1\">",
"     1",
"    </a>",
"    ]. Major risk factors for nosocomial meningitis include neurosurgery or head trauma within the past month, presence of a neurosurgical device, and a cerebrospinal fluid (CSF) leak. Gram-negative bacilli remain an uncommon cause of community-acquired bacterial meningitis in adults, accounting for 3 to 11 percent of episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gram-negative bacillary meningitis is often fatal with reported mortality rates of 40 to 80 percent in adults and children and complications are common in patients who survive [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. In one study conducted over a 21-year period, 61 percent of infants who survived gram-negative meningitis had developmental disabilities and neurologic sequelae [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/6\">",
"     6",
"    </a>",
"    ]. Thus, timely identification of the infection and early commencement of therapy are vital.",
"   </p>",
"   <p>",
"    The diagnosis and treatment of gram-negative bacillary meningitis will be reviewed here. The epidemiology and clinical manifestations of this infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/13/16600?source=see_link\">",
"     \"Epidemiology and clinical features of gram-negative bacillary meningitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of gram-negative meningitis predominantly relies upon examination of the cerebrospinal fluid (CSF). Although not always diagnostic, CSF analysis remains the mainstay of early diagnosis. However, in patients who have undergone neurosurgical procedures, CSF protein, glucose, leukocyte counts and Gram stain do not reliably distinguish bacterial meningitis from nonbacterial processes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gram-negative meningitis rarely causes nosocomial infection in patients who have no history of head trauma, neurosurgical procedures, or immunosuppression. Thus, lumbar puncture performed to exclude nosocomial meningitis as the cause of mental status changes in a hospitalized patient without the preceding conditions has a low yield and rarely changes management [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/8\">",
"     8",
"    </a>",
"    ]. The rarity of nosocomial meningitis was documented in a study done in a university hospital in Turkey [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/9\">",
"     9",
"    </a>",
"    ]. Nosocomial meningitis occurred in 0.3 percent of all admissions and accounted for 0.5 percent of all hospital-acquired infections during an eight year period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Cerebrospinal fluid analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The appropriate CSF analysis for patients with suspected bacterial meningitis includes protein, glucose, and cell count determinations and a Gram stain. CSF lactate levels can also be measured.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Protein &mdash; CSF protein levels in gram-negative bacillary meningitis are usually but not invariably high. As an example, CSF protein ranged from 17 to 1900",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      in one series, but in 62 percent of patients, levels exceeded 200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/6\">",
"       6",
"      </a>",
"      ]. In another review, mean protein levels ranged from 171 to 1123",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Glucose &mdash; The CSF glucose concentration is usually low in gram-negative bacillary meningitis. CSF glucose ranged from 0 to 4.3",
"      <span class=\"nowrap\">",
"       mmol/L",
"      </span>",
"      (77",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      in one study; in 88 percent of patients, the value was &lt;2.8",
"      <span class=\"nowrap\">",
"       mmol/L",
"      </span>",
"      (&lt;50",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/6\">",
"       6",
"      </a>",
"      ]. The glucose level in another case series ranged from 32 to 72",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/7\">",
"       7",
"      </a>",
"      ]. Nearly three quarters of patients with gram-negative meningitis have CSF to blood glucose concentration ratios less than 0.5 [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/6\">",
"       6",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      It appears that the mean CSF glucose is lower in cases of spontaneous gram-negative bacillary meningitis than in those cases that follow neurosurgical procedures, despite similar CSF protein and leukocyte counts [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/11\">",
"       11",
"      </a>",
"      ]. The reasons for this observation remain obscure. It is important to note that CSF to serum glucose ratios of less than 50 percent are infrequent after uncomplicated neurosurgical procedures [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cell count &mdash; Patients with gram-negative bacillary meningitis typically have elevated leukocyte counts. CSF leukocyte counts range from 0 to 80,600",
"      <span class=\"nowrap\">",
"       cells/mm3",
"      </span>",
"      in various reviews of gram-negative bacillary meningitis [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/6,13\">",
"       6,13",
"      </a>",
"      ]; polymorphonuclear leukocytes (PMNs) account for more than 50 percent of these cells in 90 percent of cases. In one series, CSF white cell counts ranged from 3,174 to 12,495",
"      <span class=\"nowrap\">",
"       cells/mm3",
"      </span>",
"      depending upon which species of gram-negative bacillus was isolated, and 57 to 80 percent of these cells consisted of PMNs [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/10\">",
"       10",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In one pediatric case series, six percent of patients with gram-negative bacillary meningitis had normal CSF leukocyte counts [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/6\">",
"       6",
"      </a>",
"      ]. Possible explanations for this infrequent and sometimes misleading finding include early timing of the lumbar puncture (LP) prior to the development of inflammation, failure of fluid obtained from the lumbar space to mirror the inflammatory changes present in ventricular fluid, or inability of young infants to mount an inflammatory response.",
"     </li>",
"     <li>",
"      Gram stain &mdash; The Gram stain of CSF is a crucial component of the diagnostic process. This test can be performed rapidly and may be a crucially important early clue to the diagnosis and appropriate early therapy. The Gram stain is positive for gram-negative bacilli in more than 50 percent of adult patients with a positive culture result [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/12\">",
"       12",
"      </a>",
"      ]. In a large pediatric series, the CSF Gram stain was positive in 61 percent of patients with culture-proven gram-negative meningitis. The Gram stain was negative in all patients with a sterile CSF culture in this same case series [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/6\">",
"       6",
"      </a>",
"      ]. However it is important to emphasize that false negative and false positive Gram stain results occasionally occur, and the properties and morphology of organisms seen on CSF Gram stain can be misinterpreted [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/12\">",
"       12",
"      </a>",
"      ]. Thus, a negative or positive Gram stain should not be the sole basis for starting empiric therapy.",
"     </li>",
"     <li>",
"      Culture &mdash; CSF culture is essential to establish the etiology of meningitis and to determine the antimicrobial susceptibilities of the pathogen [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Polymerase chain reaction &mdash; Polymerase chain reaction (PCR) amplification and sequencing of 16S ribosomal DNA can be performed on CSF for the diagnosis of meningitis. This method has shown a sensitivity of 86 percent and a specificity of 97 percent compared to culture. Importantly, this may be the diagnostic method of choice when antimicrobial therapy has already started or when cultures remain negative [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/14\">",
"       14",
"      </a>",
"      ]. However, this technology is not available in most hospital laboratories and careful quality control measures are mandatory to prevent false positive results.",
"     </li>",
"     <li>",
"      Lactate &mdash; Measurement of the CSF lactate concentration is a rapid and inexpensive ancillary test, that occasionally may help support an early diagnosis of bacterial meningitis. Because lactate levels are not affected by the presence of red blood cells in the CSF, lactate testing can sometimes be helpful when the CSF is bloody or when routine tests give inconclusive results. In one study of CSF lactate levels in the diagnosis of bacterial meningitis following neurosurgery, lactate levels had a higher sensitivity and specificity compared to the CSF to blood glucose ratios (88 versus 77 percent and 98 versus 87 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/7\">",
"       7",
"      </a>",
"      ]. Cases of proven bacterial meningitis in this study had mean CSF lactate levels of 7.8",
"      <span class=\"nowrap\">",
"       mmol/L,",
"      </span>",
"      while nonbacterial cases had mean lactate levels of 2.3",
"      <span class=\"nowrap\">",
"       mmol/L.",
"       <br/>",
"       <br/>",
"       Despite",
"      </span>",
"      these data, testing for CSF lactate levels is not routinely ordered or performed in clinical practice because many physicians perceive that this test does not offer substantially more information than standard CSF analysis for the diagnosis of bacterial meningitis. There have also been inconsistencies in the reported diagnostic power of the test [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Blood cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood cultures are also important for the isolation of a pathogen in patients with meningitis. Bacteremia is detectable in approximately 50 percent of adult patients with gram-negative bacillary meningitis, and bacteremic infection may precede clinical evidence of central nervous system (CNS) infection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/12\">",
"     12",
"    </a>",
"    ]. In fact, bacteremia is an important prognostic feature of gram-negative bacillary meningitis; patients with accompanying bloodstream infection have mortality rates up to five times higher than non-bacteremic patients in some studies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Computed tomographic scanning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Performing cranial computed tomographic (CT) scanning has become almost routine practice prior to LP in many medical centers, despite the fact that cerebral herniation is a very rare complication of LP even in patients with purulent meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/15\">",
"     15",
"    </a>",
"    ]. A study has identified clinical criteria which are associated with a high risk of abnormal findings on CT [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/16\">",
"     16",
"    </a>",
"    ]. These criteria include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age over 60 years",
"     </li>",
"     <li>",
"      The presence of an immunocompromising condition or therapy",
"     </li>",
"     <li>",
"      History of CNS lesion",
"     </li>",
"     <li>",
"      History of seizure within previous week",
"     </li>",
"     <li>",
"      Abnormal level of consciousness",
"     </li>",
"     <li>",
"      Inability to answer two consecutive questions correctly, or to follow two consecutive commands",
"     </li>",
"     <li>",
"      Abnormal neurologic signs: gaze palsy, abnormal visual fields, facial palsy, arm drift, leg drift, abnormal language",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We support the use of a focused approach, in which CT is performed only in patients who have one or more clinical features (as mentioned above) consistent with an intracranial mass lesion, or increased CSF pressure. Patients who have undergone neurosurgical procedures are one important exception to this recommendation; all such patients should have a CT scan prior to LP.",
"   </p>",
"   <p>",
"    When cranial imaging is indicated, it is prudent to obtain blood cultures and commence empiric antibiotic therapy before sending the patient for the CT since delay in administering antibiotics may have a deleterious effect on the outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/17\">",
"     17",
"    </a>",
"    ]. The LP should be immediately performed after the imaging, if no intracranial mass lesion is visualized [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/18\">",
"     18",
"    </a>",
"    ]. A single dose of antibiotic administered before lumbar puncture is unlikely to influence the outcome of CSF culture results [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22810?source=see_link\">",
"     \"Initial therapy and prognosis of bacterial meningitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES FOR TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of gram-negative bacillary meningitis remains a therapeutic challenge. Despite appropriate therapy and an apparent clinical response, CSF cultures may remain positive for as long as 13 days after treatment is begun [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. The average duration of therapy needed to sterilize the CSF is two to four days in adults and 2.8 to 8.2 days in neonates [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/20\">",
"     20",
"    </a>",
"    ]. In a series of 98 neonates and infants, positive results were obtained on CSF cultures for one to 18 days after the commencement of antibiotic therapy (mean 2.9 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/6\">",
"     6",
"    </a>",
"    ]. The longer the CSF remains positive in neonates, the greater the chance of neurologic deficits in the survivors [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/6,20\">",
"     6,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Antimicrobial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Effective antimicrobial therapy for gram-negative bacillary meningitis is limited by several factors. These include [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/12,22\">",
"     12,22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antibiotic resistance among many pathogens",
"     </li>",
"     <li>",
"      Poor diffusion of some antibiotics with activity against gram-negative pathogens into the subarachnoid space",
"     </li>",
"     <li>",
"      Serious coexisting comorbidities",
"     </li>",
"     <li>",
"      The absence of intrinsic opsonic and bactericidal activity of CSF",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intravenous antibiotic therapy is the standard of care for gram-negative bacillary meningitis. Intrathecal or intraventricular therapy (with aminoglycosides) is used on rare occasions concomitantly with intravenous aminoglycoside therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/23\">",
"     23",
"    </a>",
"    ]. These invasive methods of delivery overcome the problem of poor penetration of aminoglycosides into the CSF but have been associated with poorer outcomes when compared with intravenous therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/18,23\">",
"     18,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bacterial meningitis should be treated with an antibiotic agent that penetrates the CSF in adequate concentrations to exhibit bactericidal activity against the responsible pathogen [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22810?source=see_link\">",
"     \"Initial therapy and prognosis of bacterial meningitis in adults\"",
"    </a>",
"    .) Patients with gram-negative bacillary meningitis who are treated with bacteriostatic antibiotics have poor clinical outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bactericidal activity of antibiotic therapy in the CSF is affected by the penetration, concentration, and intrinsic activity of the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/18\">",
"     18",
"    </a>",
"    ]. The minimum concentration of a drug in the CSF needed for bactericidal activity is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/18\">",
"     18",
"    </a>",
"    ]. Some authorities advocate that antibiotics should be chosen that achieve CSF levels ten or more times above the minimum bactericidal concentration (MBC) of the organism [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/25\">",
"     25",
"    </a>",
"    ], and we subscribe to this view.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no comparative studies of the duration of treatment in patients with gram-negative meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/18\">",
"     18",
"    </a>",
"    ]. We recommend at least 21 days of therapy, because high rates of relapse occur in patients treated with shorter courses [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/23,26\">",
"     23,26",
"    </a>",
"    ]. However, the length of therapy ultimately should be tailored to each individual patient.",
"   </p>",
"   <p>",
"    The CSF should be reanalyzed after the commencement of therapy to assess response. There are no definitive published data on the ideal timing of a repeat LP. Since the average duration of therapy needed to sterilize the CSF in adults is two to four days [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/20\">",
"     20",
"    </a>",
"    ], we believe that the CSF should be sampled again after four to five days of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Role of dexamethasone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     Dexamethasone",
"    </a>",
"    is not warranted for management of raised intracranial pressure and of the inflammation associated with gram-negative bacillary meningitis, given the lack of evidence for benefit and risk of toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although treatment of raised intracranial pressure and of the inflammation associated with bacterial meningitis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    improves the neurologic outcome in selected children and adults, trials have not generally included patients with gram-negative infections. Caution should be exercised regarding use of dexamethasone for types of meningitis where no beneficial effect has been found [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Human studies on the benefit of adjunctive steroid therapy in patients with gram-negative meningitis are not likely to be performed for multiple reasons: (1) gram-negative meningitis is uncommon, and (2) affected patients often have co-morbid conditions that are either confounding",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    could be adversely affected by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23080?source=see_link\">",
"     \"Dexamethasone to prevent neurologic complications of bacterial meningitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/21/4442?source=see_link&amp;anchor=H3#H3\">",
"     \"Dexamethasone and other measures to prevent neurologic complications of bacterial meningitis in children\", section on 'Dexamethasone'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CHOICE OF ANTIMICROBIAL DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Until expanded-spectrum cephalosporins became available, the treatment of gram-negative bacillary meningitis relied mainly upon parenteral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/24\">",
"     24",
"    </a>",
"    ] or direct instillation of antimicrobials into the CNS [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/20,29\">",
"     20,29",
"    </a>",
"    ]. Relapses and chronicity were common with this type of meningitis until highly active cephalosporins were first released [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Cephalosporins",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Third generation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Broad-spectrum cephalosporins have been the treatment of choice for gram-negative bacillary meningitis since the late 1980s [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. These antibiotics have a high level of in vitro activity against gram-negative pathogens and penetrate extremely well into the CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/18\">",
"     18",
"    </a>",
"    ]. Clinical outcomes improved remarkably since their introduction; success rates of 85 to 90 percent were reported in some studies when these drugs were used [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/18\">",
"     18",
"    </a>",
"    ]. As an example,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    is effective in treating meningitis due to this organism (cure rate 70 to 75 percent, with or without concomitant systemic aminoglycoside therapy) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, despite these optimistic results with the third generation cephalosporins, some specialists expressed caution and predicted that monotherapy with cephalosporins would likely fail as therapy for CNS infections due to Enterobacter, Serratia, Pseudomonas and Acinetobacter [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/25\">",
"     25",
"    </a>",
"    ]. Indeed, these predictions were accurate.",
"   </p>",
"   <p>",
"    Therapeutic failures have now been reported with the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    in meningitis due to Pseudomonas, Enterobacter, Citrobacter and Klebsiella [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/32\">",
"     32",
"    </a>",
"    ]. Third generation cephalosporins also did not reduce the mortality rate in cases of Klebsiella pneumoniae meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nine percent of patients with gram-negative bacillary meningitis had isolates resistant to third-generation cephalosporins in one series of patients treated over a 12-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/33\">",
"     33",
"    </a>",
"    ]. In a series of patients treated over a six year period, 25 percent of isolates were resistant to third-generation cephalosporins [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/34\">",
"     34",
"    </a>",
"    ]. The authors noted an increase in resistance to these drugs from 1994 onwards. Cephalosporin-resistant pathogens included Acinetobacter baumannii, K. pneumoniae, C. freundii and Morganella morganii. These authors cautioned that third-generation cephalosporin resistance should be highly suspected in cases of nosocomially-acquired post-neurosurgical gram-negative meningitis.",
"   </p>",
"   <p>",
"    In addition to the problem of innate resistance, the emergence of resistance to multiple beta-lactam antibiotics has occurred in 14 to 56 percent of patients infected with gram-negative bacilli that possess inducible beta-lactamases [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/33\">",
"     33",
"    </a>",
"    ]. This type of secondary resistance to beta-lactam agents was present in 30 percent of cases of meningitis due to Enterobacter in a case series [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, a case report has highlighted the management challenge of nosocomial meningitis due to ESBL positive K. pneumoniae [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/35\">",
"     35",
"    </a>",
"    ]. As a result of the above observations, monotherapy with a third generation cephalosporin should only be continued when the identity of the organism and its susceptibility patterns are known is known and secondary resistance is deemed to be unlikely to occur.",
"   </p>",
"   <p>",
"    Serial testing for the emergence of resistance during therapy of gram-negative meningitis may be warranted even when initial in vitro susceptibility is documented. Such emergence of resistance during therapy is illustrated by a case report of two patients with E. cloacae meningitis who developed serial step-wise decreases in susceptibility to cephalosporins during treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/36\">",
"     36",
"    </a>",
"    ]. For this reason, some authors recommend that initial therapy for patients with gram-negative meningitis include an aminoglycoside plus a third-generation cephalosporin [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Fourth generation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The in vitro data on fourth generation cephalosporins suggest that these drugs may have utility in the treatment of gram-negative meningitis. However, clinical data are limited.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"       Cefepime",
"      </a>",
"      &mdash; Cefepime is a fourth-generation cephalosporin with a gram-negative spectrum similar to that of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"       ceftazidime",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/37\">",
"       37",
"      </a>",
"      ]. Some organisms resistant to the third-generation cephalosporins remain susceptible to cefepime because it is less likely to be hydrolyzed by beta-lactamases [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/37\">",
"       37",
"      </a>",
"      ]. Cefepime penetrates into the CSF as well as most third generation cephalosporins (5 to 20 percent of serum levels [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/12\">",
"       12",
"      </a>",
"      ]). Cefepime has been studied as a therapy for meningitis in children [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/37\">",
"       37",
"      </a>",
"      ]. Cefepime resulted in a similar outcome and number of adverse events when compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"       cefotaxime",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      in the treatment of gram-negative meningitis due to susceptible organisms [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/37\">",
"       37",
"      </a>",
"      ]. Concentrations of cefepime in the CSF varied from 55 to 95 times greater than the maximal minimum inhibitory concentration (MIC) required by the causative pathogens in one study of predominantly gram-positive bacteria [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cefpirome &mdash; Cefpirome has a broad range of in vitro antibacterial activity that includes P. aeruginosa [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/39\">",
"       39",
"      </a>",
"      ]. Cefpirome produces levels in the CSF that are 5 to 20 percent of the serum concentration of the drug [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/23\">",
"       23",
"      </a>",
"      ]. The concentrations of drug in the CSF after a single intravenous dose are in excess of the reported MBCs for most pathogens responsible for community and hospital-acquired bacterial meningitis [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/39,40\">",
"       39,40",
"      </a>",
"      ]. The CSF to serum concentration is also 11 to 49 percent of serum levels at two hours after a dose of cefpirome, and the antibiotic concentration after eight hours is still well in excess of the MBC for the most common gram-negative organisms that cause meningitis [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/40\">",
"       40",
"      </a>",
"      ]. This agent is not available in the United States or Australia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of classes of antibiotics with substantial activity against gram-negative bacilli. A number of these drugs also penetrate into the cerebrospinal fluid (CSF). However, clinical data on the treatment of gram-negative bacillary meningitis with some of these agents are not extensive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Aztreonam",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=see_link\">",
"     Aztreonam",
"    </a>",
"    is a monobactam that is highly active against aerobic gram-negative bacteria that are common causes of gram-negative bacillary meningitis, including Pseudomonas aeruginosa [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. It is ineffective against anaerobic pathogens and gram-positive cocci.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=see_link\">",
"     Aztreonam",
"    </a>",
"    has excellent CSF penetration into either inflamed or uninflamed meninges [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. In an animal meningitis model, for example, the CSF penetration of aztreonam was 23 percent of serum levels, which is comparable to levels achieved with other beta-lactams in the same model [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/41,44\">",
"     41,44",
"    </a>",
"    ]. A single-dose pharmacokinetic study [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/45\">",
"     45",
"    </a>",
"    ] and a clinical trial in pediatric patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/44\">",
"     44",
"    </a>",
"    ] demonstrated that aztreonam produced CSF levels that were 17 and 38 percent, respectively, of simultaneous serum concentrations. These levels are adequate for the treatment of meningitis caused by most gram-negative bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical studies in both adults and children have demonstrated the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=see_link\">",
"     aztreonam",
"    </a>",
"    in cases of meningitis caused by Serratia marcescens, Klebsiella pneumoniae, Enterobacter spp, Pseudomonas spp, Proteus mirabilis, Escherichia coli, and Morganella morganii [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. However, there were microbiologic and clinical failures reported in meningitis caused by Proteus vulgaris and Salmonella spp [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/42,44\">",
"     42,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Carbapenems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both imipenem and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    penetrate well into the CSF of children with inflamed meninges. In addition, imipenem shows both good in vitro activity against many highly-resistant gram-negative bacilli [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/46,47\">",
"     46,47",
"    </a>",
"    ], and overall good efficacy in the treatment of meningitis in both children and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/46,48\">",
"     46,48",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/36/38472?source=see_link\">",
"     Imipenem-cilastatin",
"    </a>",
"    penetrates the CSF well and achieves CSF concentrations that are 15 to 27 percent of serum levels for imipenem and 16 to 66 percent for cilastatin [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/49\">",
"     49",
"    </a>",
"    ]. However, despite the ability of imipenem to sterilize the CSF in cases of bacterial meningitis, its use has been limited by its potential to cause seizures as a side effect in up to 33 percent of pediatric patients with meningitis who were treated with this drug [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/46,50,51\">",
"     46,50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one review of gram-negative bacillary meningitis in adults, imipenem appeared to be an appropriate choice for organisms resistant to third-generation cephalosporins [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/33\">",
"     33",
"    </a>",
"    ]. However, we generally advise using the related drug,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    . Meropenem does not share the epileptogenic potential of imipenem, and it has efficacy equivalent to that of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    for meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/31,46\">",
"     31,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"     Meropenem",
"    </a>",
"    therapy is indicated for the treatment of nosocomial infections of the central nervous system (CNS) by multiresistant gram-negative bacilli, such as Klebsiella, Serratia, Enterobacter, and Acinetobacter [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/46,52\">",
"     46,52",
"    </a>",
"    ]. Carbapenem therapy has also been used successfully to treat Salmonella meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/53\">",
"     53",
"    </a>",
"    ], C. diversus meningitis, and brain abscess in infants [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/54\">",
"     54",
"    </a>",
"    ]. Meropenem may also be useful in the treatment of meningitis caused by P. aeruginosa, when other treatments have failed [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/31,52\">",
"     31,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite good in vitro activity,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    therapy can fail because of the emergence of resistance during therapy. As an example, there are reports of the appearance of resistance to meropenem during the treatment of meningitis caused by Acinetobacter [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/55\">",
"     55",
"    </a>",
"    ]. In addition, imipenem resistance has appeared during the treatment of meningitis due to P. aeruginosa [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23402?source=see_link\">",
"     \"Treatment and prevention of Acinetobacter infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23402?source=see_link&amp;anchor=H1211160#H1211160\">",
"     \"Treatment and prevention of Acinetobacter infection\", section on 'Meningitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another source of concern is the emergence of carbapenem-resistant K. pneumoniae in New York City [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/56\">",
"     56",
"    </a>",
"    ]. These isolates are also resistant to all beta-lactam antibiotics and most are resistant to aminoglycosides and fluoroquinolones. In addition, detection of carbapenem resistance in some of these organisms is difficult if automated susceptibility testing systems are used [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2226912\">",
"    <span class=\"h3\">",
"     Trimethoprim-sulfamethoxazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     Trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX) penetrates well into the CSF and has bactericidal activity in vitro against numerous gram-negative organisms responsible for causing meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/12\">",
"     12",
"    </a>",
"    ]. Many species of Klebsiella, Enterobacter, Serratia, Citrobacter, and Salmonella are susceptible in vitro to TMP-SMX [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/12\">",
"     12",
"    </a>",
"    ]. However, some gram-negative bacilli are not killed by TMP-SMX. Consistent bactericidal activity, for example, has not been shown against Klebsiella or Providencia, and treatment failures have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TMP-SMX is a valuable treatment option, especially in cases of meningitis caused by gram-negative bacilli such as Salmonella, Acinetobacter calcoaceticus, Burkholderia cepacia or Flavobacterium meningosepticum, which are often resistant to third-generation cephalosporins [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/24\">",
"     24",
"    </a>",
"    ]. Therapy with TMP-SMX may also be indicated for patients with meningitis caused by gram-negative bacilli that are only moderately sensitive to cephalosporins [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/24\">",
"     24",
"    </a>",
"    ], or by organisms that have the propensity to acquire resistance to cephalosporins via an inducible beta-lactamase [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/2\">",
"     2",
"    </a>",
"    ]. This latter group includes Enterobacter, for which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    treatment failures have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/24\">",
"     24",
"    </a>",
"    ]. Enterobacter meningitis has been successfully treated with TMP-SMX, which was a more effective therapy than the cephalosporins in one review [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In vitro studies suggest synergy between TMP-SMX and aminoglycosides against gram-negative bacilli [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/24\">",
"     24",
"    </a>",
"    ]. Thus, occasionally these drugs may be useful in combination.",
"   </p>",
"   <p>",
"    It is noteworthy that the use of TMP-SMX for prophylaxis of Pneumocystis jiroveci pneumonia (PCP) in patients with human immunodeficiency virus (HIV) infection or other types of immunosuppression may cause various body sites to become colonized with resistant species of organisms, such as Pseudomonas. Thus, TMP-SMX is not a good choice for empiric therapy in individuals with gram-negative bacillary meningitis who are currently, or were recently, taking this drug [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2227105\">",
"    <span class=\"h3\">",
"     Aminoglycosides",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aminoglycosides penetrate the blood-brain barrier poorly [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/21\">",
"     21",
"    </a>",
"    ], and do not usually achieve sufficient concentrations in the CSF to kill meningeal pathogens when administered parenterally [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/4,23\">",
"     4,23",
"    </a>",
"    ]. Parenteral aminoglycosides are useful only when given with another bactericidal drug that penetrates the CSF well [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/25\">",
"     25",
"    </a>",
"    ]. For this reason, they are usually combined with a third-generation cephalosporin, especially for treatment of fastidious gram-negative microorganisms [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/23\">",
"     23",
"    </a>",
"    ]. Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    is most often used,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    can be substituted if either is substantially more potent in vitro than gentamicin.",
"   </p>",
"   <p>",
"    Intrathecal plus simultaneous intravenous therapy with aminoglycosides can be used to treat gram-negative bacillary meningitis resistant to cephalosporins [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/55\">",
"     55",
"    </a>",
"    ]. However, intrathecal administration of aminoglycosides has been associated with high mortality rates in neonates [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/18\">",
"     18",
"    </a>",
"    ]. A nonrandomized observational study that evaluated the efficacy of a combination of various intravenous antimicrobial agents plus intraventricular",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    therapy in 13 of 31 consecutive patients with gram-negative meningitis seen at a single medical center suggested that combination therapy was superior to intravenous antimicrobial therapy. The group of 13 patients treated with combination therapy had a higher cure rate (p = 0.03) and a lower relapse rate (0 of 13 versus 6 of 18) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2226637\">",
"    <span class=\"h3\">",
"     Ciprofloxacin and other quinolones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluoroquinolones are highly active in vitro against most gram-negative organisms that cause meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/59\">",
"     59",
"    </a>",
"    ]. The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    in the treatment of meningitis has been the topic of several reviews [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]; ciprofloxacin or pefloxacin therapy was curative in more than 50 cases of meningitis to date [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/62\">",
"     62",
"    </a>",
"    ]. There have also been case reports describing the successful use of ciprofloxacin in neonates with meningitis caused by multiply resistant gram-negative bacilli, in some of these cases ciprofloxacin concentrations in the CSF exceeded 50 percent of serum concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/61\">",
"     61",
"    </a>",
"    ]. An early review of ciprofloxacin for the treatment of gram-negative bacillary meningitis in adults reported a 90 percent cure rate (18 out of 20 patients), with rapid sterilization of the CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite such promising results, a decision to use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    in the treatment of gram-negative bacillary meningitis should be based upon the minimum inhibitory concentration (MIC) of the causative pathogen, since this antibiotic has variable penetration into the CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/60\">",
"     60",
"    </a>",
"    ]. As an example, compared to serum concentration, the mean concentration of ciprofloxacin in the CSF was 8 and 37 percent, respectively, in patients with uninflamed and inflamed meninges [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/61\">",
"     61",
"    </a>",
"    ]. In other studies, ciprofloxacin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    reached 11 to 50 percent of serum concentrations in the CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/62\">",
"     62",
"    </a>",
"    ]. As a result of these data, we and others advise caution in the use of fluoroquinolones in the treatment of gram-negative bacillary meningitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28618?source=see_link\">",
"     \"Fluoroquinolones\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fluoroquinolones may be useful in selected patients with infections due to organisms that are resistant to beta-lactam antibiotics. As an example, 10 of 12 neonates and infants (83 percent) in one study of nosocomial meningitis were cured with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    after failing previous therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/59\">",
"     59",
"    </a>",
"    ]. In addition, success has been reported in the treatment of P. aeruginosa meningitis with ciprofloxacin [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are limited data available on the efficacy of newer quinolones, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    , in gram-negative bacillary meningitis. Moxifloxacin is reported to achieve CSF concentrations up to 80 percent of serum levels, with most recent data coming from patients with tuberculous meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/23,64\">",
"     23,64",
"    </a>",
"    ]. In light of the paucity of clinical data associated with its use, we believe moxifloxacin should be reserved for the treatment of multiresistant isolates and used only by physicians who are familiar with its pharmacokinetics, dosing, and in vitro activity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Chloramphenicol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    for the treatment of meningitis caused by susceptible organisms (such as E. coli and Klebsiella) has a high failure rate and is associated with an increase in mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/4\">",
"     4",
"    </a>",
"    ]. These high failure rates are probably due to the fact that chloramphenicol has a bacteriostatic mechanism of action [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/24\">",
"     24",
"    </a>",
"    ]. Despite high concentrations of chloramphenicol in CSF, the enteric pathogens may persist because the levels of drug are still below the minimum bactericidal concentration (MBC) required to kill the infecting organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/4\">",
"     4",
"    </a>",
"    ]. Chloramphenicol-resistant organisms also may emerge during therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/22\">",
"     22",
"    </a>",
"    ]. For these reasons, other more effective drugs have replaced chloramphenicol as a first-line therapy for gram-negative bacillary meningitis. Chloramphenicol use should be reserved for very few clinical scenarios, including adjunctive therapy along with other agents in the treatment of a multiply-resistant organism, infections for which alternative therapies are not available, or cases where an oral agent is required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Tigecycline",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"     Tigecycline",
"    </a>",
"    is active against most Enterobacteriaceae, including extended-spectrum producing species, Acinetobacter baumannii, AmpC-, serine carbapenemase- and metallo-beta-lactamase (MBL)- producing organisms. Some strains of E. coli, K. pneumoniae, Morganella morganii, and Proteus mirabilis have reduced susceptibility to tigecycline, but this may be overcome by combining tigecycline with other agents. Tigecycline has not been evaluated as part of combination therapy for gram-negative bacillary meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"     tigecycline",
"    </a>",
"    in gram negative bacillary meningitis appears limited, since tigecycline CSF penetration is only 11 percent of serum levels [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. However, high-dose tigecycline was successful in a report of meningitis due to multi-resistant K. pneumoniae despite drug concentrations in the CSF that did not exceed the minimum inhibitory concentration of the infecting pathogen [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     INTRATHECAL AND INTRAVENTRICULAR THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrathecal administration of aminoglycosides,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/20/17733?source=see_link\">",
"     polymyxin B",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    has been used in the treatment of meningitis (",
"    <a class=\"graphic graphic_table graphicRef71395 \" href=\"UTD.htm?8/53/9052\">",
"     table 1",
"    </a>",
"    ). Aminoglycosides, colistin, and polymyxin B are the only drugs for intrathecal or intraventricular use which apply to gram-negative bacillary meningitis. Intrathecal or intraventricular aminoglycosides are rarely needed in current practice. Their use should be reserved for the treatment of cephalosporin-resistant, extended-spectrum, beta-lactamase-producing strains of Enterobacteriaceae [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/30\">",
"     30",
"    </a>",
"    ], and cases of failure to respond to conventional therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/26\">",
"     26",
"    </a>",
"    ]. Careful calculation of dose and careful attention to the diluents used to administer intrathecal therapy are critically important issues when intrathecal therapy is given.",
"   </p>",
"   <p>",
"    Ventriculitis accompanies gram-negative bacillary meningitis in more than 70 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/30\">",
"     30",
"    </a>",
"    ]. Direct instillation of antibiotics into the ventricle is an alternative to intrathecal therapy and achieves high aminoglycoside concentrations throughout the subarachnoid space [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/21\">",
"     21",
"    </a>",
"    ]. Intraventricular aminoglycosides can be administered via an external ventricular drainage system, such as an Ommaya reservoir [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/30\">",
"     30",
"    </a>",
"    ]. When used to treat ventriculitis, IV systemic antibiotics should be given simultaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/69\">",
"     69",
"    </a>",
"    ]. Intraventricular therapy is superior to intrathecal therapy, because higher CSF concentrations of aminoglycoside can be achieved by the former route [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Gentamicin",
"    </span>",
"    &nbsp;&mdash;&nbsp;When",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    is given via the intrathecal or intraventricular route, it should be administered as a 0.2 to 0.5 percent solution (2 to 5",
"    <span class=\"nowrap\">",
"     mg/mL),",
"    </span>",
"    prepared by diluting the parenteral solution of drug in preservative-free normal saline [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/21,29,69\">",
"     21,29,69",
"    </a>",
"    ]. The starting dose should be 1 to 5 mg [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/21,22,29,69\">",
"     21,22,29,69",
"    </a>",
"    ] every 18 to 24 hours, in conjunction with gentamicin (5",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    parenterally [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/29,69\">",
"     29,69",
"    </a>",
"    ]. If CSF cultures are positive after 36 hours of therapy, the intrathecal dose can be increased to 8 to 12 mg every 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When instituting this type of invasive therapy, there is a need for careful monitoring of CSF levels of aminoglycoside, since the level of drug in the CSF can vary widely from patient to patient after administration of a fixed dose [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/22,29\">",
"     22,29",
"    </a>",
"    ]. In addition, it is important to use scrupulous aseptic technique to administer the drug.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Amikacin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrathecally administered",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    can be used to treat gram-negative bacillary meningitis and enables higher CSF drug concentrations than those achieved with intravenous administration [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/30\">",
"     30",
"    </a>",
"    ]. Amikacin administered intravenously achieves CSF concentrations 15 to 25 percent of serum concentrations, but such concentrations usually are below the MIC of the infecting organism [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/30\">",
"     30",
"    </a>",
"    ]. Such therapy is rarely used because of the potential for ototoxicity and nephrotoxicity, and is usually a last resort for patients who have failed other therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Polymyxin B and colistin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrathecal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/20/17733?source=see_link\">",
"     polymyxin B",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    (polymyxin E) have been used to treated gram-negative bacillary meningitis as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intrathecal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/20/17733?source=see_link\">",
"       polymyxin B",
"      </a>",
"      plus intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"       meropenem",
"      </a>",
"      has been successful in the treatment of meningitis due to multiresistant strains of Klebsiella [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intrathecal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"       colistin",
"      </a>",
"      (10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      [125,000 international",
"      <span class=\"nowrap\">",
"       units/day]",
"      </span>",
"      or 5 mg every 12 hr) alone successfully treated two patients with ventriculoperitoneal shunt infections due to P. aeruginosa strains that were resistant to other antimicrobial agents [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/71\">",
"       71",
"      </a>",
"      ]. In another study 10 mg was administered every 12 hours intrathecally without an increase in observed toxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/72\">",
"       72",
"      </a>",
"      ]. Intrathecal therapy appears to lack the nephrotoxicity of intravenous colistin.",
"     </li>",
"     <li>",
"      Intrathecal or intraventricular",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"       colistin",
"      </a>",
"      have been used to treat multidrug-resistant Acinetobacter meningitis [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/73\">",
"       73",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23402?source=see_link&amp;anchor=H1211160#H1211160\">",
"       \"Treatment and prevention of Acinetobacter infection\", section on 'Meningitis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The optimal approach to intraventricular administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    is uncertain; a small number of case reports suggest clamping the tubing for one hour after administration to prevent dilution if there is a large volume of CSF drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/73-75\">",
"     73-75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intrathecal and intraventricular",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    may be complicated by aseptic chemical meningitis or ventriculitis requiring dose reduction as the CSF white blood cell count increases [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/73\">",
"     73",
"    </a>",
"    ]. Of note, the selection of colistin-resistant strains of Acinetobacter baumannii during treatment has been observed in a patient with postneurosurgical meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     TREATMENT RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because much of the published experience with the treatment of gram-negative bacillary meningitis takes the form of case reports or small case series or is based mostly upon pharmacokinetic and in vitro data, we have formulated the following recommendations based upon our experience and a thorough review of the available literature.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Empiric therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Empiric therapy should include coverage for gram-negative bacilli in the following clinical scenarios:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical evidence of meningitis in a patient at risk for gram-negative CNS infections (eg, patients with head trauma or neurosurgery, alcoholics or neonates). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/13/16600?source=see_link&amp;anchor=H4#H4\">",
"       \"Epidemiology and clinical features of gram-negative bacillary meningitis\", section on 'Epidemiology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with CSF Gram stain revealing gram-negative bacilli when culture results are not available.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pending culture and susceptibility data, we typically use a third generation cephalosporin, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (2 g IV every 12 hours) or, if Pseudomonas is suspected,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    (2 g IV every eight hours). Because of reports of increasing resistance to third generation cephalosporins among gram-negative bacilli causing meningitis, local resistance patterns (eg, as reflected through individual hospital antibiograms) should inform the choice of empiric therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Empiric antibiotic regimens for suspected acute bacterial meningitis in specific patient populations are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22810?source=see_link&amp;anchor=H18#H18\">",
"     \"Initial therapy and prognosis of bacterial meningitis in adults\", section on 'Empiric regimens'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/47/16121?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment and outcome of bacterial meningitis in the neonate\", section on 'Empirical therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44552?source=see_link&amp;anchor=H13#H13\">",
"     \"Infections of central nervous system shunts and other devices\", section on 'Antibiotic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Directed treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;When culture results are already known, the following applies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Broad spectrum cephalosporins, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"       cefotaxime",
"      </a>",
"      (2 g IV every four to six hours) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      (2 g IV every 12 hours), are most appropriate for Enterobacteriaceae. If the organism is known to have inducible beta-lactamase production or if it produces an extended-spectrum beta-lactamase, use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"       meropenem",
"      </a>",
"      (1 g IV every eight hours) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      (15 to 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day divided every six to eight hours based upon the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"       trimethoprim",
"      </a>",
"      component) or both.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"       Ceftazidime",
"      </a>",
"      (2 g IV every eight hours) plus an aminoglycoside (dosed based upon renal function) should be used for P. aeruginosa [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For organisms resistant to cephalosporins,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"       meropenem",
"      </a>",
"      or alternatives, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=see_link\">",
"       aztreonam",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"       cefepime",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      , can be chosen based upon susceptibility testing [",
"      <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Dual therapy should be used for patients with persistently positive CSF cultures on therapy. Intrathecal or intraventricular therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    is a reasonable option for patients with meningitis due to organisms resistant to the above agents or when therapy with the above agents has failed to sterilize the CSF after 5 to 7 days of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Adjuvant dexamethasone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the lack of evidence of benefit and concerns about possible toxicity,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    is not recommended in adults with gram-negative bacillary meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/20/25930/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Role of dexamethasone'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23080?source=see_link\">",
"     \"Dexamethasone to prevent neurologic complications of bacterial meningitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    in children with H. influenzae meningitis is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/21/4442?source=see_link&amp;anchor=H3#H3\">",
"     \"Dexamethasone and other measures to prevent neurologic complications of bacterial meningitis in children\", section on 'Dexamethasone'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2226117\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nosocomial gram-negative bacillary meningitis in adults occurs mainly in the setting of head trauma, neurosurgical procedures, a neurosurgical device, or cerebrospinal fluid (CSF) leak. Gram-negative bacilli, however, remain an uncommon cause of community-acquired bacterial meningitis in adults. In contrast, Escherichia coli is a common pathogen in early neonatal meningitis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/13/16600?source=see_link&amp;anchor=H4#H4\">",
"       \"Epidemiology and clinical features of gram-negative bacillary meningitis\", section on 'Epidemiology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      As with meningitis in general, the diagnosis of gram-negative bacillary meningitis predominantly relies upon examination of the CSF for protein, glucose, cell count determinations, Gram stain, and culture. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Cerebrospinal fluid analysis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23129?source=see_link&amp;anchor=H16#H16\">",
"       \"Clinical features and diagnosis of acute bacterial meningitis in adults\", section on 'CSF analysis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The Gram stain is positive for gram-negative bacilli in more than 50 percent of adult patients with a positive culture result. CSF culture is essential to establish the etiology of meningitis and to determine the antimicrobial susceptibilities of the pathogen. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Cerebrospinal fluid analysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Indications for performing computed tomographic (CT) scanning of the head prior to lumbar puncture are similar to those for patients with suspected acute bacterial meningitis in general. However, patients who have undergone prior neurosurgical procedures should undergo CT scan prior to lumbar puncture. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Computed tomographic scanning'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23129?source=see_link&amp;anchor=H12#H12\">",
"       \"Clinical features and diagnosis of acute bacterial meningitis in adults\", section on 'Indications for CT scan before LP'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bacterial meningitis should be treated with an antimicrobial agent that penetrates the CSF in adequate concentrations to exhibit bactericidal activity against the responsible pathogen. Third generation cephalosporins penetrate well into the CSF, and clinical experience with these agents in the treatment of meningitis is relatively extensive. However, innate and emerging resistance of gram-negative bacilli to this class of drugs may limit its widespread utility. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Choice of antimicrobial drugs'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Cephalosporins'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fourth generation cephalosporins,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=see_link\">",
"       aztreonam",
"      </a>",
"      , carbapenems, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      are other agents for which there are less clinical data available but which nevertheless may be useful if the gram-negative organism retains susceptibility. Intravenous aminoglycosides are useful only when given with another drug that penetrates the CSF well. Other agents should be used with caution or only if no other options exist: CSF penetration of fluoroquinolones can be variable,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"       tigecycline",
"      </a>",
"      poorly penetrates the CSF, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"       chloramphenicol",
"      </a>",
"      has a high failure rate. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Other drugs'",
"      </a>",
"      above.) &nbsp; &nbsp; &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      Empiric therapy for suspected acute bacterial meningitis should include coverage for gram-negative bacilli in patients at risk for gram-negative central nervous system (CNS) infections (eg, patients with head trauma or neurosurgery, immunosuppressed patients, alcoholics, or neonates) or in those who have a CSF Gram stain that reveals gram-negative bacilli. We use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      or, if Pseudomonas is suspected,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"       ceftazidime",
"      </a>",
"      . The empiric therapy of suspected acute bacterial meningitis in various populations is discussed in detail elsewhere. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Empiric therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22810?source=see_link&amp;anchor=H18#H18\">",
"       \"Initial therapy and prognosis of bacterial meningitis in adults\", section on 'Empiric regimens'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/47/16121?source=see_link&amp;anchor=H4#H4\">",
"       \"Treatment and outcome of bacterial meningitis in the neonate\", section on 'Empirical therapy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44552?source=see_link&amp;anchor=H13#H13\">",
"       \"Infections of central nervous system shunts and other devices\", section on 'Antibiotic therapy'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      Once the organism is identified, directed antimicrobial therapy should be based on susceptibility patterns, including whether the organism is known to have inducible beta-lactamase production or is suspected of producing an extended-spectrum beta-lactamase. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Directed treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Despite appropriate therapy and an apparent clinical response, CSF cultures may remain positive for several days; the average duration of therapy needed to sterilize the CSF is two to four days in adults and three to eight days in neonates. In adults, we typically resample CSF again after four to five days of therapy to evaluate for sterilization. Repeat lumbar puncture in neonates with gram-negative bacillary meningitis is discussed elsewhere. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'General principles for treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/47/16121?source=see_link&amp;anchor=H17#H17\">",
"       \"Treatment and outcome of bacterial meningitis in the neonate\", section on 'Repeat lumbar puncture'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Aminoglycosides,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"       colistin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/20/17733?source=see_link\">",
"       polymyxin B",
"      </a>",
"      can be administered via the intrathecal or intraventricular route (",
"      <a class=\"graphic graphic_table graphicRef71395 \" href=\"UTD.htm?8/53/9052\">",
"       table 1",
"      </a>",
"      ) and often retain activity against resistant gram-negative bacilli, but their use in this manner is rarely indicated. Intrathecal or intraventricular therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      is a reasonable option for patients with meningitis due to aminoglycoside susceptible organisms that produce an extended-spectrum beta-lactamase or are otherwise resistant to cephalosporins and other alternative agents, or when therapy with the intravenous agents has failed to sterilize the CSF after five to seven days. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Intrathecal and intraventricular therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       Dexamethasone",
"      </a>",
"      is not warranted for management of raised intracranial pressure and of the inflammation associated with gram-negative bacillary meningitis, given the lack of evidence for benefit and risk of toxicity. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Adjuvant dexamethasone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We typically treat gram-negative bacillary meningitis in adults for at least 21 days because high rates of relapse occur in patients treated with shorter courses. However, the length of therapy ultimately should be tailored to each individual patient, taking into account factors such as the underlying risk factors for infection, the infecting organism, the antimicrobial susceptibilities, the agent used, and the clinical response. Treatment duration of gram-negative bacillary meningitis in neonates is discussed in detail elsewhere. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Duration'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/47/16121?source=see_link&amp;anchor=H9#H9\">",
"       \"Treatment and outcome of bacterial meningitis in the neonate\", section on 'Gram-negative enteric bacteria'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/1\">",
"      Durand ML, Calderwood SB, Weber DJ, et al. Acute bacterial meningitis in adults. A review of 493 episodes. N Engl J Med 1993; 328:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/2\">",
"      Wolff MA, Young CL, Ramphal R. Antibiotic therapy for enterobacter meningitis: a retrospective review of 13 episodes and review of the literature. Clin Infect Dis 1993; 16:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/3\">",
"      Taziarova M, Holeckova K, Lesnakova A, et al. Gram-negative bacillary community acquired meningitis is not a rare entity in last two decades. Neuro Endocrinol Lett 2007; 28 Suppl 3:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/4\">",
"      Landesman SH, Cherubin CE, Corrado ML. Gram-negative bacillary meningitis. New therapy and changing concepts. Arch Intern Med 1982; 142:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/5\">",
"      Tang LM, Chen ST. Klebsiella pneumoniae meningitis: prognostic factors. Scand J Infect Dis 1994; 26:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/6\">",
"      Unhanand M, Mustafa MM, McCracken GH Jr, Nelson JD. Gram-negative enteric bacillary meningitis: a twenty-one-year experience. J Pediatr 1993; 122:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/7\">",
"      Leib SL, Boscacci R, Gratzl O, Zimmerli W. Predictive value of cerebrospinal fluid (CSF) lactate level versus CSF/blood glucose ratio for the diagnosis of bacterial meningitis following neurosurgery. Clin Infect Dis 1999; 29:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/8\">",
"      Jackson WL Jr, Shorr AF. The yield of lumbar puncture to exclude nosocomial meningitis as aetiology for mental status changes in the medical intensive care unit. Anaesth Intensive Care 2006; 34:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/9\">",
"      Palabiyikoglu I, Tekeli E, Cokca F, et al. Nosocomial meningitis in a university hospital between 1993 and 2002. J Hosp Infect 2006; 62:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/10\">",
"      Cherubin CE, Marr JS, Sierra MF, Becker S. Listeria and gram-negative bacillary meningitis in New York City, 1972-1979. Frequent causes of meningitis in adults. Am J Med 1981; 71:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/11\">",
"      Berk SL, McCabe WR. Meningitis caused by gram-negative bacilli. Ann Intern Med 1980; 93:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/12\">",
"      Rahal JJ, Simberkoff MS. Host defense and antimicrobial therapy in adult gram-negative bacillary meningitis. Ann Intern Med 1982; 96:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/13\">",
"      Tang LM, Chen ST. Klebsiella oxytoca meningitis: frequent association with neurosurgical procedures. Infection 1995; 23:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/14\">",
"      Schuurman T, de Boer RF, Kooistra-Smid AM, van Zwet AA. Prospective study of use of PCR amplification and sequencing of 16S ribosomal DNA from cerebrospinal fluid for diagnosis of bacterial meningitis in a clinical setting. J Clin Microbiol 2004; 42:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/15\">",
"      Oliver WJ, Shope TC, Kuhns LR. Fatal lumbar puncture: fact versus fiction--an approach to a clinical dilemma. Pediatrics 2003; 112:e174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/16\">",
"      Hasbun R, Abrahams J, Jekel J, Quagliarello VJ. Computed tomography of the head before lumbar puncture in adults with suspected meningitis. N Engl J Med 2001; 345:1727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/17\">",
"      Aronin SI, Peduzzi P, Quagliarello VJ. Community-acquired bacterial meningitis: risk stratification for adverse clinical outcome and effect of antibiotic timing. Ann Intern Med 1998; 129:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/18\">",
"      Quagliarello VJ, Scheld WM. Treatment of bacterial meningitis. N Engl J Med 1997; 336:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/19\">",
"      Talan DA, Hoffman JR, Yoshikawa TT, Overturf GD. Role of empiric parenteral antibiotics prior to lumbar puncture in suspected bacterial meningitis: state of the art. Rev Infect Dis 1988; 10:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/20\">",
"      Olson DA, Hoeprich PD, Nolan SM, Goldstein E. Successful treatment of gram-negative bacillary meningitis with moxalactam. Ann Intern Med 1981; 95:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/21\">",
"      Kaiser AB, McGee ZA. Aminoglycoside therapy of gram-negative bacillary meningitis. N Engl J Med 1975; 293:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/22\">",
"      Swartz MN. Intraventricular use of aminoglycosides in the treatment of gram-negative bacillary meningitis: conflicting views. J Infect Dis 1981; 143:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/23\">",
"      S&aacute;ez-Llorens X, McCracken GH Jr. Antimicrobial and anti-inflammatory treatment of bacterial meningitis. Infect Dis Clin North Am 1999; 13:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/24\">",
"      Levitz RE, Quintiliani R. Trimethoprim-sulfamethoxazole for bacterial meningitis. Ann Intern Med 1984; 100:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/25\">",
"      Corrado ML, Gombert ME, Cherubin CE. Designing appropriate therapy in the treatment of gram-negative bacillary meningitis. JAMA 1982; 248:71.",
"     </a>",
"    </li>",
"    <li>",
"     Tunkel AR, Scheld WM. Acute meningitis. In: Principles and Practice of Infectious Diseases, 6th Ed, Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone, Phhiladelphia 2005. p.1083.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/27\">",
"      Chaudhuri A. Adjunctive dexamethasone treatment in acute bacterial meningitis. Lancet Neurol 2004; 3:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/28\">",
"      Spreer A, Gerber J, Hanssen M, et al. Dexamethasone increases hippocampal neuronal apoptosis in a rabbit model of Escherichia coli meningitis. Pediatr Res 2006; 60:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/29\">",
"      Rahal JJ Jr, Hyams PJ, Simberkoff MS, Rubinstein E. Combined intrathecal and intramuscular gentamicin for gram-negative meningitis. Pharmacologic study of 21 patients. N Engl J Med 1974; 290:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/30\">",
"      Preston SL, Briceland LL. Intrathecal administration of amikacin for treatment of meningitis secondary to cephalosporin-resistant Escherichia coli. Ann Pharmacother 1993; 27:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/31\">",
"      Klugman KP, Dagan R. Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Meropenem Meningitis Study Group. Antimicrob Agents Chemother 1995; 39:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/32\">",
"      Cherubin CE, Eng RH. Experience with the use of cefotaxime in the treatment of bacterial meningitis. Am J Med 1986; 80:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/33\">",
"      Lu CH, Chang WN, Chuang YC. Resistance to third-generation cephalosporins in adult gram-negative bacillary meningitis. Infection 1999; 27:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/34\">",
"      O'Neill E, Humphreys H, Phillips J, Smyth EG. Third-generation cephalosporin resistance among Gram-negative bacilli causing meningitis in neurosurgical patients: significant challenges in ensuring effective antibiotic therapy. J Antimicrob Chemother 2006; 57:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/35\">",
"      Oztoprak N, Celebi G, Baru&ouml;n&uuml; F, Kalayci M. [Nosocomial meningitis with dual agents and treatment with intraventricular gentamicin]. Mikrobiyol Bul 2008; 42:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/36\">",
"      Briggs S, Ellis-Pegler R, Raymond N, et al. Gram-negative bacillary meningitis after cranial surgery or trauma in adults. Scand J Infect Dis 2004; 36:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/37\">",
"      Friedland IR, Lutsar I. New antibiotics. Curr Opin Pediatr 1998; 10:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/38\">",
"      S&aacute;ez-Llorens X, Casta&ntilde;o E, Garc&iacute;a R, et al. Prospective randomized comparison of cefepime and cefotaxime for treatment of bacterial meningitis in infants and children. Antimicrob Agents Chemother 1995; 39:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/39\">",
"      Wolff M, Chavanet P, Kazmierczak A, et al. Diffusion of cefpirome into the cerebrospinal fluid of patients with purulent meningitis. J Antimicrob Chemother 1992; 29 Suppl A:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/40\">",
"      Friedland IR, Sultan E, Lehr KH, Lenfant B. Concentrations of cefpirome in cerebrospinal fluid of children with bacterial meningitis after a single intravenous dose. Antimicrob Agents Chemother 1998; 42:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/41\">",
"      Trujillo H, Harry N, Arango A, et al. Aztreonam in the treatment of aerobic, gram-negative bacillary infections in pediatric patients. Chemotherapy 1989; 35 Suppl 1:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/42\">",
"      Lentnek AL, Williams RR. Aztreonam in the treatment of gram-negative bacterial meningitis. Rev Infect Dis 1991; 13 Suppl 7:S586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/43\">",
"      Peeters A, Vandercam B, Sindic CJ, et al. Community-acquired Serratia marcescens meningitis. J Infect 1997; 35:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/44\">",
"      Feris J, Moledina N, Rodriguez WJ, et al. Aztreonam in the treatment of gram-negative meningitis and other gram-negative infections. Chemotherapy 1989; 35 Suppl 1:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/45\">",
"      Stutman HR, Welch DF, Scribner RK, Marks MI. In vitro antimicrobial activity of aztreonam alone and in combination against bacterial isolates from pediatric patients. Antimicrob Agents Chemother 1984; 25:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/46\">",
"      Klugman KP, Dagan R. Carbapenem treatment of meningitis. Scand J Infect Dis Suppl 1995; 96:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/47\">",
"      Huang CR, Lu CH, Chang WN. Adult Enterobacter meningitis: a high incidence of coinfection with other pathogens and frequent association with neurosurgical procedures. Infection 2001; 29:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/48\">",
"      Ayalew K, Nambiar S, Yasinskaya Y, Jantausch BA. Carbapenems in pediatrics. Ther Drug Monit 2003; 25:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/49\">",
"      Jacobs RF, Kearns GL, Brown AL, Longee DC. Cerebrospinal fluid penetration of imipenem and cilastatin (primaxin) in children with central nervous system infections. Antimicrob Agents Chemother 1986; 29:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/50\">",
"      Eng RH, Lynch AM, Smith SM, et al. Imipenem resistance in a case of AIDS with relapsing Pseudomonas meningitis. South Med J 1990; 83:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/51\">",
"      Wong VK, Wright HT Jr, Ross LA, et al. Imipenem/cilastatin treatment of bacterial meningitis in children. Pediatr Infect Dis J 1991; 10:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/52\">",
"      Fern&aacute;ndez Viladrich P. [The role of meropenem in bacterial meningitis]. Enferm Infecc Microbiol Clin 1997; 15 Suppl 1:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/53\">",
"      Ko&ccedil; E, Turkyilmaz C, Atalay Y, Sen E. Imipenem for treatment of relapsing Salmonella meningitis in a newborn infant. Acta Paediatr Jpn 1997; 39:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/54\">",
"      Haimi-Cohen Y, Amir J, Weinstock A, Varsano I. The use of imipenem-cilastatin in neonatal meningitis caused by Citrobacter diversus. Acta Paediatr 1993; 82:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/55\">",
"      N&uacute;&ntilde;ez ML, Mart&iacute;nez-Toldos MC, Bru M, et al. Appearance of resistance to meropenem during the treatment of a patient with meningitis by Acinetobacter. Scand J Infect Dis 1998; 30:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/56\">",
"      Bradford PA, Bratu S, Urban C, et al. Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City. Clin Infect Dis 2004; 39:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/57\">",
"      Tenover FC, Kalsi RK, Williams PP, et al. Carbapenem resistance in Klebsiella pneumoniae not detected by automated susceptibility testing. Emerg Infect Dis 2006; 12:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/58\">",
"      T&auml;ngd&eacute;n T, Enblad P, Ullberg M, Sj&ouml;lin J. Neurosurgical gram-negative bacillary ventriculitis and meningitis: a retrospective study evaluating the efficacy of intraventricular gentamicin therapy in 31 consecutive cases. Clin Infect Dis 2011; 52:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/59\">",
"      Krcm&eacute;ry V Jr, Filka J, Uher J, et al. Ciprofloxacin in treatment of nosocomial meningitis in neonates and in infants: report of 12 cases and review. Diagn Microbiol Infect Dis 1999; 35:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/60\">",
"      Sch&ouml;nwald S, Beus I, Lisi�� M, et al. Ciprofloxacin in the treatment of gram-negative bacillary meningitis. Am J Med 1989; 87:248S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/61\">",
"      Green SD, Ilunga F, Cheesbrough JS, et al. The treatment of neonatal meningitis due to gram-negative bacilli with ciprofloxacin: evidence of satisfactory penetration into the cerebrospinal fluid. J Infect 1993; 26:253.",
"     </a>",
"    </li>",
"    <li>",
"     Gilbert D, Moellering KC, Sande M. Cerebrospinal fluid concentrations of antimicrobials. In: Guide to Antimicrobial Therapy, 8th Ed, Sanford J (Ed), Antimicrobial Therapy, Inc, Vienna 2000. p.58.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/63\">",
"      Lipman J, Allworth A, Wallis SC. Cerebrospinal fluid penetration of high doses of intravenous ciprofloxacin in meningitis. Clin Infect Dis 2000; 31:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/64\">",
"      Alffenaar JW, van Altena R, B&ouml;kkerink HJ, et al. Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis. Clin Infect Dis 2009; 49:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/65\">",
"      Entenza JM, Moreillon P. Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies. Int J Antimicrob Agents 2009; 34:8.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/66\">",
"      Rodvold KA, Gotfried MH, Cwik M, et al. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 2006; 58:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/67\">",
"      Ray L, Levasseur K, Nicolau DP, Scheetz MH. Cerebral spinal fluid penetration of tigecycline in a patient with Acinetobacter baumannii cerebritis. Ann Pharmacother 2010; 44:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/68\">",
"      Dandache P, Nicolau DP, Sakoulas G. Tigecycline for the Treatment of Multidrug-Resistant Klebsiella pneumoniae Meningitis. Infect Dis Clin Pract 2009; 17:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/69\">",
"      Frenkel LD, Patno K, Rayport M, Voeller KS. Safety and effectiveness of intraventricular gentamicin in CNS infections. Infect Surg 1986; 163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/70\">",
"      Segal-Maurer S, Mariano N, Qavi A, et al. Successful treatment of ceftazidime-resistant Klebsiella pneumoniae ventriculitis with intravenous meropenem and intraventricular polymyxin B: case report and review. Clin Infect Dis 1999; 28:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/71\">",
"      Quinn AL, Parada JP, Belmares J, O'Keefe JP. Intrathecal colistin and sterilization of resistant Pseudomonas aeruginosa shunt infection. Ann Pharmacother 2005; 39:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/72\">",
"      Rodr&iacute;guez Guardado A, Blanco A, Asensi V, et al. Multidrug-resistant Acinetobacter meningitis in neurosurgical patients with intraventricular catheters: assessment of different treatments. J Antimicrob Chemother 2008; 61:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/73\">",
"      Ng J, Gosbell IB, Kelly JA, et al. Cure of multiresistant Acinetobacter baumannii central nervous system infections with intraventricular or intrathecal colistin: case series and literature review. J Antimicrob Chemother 2006; 58:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/74\">",
"      Dalgic N, Ceylan Y, Sancar M, et al. Successful treatment of multidrug-resistant Acinetobacter baumannii ventriculitis with intravenous and intraventricular colistin. Ann Trop Paediatr 2009; 29:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/75\">",
"      Baiocchi M, Catena V, Zago S, et al. Intrathecal colistin for treatment of multidrug resistant (MDR) Pseudomonas aeruginosa after neurosurgical ventriculitis. Infez Med 2010; 18:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/20/25930/abstract/76\">",
"      Rodriguez CH, Hernan RC, Bombicino K, et al. Selection of colistin-resistant Acinetobacter baumannii isolates in postneurosurgical meningitis in an intensive care unit with high presence of heteroresistance to colistin. Diagn Microbiol Infect Dis 2009; 65:188.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1301 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-E4AAF914B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_20_25930=[""].join("\n");
var outline_f25_20_25930=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2226117\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Cerebrospinal fluid analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Blood cultures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Computed tomographic scanning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      GENERAL PRINCIPLES FOR TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Antimicrobial therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Role of dexamethasone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CHOICE OF ANTIMICROBIAL DRUGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Cephalosporins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Third generation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Fourth generation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Aztreonam",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Carbapenems",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2226912\">",
"      - Trimethoprim-sulfamethoxazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2227105\">",
"      - Aminoglycosides",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2226637\">",
"      - Ciprofloxacin and other quinolones",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Chloramphenicol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Tigecycline",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      INTRATHECAL AND INTRAVENTRICULAR THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Gentamicin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Amikacin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Polymyxin B and colistin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      TREATMENT RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Empiric therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Directed treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Adjuvant dexamethasone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2226117\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/1301\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1301|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/53/9052\" title=\"table 1\">",
"      Intraventricular dosing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23129?source=related_link\">",
"      Clinical features and diagnosis of acute bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/21/4442?source=related_link\">",
"      Dexamethasone and other measures to prevent neurologic complications of bacterial meningitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23080?source=related_link\">",
"      Dexamethasone to prevent neurologic complications of bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/13/16600?source=related_link\">",
"      Epidemiology and clinical features of gram-negative bacillary meningitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28618?source=related_link\">",
"      Fluoroquinolones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44552?source=related_link\">",
"      Infections of central nervous system shunts and other devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22810?source=related_link\">",
"      Initial therapy and prognosis of bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/47/16121?source=related_link\">",
"      Treatment and outcome of bacterial meningitis in the neonate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23402?source=related_link\">",
"      Treatment and prevention of Acinetobacter infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_20_25931="Severity of MS in adults";
var content_f25_20_25931=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56145&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56145&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Severity of mitral stenosis in adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mean gradient, mmHg",
"       </td>",
"       <td class=\"subtitle1\">",
"        Valve area, cm2",
"       </td>",
"       <td class=\"subtitle1\">",
"        PA systolic pressure, mmHg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"_left\">",
"        Normal",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        4.0 to 6.0",
"       </td>",
"       <td>",
"        Less than 30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"_left\">",
"        Mild",
"       </td>",
"       <td>",
"        Less than 5",
"       </td>",
"       <td>",
"        Greater than 1.5",
"       </td>",
"       <td>",
"        Less than 30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        5 to 10",
"       </td>",
"       <td>",
"        1.0 to 1.5",
"       </td>",
"       <td>",
"        30 to 50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"_left\">",
"        Severe",
"       </td>",
"       <td>",
"        Greater than 10",
"       </td>",
"       <td>",
"        Less than 1.0",
"       </td>",
"       <td>",
"        Greater than 50",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_20_25931=[""].join("\n");
var outline_f25_20_25931=null;
var title_f25_20_25932="Euthanasia PAS Europe";
var content_f25_20_25932=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F58741&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F58741&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Euthanasia and PAS* practices in Europe",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Belgium",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Denmark",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Italy",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sweden",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Switzerland",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Netherlands, 2010",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Percent of deaths from any type of doctor-assisted dying",
"       </td>",
"       <td>",
"        3.8",
"       </td>",
"       <td>",
"        0.79",
"       </td>",
"       <td>",
"        0.10",
"       </td>",
"       <td>",
"        0.23",
"       </td>",
"       <td>",
"        1.04",
"       </td>",
"       <td>",
"        3.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Percent of deaths from euthanasia",
"       </td>",
"       <td>",
"        1.9",
"       </td>",
"       <td>",
"        0.06",
"       </td>",
"       <td>",
"        0.04",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0.27",
"       </td>",
"       <td>",
"        2.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Percent of deaths from PAS",
"       </td>",
"       <td>",
"        0.07",
"       </td>",
"       <td>",
"        0.06",
"       </td>",
"       <td>",
"        0.00",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0.36",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Percent of deaths from lethal medication without patient's consent",
"       </td>",
"       <td>",
"        1.8",
"       </td>",
"       <td>",
"        0.67",
"       </td>",
"       <td>",
"        0.06",
"       </td>",
"       <td>",
"        0.23",
"       </td>",
"       <td>",
"        0.42",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Percent of doctor-assisted deaths involving cancer patients",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        37",
"       </td>",
"       <td>",
"        31&Delta;",
"       </td>",
"       <td>",
"        84",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     N/A: not applicable; N/R: not reported.",
"     <br>",
"      * PAS: physician-assisted suicide.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Data from: Bilsen J, et al. N Engl J Med 2009; 361:1119.",
"       </li>",
"       <li>",
"        Data from: van der Heide A, et al. Lancet 2003; 362:345.",
"       </li>",
"       <li>",
"        Data from Onwuteaka-Philipsen BD, et al. Lancet 2012; published online July 11, 2012 (file://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)61034-4/abstract, accessed July 27, 2012).",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_20_25932=[""].join("\n");
var outline_f25_20_25932=null;
var title_f25_20_25933="Member roles and functions for rehab team";
var content_f25_20_25933=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F86413&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F86413&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Primary roles and functions of members of the multidisciplinary rehabilitation team",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"20%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"40%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Discipline",
"       </td>",
"       <td class=\"subtitle1\">",
"        Evaluation and treatment methods",
"       </td>",
"       <td class=\"subtitle1\">",
"        Targeted aspect of the disablement process",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Assistive Technology Provider (ATP*)",
"       </td>",
"       <td>",
"        Determine need for assistive technology and optimal technology to best meet needs",
"       </td>",
"       <td>",
"        <p>",
"         Activities",
"        </p>",
"        Participation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dietician",
"       </td>",
"       <td>",
"        <p>",
"         Assess nutritional status",
"        </p>",
"        Alter diet to maximize nutrition",
"       </td>",
"       <td>",
"        Health condition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hand therapist",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         Exercise",
"        </p>",
"        <p>",
"         Physical modalities (heat, ultrasound, etc.)",
"        </p>",
"        Fabrication of splints",
"       </td>",
"       <td>",
"        Impairment (upper extremity)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medical provider",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         Assess health conditions",
"        </p>",
"        Treat health conditions (medications, surgery)",
"       </td>",
"       <td>",
"        Health condition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nursing",
"       </td>",
"       <td>",
"        <p>",
"         Assessment of physical condition",
"        </p>",
"        <p>",
"         Wound care and medication management",
"        </p>",
"        <p>",
"         Evaluate self-care skills",
"        </p>",
"        <p>",
"         Evaluate family and home care factors",
"        </p>",
"        <p>",
"         Self-care training",
"        </p>",
"        Patient and family education",
"       </td>",
"       <td>",
"        <p>",
"         Health condition",
"        </p>",
"        <p>",
"         Impairment",
"        </p>",
"        <p>",
"         Activities",
"        </p>",
"        Contextual factors (especially social)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Occupational therapist",
"       </td>",
"       <td>",
"        <p>",
"         Evaluate self-care skills and other activities of daily living",
"        </p>",
"        <p>",
"         Home safety evaluation",
"        </p>",
"        <p>",
"         Self-care skills training",
"        </p>",
"        <p>",
"         Recommendations for assistive technology",
"        </p>",
"        <p>",
"         Fabrication of splints",
"        </p>",
"        Treatment of upper extremity deficits",
"       </td>",
"       <td>",
"        <p>",
"         Impairment (upper extremity)",
"        </p>",
"        <p>",
"         Activities",
"        </p>",
"        <p>",
"         Participation",
"        </p>",
"        Contextual factors (especially environment)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Physical therapist",
"       </td>",
"       <td>",
"        <p>",
"         Assessment of range of motion and strength",
"        </p>",
"        <p>",
"         Assessment of gait and mobility",
"        </p>",
"        <p>",
"         Exercise training",
"        </p>",
"        Treatment with physical modalities (heat, cold, ultrasound, massage, electrical stimulation)",
"       </td>",
"       <td>",
"        <p>",
"         Impairment (lower extremity, back, shoulder)",
"        </p>",
"        Activities (mobility)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prosthetist",
"       </td>",
"       <td>",
"        Fabricate prosthetic limbs and other prosthetic devices (eg, prosthetic eye)",
"       </td>",
"       <td>",
"        Impairment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psychologist/psychiatrist",
"       </td>",
"       <td>",
"        <p>",
"         Assessment of mental and emotional function",
"        </p>",
"        Treatment of mental/emotional disorder (medication, counseling)",
"       </td>",
"       <td>",
"        <p>",
"         Health condition",
"        </p>",
"        <p>",
"         Impairment (psychological)",
"        </p>",
"        Context (personal)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recreation therapist",
"       </td>",
"       <td>",
"        <p>",
"         Assess leisure skills and interests",
"        </p>",
"        Involve patients in recreational activities to maintain social roles",
"       </td>",
"       <td>",
"        Participation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Speech/language therapist",
"       </td>",
"       <td>",
"        <p>",
"         Assessment of all aspects of communication",
"        </p>",
"        <p>",
"         Assessment of swallowing disorders",
"        </p>",
"        <p>",
"         Treatment of communications deficits",
"        </p>",
"        Recommendations for alterations of diet and positioning to treat dysphagia",
"       </td>",
"       <td>",
"        <p>",
"         Impairment",
"        </p>",
"        Participation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Social worker",
"       </td>",
"       <td>",
"        <p>",
"         Evaluation of family and home care factors",
"        </p>",
"        <p>",
"         Assessment of psychosocial factors",
"        </p>",
"        <p>",
"         Counseling",
"        </p>",
"        Liaison with the community",
"       </td>",
"       <td>",
"        <p>",
"         Participation",
"        </p>",
"        Context (social)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Successful completion of a certifying exam offered by the Rehabilitation Engineering and Assistive Technology Society of North America.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Occupational or physical therapist who has complete additional training and passed a national certification exam in hand therapy.",
"     <br/>",
"     &Delta; Depending on the settings, the medical provider may be a physician such as a physical medicine and rehabilitation specialist (\"physiatrist\"), neurologist, orthopedic surgeon, or geriatrician and/or mid-level practitioners such as nurse practitioner or physician assistant.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_20_25933=[""].join("\n");
var outline_f25_20_25933=null;
var title_f25_20_25934="Contents: Medical neurology";
var content_f25_20_25934=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?0/63/1022\">",
"       Neurology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Medical neurology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Medical neurology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Cognitive disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/10/39081\">",
"           Diagnosis of delirium and confusional states",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/33/28185\">",
"           Prevention and treatment of delirium and confusional states",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/27/38328\">",
"           Transient global amnesia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Complications of alcohol",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/61/20441\">",
"           Management of moderate and severe alcohol withdrawal syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/24/40328\">",
"           Overview of the chronic neurologic complications of alcohol",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/62/10217\">",
"           Wernicke's encephalopathy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Consultation neurology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/2/30761\">",
"           Diagnosis of brain death",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/56/19337\">",
"           Hypoxic-ischemic brain injury: Evaluation and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/6/19561\">",
"           Lumbar puncture: Technique; indications; contraindications; and complications in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/9/10394\">",
"           Perioperative care of the surgical patient with neurologic disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/16/43273\">",
"           Reversible posterior leukoencephalopathy syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Endocrine disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/47/33527\">",
"           Hashimoto's encephalopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/26/29093\">",
"           Hypothyroid myopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/23/8566\">",
"           Myxedema coma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/22/30057\">",
"           Neurologic manifestations of hyperthyroidism and Graves' disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/46/36585\">",
"           Neurologic manifestations of hypothyroidism",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hematology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/2/33833\">",
"           Neuroacanthocytosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Metabolic disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/38/11880\">",
"           Copper deficiency myeloneuropathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/58/23464\">",
"           Manifestations of hyponatremia and hypernatremia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neurologic emergencies",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/26/6570\">",
"           Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/4/20553\">",
"           Neuroleptic malignant syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/17/21783\">",
"           Cannabis use disorders: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/3/1079\">",
"           Cannabis use disorders: Epidemiology, comorbidity, and pathogenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/28/4554\">",
"           Cannabis use disorders: Treatment, prognosis, and long-term medical effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/8/20616\">",
"           Neurologic sarcoidosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pregnancy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/56/24458\">",
"           Cerebrovascular disorders complicating pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/63/5114\">",
"           Headache in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/9/20634\">",
"           Neurologic disorders complicating pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/6/22633\">",
"           Risks associated with epilepsy and pregnancy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Rheumatic disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/18/27944\">",
"           Cervical spondylotic myelopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/43/5816\">",
"           Diagnostic approach to the neuropsychiatric manifestations of systemic lupus erythematosus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/55/11129\">",
"           Neurologic manifestations of rheumatoid arthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/11/33978\">",
"           Neurologic manifestations of systemic lupus erythematosus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/48/778\">",
"           Neuromuscular manifestations of systemic sclerosis (scleroderma)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Trauma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/11/26810\">",
"           Acute traumatic spinal cord injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/48/37642\">",
"           Chronic complications of spinal cord injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/59/29626\">",
"           Concussion and mild traumatic brain injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/2/35882\">",
"           Management of acute severe traumatic brain injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/8/33929\">",
"           Postconcussion syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/9/39062\">",
"           Traumatic brain injury: Epidemiology, classification, and pathophysiology",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-C666579EAA-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f25_20_25934=[""].join("\n");
var outline_f25_20_25934=null;
var title_f25_20_25935="Neck tilting exercise";
var content_f25_20_25935=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F61243&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F61243&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Neck tilting",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 365px; height: 280px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tilt your head to the right, trying to touch your ear to the tip of your shoulder. Place tension on the temple with your fingertips. Hold for a few seconds and return to the center. Repeat to the left.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_20_25935=[""].join("\n");
var outline_f25_20_25935=null;
